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Abstract 
 
Serogroup 6 pneumococcal oligosaccharides as potential targets towards the 
development of a fully synthetic conjugate vaccine 
 
Archana R. Parameswar 
Doctor of Philosophy 
University of Missouri - St. Louis 
Prof. Alexei V. Demchenko, Chairperson 
 
Involvement of complex glycostructures in a variety of damaging and healing processes 
has already been acknowledged by development of carbohydrate-based vaccines and 
therapeutics. The bacteria Streptococcus pneumoniae (SPn) have become one of the most 
frequent causes of pneumonia, bacteremia, and meningitis in the elderly, 
immunocompromised, and, especially, in young children. SPn has one of the largest 
public health and economic impacts amongst all bacterial infectious diseases. Over 2 
million children die annually worldwide due to pneumonia, accounting for almost 20% of 
deaths under age five with more than half of these deaths attributed to SPn.   
Amongst over ninety elucidated SPn serotypes, the SPn serogroup6 has been consistently 
ranked within the top three causes of invasive pneumococcal disease worldwide. The SPn 
bacterial cell is surrounded by a polysaccharide capsule and preventive vaccination is a 
viable tool against the bacterial invasion. Usually, serotype-specific antibodies are 
formed in response. Synthetic oligosaccharide components can be conjugated to a carrier 
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protein with conventional coupling chemistry, to obtain semi-synthetic conjugate 
vaccines (glycoconjugates).  
This doctoral dissertation describes the application of a new glycosylation method for the 
synthesis of glycostructures to study immunological properties of serogroup 6. The 
development of an expeditious strategy to obtain synthetic saccharides of SPn6 and 
glycoconjugates thereof will ensure reliable and reproducible immunological studies. 
Consequently, by identifying the immunogenic responses of these glycoconjugates, will 
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Introduction 




1.1 Pneumococcal Disease: Background 
 
 
The gram positive bacteria Streptococcus pneumoniae (SPn) have become one of the 
most frequent causes of pneumonia, bacteremia and meningitis in the elderly, 
immunocompromised, and, especially, in young children. The incidence of 
pneumococcal infection varies geographically, but elevated rates have been observed in 
both developed and developing countries. In accordance with the joint United Nations 
Children's Fund (UNISEF)/World Health Organization (WHO) survey, over 2 million 
children die annually worldwide due to pneumonia, accounting for almost 20% of 
deaths under age five.1 More than half of these deaths are attributed to SPn. This 
situation is further complicated by the rapid increase in anti-microbial drug resistance 
during the last decade. SPn has one of the largest public health and economic impacts 
amongst all bacterial infectious diseases. Throughout the decades, SPn has become one 
of the most extensively studied microorganisms since its first isolation back in 1881; 
nevertheless, significant gaps in our knowledge remain. 
 
1.1.1 Polysaccharide & Conjugate Vaccines  
 
 
The development of resistance against antibiotics in the last decade is a serious threat 
for successful treatment of pneumococcal infections.2,3 Despite the widespread use of 
antibiotics, the mortality and morbidity of pneumococcal disease remains high. In 
Introduction 
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addition resistant pneumococci are increasingly observed. 4,5 An alternative approach is 
to prevent the disease by vaccination with capsular polysaccharides (CPS) isolated 
from bacterial cultures, which was shown to afford protection as early as 1923.6  
 
The SPn bacterial cell is surrounded by a polysaccharide capsule, which makes the 
organism resistant to phagocytosis. This polysaccharide capsule is the primary 
virulence factor of SPn and provides the basis for type-specific identification of 
approximately 90 different serotypes.7 It is also the most immunogenic surface that can 
induce highly protective anti-CPS antibodies8,9; hence the CPS or saccharide-protein 
conjugate10,11 vaccinations are conventional tools against the bacterial invasion; 
serotype-specific antibodies to the pneumococcal saccharide are formed in response.  
 
Currently, leading SPn vaccine manufacturers, such as Wyeth, Pasteur, Merck, Aventis, 
and SmithKline Beecham have marketed various multi-component vaccines whose 
serotype composition varies. For example, vaccines containing isolated polysaccharides 
of 23 serotypes are commercially available as Pneumovax 23. These vaccines cover 
over 90% of the infections caused by SPn in the United States.12 However 
polysaccharides are poorly immunogenic in high risk group patients.13(i) infants and 
children less than 2 years of age. (ii) Splenectomised patients and (iii) 
immunocompromised patients (e.g.) HIV infected.   
Introduction 
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Figure 1.1 Response to polysaccharide vaccine 
 
Polysaccharides are known to belong to a class of T-cell independent antigens; they 
stimulate B-cells to produce antibodies without the involvement of T-cells. Since T-
cells are not involved in the process, the antibodies formed are mainly of the IgM 
isotype (Figure 1.1) and hence no memory B-cells are produced. To overcome the 
thymus independency of these antigens, PS can be conjugated to carrier proteins.  
 
Hence, these glycoproteins belong to a class of T-cell dependent antigens. In this case 
the peptide-MHC complex is recognized by the T-cell receptor, thereby initiating the 
formation of both antibody-producing and memory B-cells and hence formation of IgG 
antibodies (Figure 1.2). 
Introduction 
Archana R. Parameswar Page 18 of 208 7/21/2008  
 
Figure 1.2  Response to conjugate vaccine 
 
Hence by using neoglycoconjugates, long lasting immunity to the encapsulated bacteria 
could be achieved. Unconjugated vaccines, on the other hand,  cause only an initial 
increase in antibody levels that soon return to the baseline levels without the induction 
of immunological memory. For high risk groups of patients, (i.e), infants or 
immunocompromised the antibodies are incapable of mounting a T-cell dependent 
immune response to the polysaccharides included in the current 23-valent formulation. 
However, by conjugation to a carrier protein a T-cell independent antigen can be 
converted to a T-cell dependent antigen thereby enhancing the immunogenicity of the 
bound molecule and/ or to elicit antibodies against the carrier which are considered 
Introduction 
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therapeutically beneficial.13  For example, PNCRM7 or Prevnar is a pneumococcal 
conjugate vaccine, which is licensed for immunization of children aged 6 weeks to 9 
years mainly in the US and European Union. Prevnar contains seven capsular 
polysaccharides of common serotypes of SPn known to cause invasive disease, each of 
which is conjugated to diphtheria protein (cross reactive material- CRM197) 
 
1.1.2 Synthetic Oligosaccharide based bacterial vaccines  
 
Vaccines based on isolated natural PS have been used very successfully to protect 
humans against various pathogens and diseases. In principle, synthetic oligosaccharides 
can also be conjugated to a carrier protein with conventional coupling chemistry, to 
obtain semi-synthetic conjugate vaccines. A major highlight in the development of the 
synthetic vaccines was the success of immunization with conjugates containing the 
purified CPS of Haemophilus Influenza type b to eradicate childhood meningitis, which 
was licensed in Cuba in 2003.14 This vaccine (the only one currently marketed), available 
under the trade name Quimi-Hib, is now routinely used for immunization of infants and 
children.  
1.1.2.1 Preparation of neoglycoconjugates- Conjugation Techniques 
 
Conjugation of polysaccharides to a protein by random activation results in lattice-type 
complexes with an undefined structure. Structural factors that affect immunogenicity of 
the conjugates are: (i) the size of the saccharide (ii) terminal residue (iii) saccharide 
loading on the protein (iv) conjugation method and (v) linker geometry. 
There are a number of techniques available for covalently linking PS to proteins. 
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Covalent linking of a molecule to a carrier confers enhanced immunogenicity and T-cell 
dependence.15 Coupling methods in which saccharides are coupled to a protein via their 
reducing end are preferred, since the resulting products are better defined. 16  
The most commonly employed methods include: 
1) Reductive amination,17wherein the aldehyde or ketone group on one component 
of the reaction reacts with the amino or hydrazide group on the other component. 
The C=N double bond formed is subsequently reduced to C-N single bond by a 
reducing agent. 
2)  Cyanylation conjugation,18wherein the polysaccharide is activated either by 
cyanogen bromide (CNBr) or by 1- cyano-4-dimethylammoniumpyridinium 
tetrafluoroborate (CDAP),19 to introduce a cyanate group to the hydroxyl group, 
which forms a covalent bond to the amino or hydrazide group upon addition of 
the protein component. 
3) Carbodiimide reaction, 20,21 wherein carbodiimide activates the carboxyl group on 
one component of the conjugation reaction, and the activated carbonyl group 
reacts with the amino or hydrazide group on the other component. These reactions 
are also frequently employed to activate the components of the conjugate prior to 
the conjugation reaction. 
4) Squaric acid diester conjugation, wherein a monoamide is formed between the 
ligand and the squaric acid diester. The derivative is then attached to an amino 
group of another low molecular weight amine (e.g.) lysine via controlled 
formation of 1,2- bisamide of the squaric acid. 22,23,24 
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1.1.2.2 Synthetic pneumococcal OS-protein conjugates: promising vaccine candidates   
1.1.2.2.1    Streptococcus pneumoniae type 3 
Oligosaccharide fragments in the spacer linked form (1.1, 1.2, and 1.3, Figure 1.3) were 
conjugated to CRM197 using the squarate coupling method. The average molar ratio of 
the carbohydrate to protein was in the range of 3 to 12. The protective immunity was 
studied in inbred female mice subcutaneously immunized twice at three week interval 
with 2.5 µg of oligosaccharide per mouse. All mice immunized with the tri- and 
tetrasaccharide conjugates developed SPn3 binding IgG antibodies.25 This study also 
proved that immunogenicity was not influenced by the number of saccharide chains per 
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1.1.2.2.2 Streptococcus pneumoniae type 6B 
 
Three overlapping fragments of the synthesized SPn6B saccharides (1.4, 1.5, 1.6, 
Figure 1.4) were coupled via the 3-aminopropyl spacer to carrier protein Keyhole 
Limpet Hemocyanin (KLH) using carbodiimide condensation method. The 
immunogenicity and protective capacity of these conjugates were studied in mice and 
rabbits.20 In rabbits all these conjugates evoked high levels of type 6B CPS- specific 
IgG antibodies. The antibody levels with the tetrasaccharide conjugate were higher than 
they were with the KLH conjugate of the native CPS. In mice, the antibodies elicited by 
the tetrasaccharide conjugate 1.6 was phagocytic and protective. Also the disaccharide 
1.4 contained a serotype 6B specific epitope, the trisaccharide contained a common 6A 
and 6B epitope, the tetrasaccharide contained both 6B specific and a common 6A and 
6B epitope. These results proved that the disaccharide and tetrasaccharide conjugates 
already contain epitopes capable of inducing 6B- specific, fully protective antibodies in 
rabbits and mice, respectively.  
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Figure 1.4 SPn6B conjugates  
 
 
1.1.2.2.3 Streptococcus pneumoniae type 14 
 
Synthetic oligosaccharide fragments 1.7 (tetra-), 1.8 (hexa-) and 1.9 (octa-) related to 
SPn14 were conjugated to CRM197 via the carbodiimide reaction and the squaric acid 
diester coupling methods. The average degree of incorporation of OS chains into 
CRM197 was in the range 4 to 24.26 In accordance to the inhibition studies, the 
tetrasaccharide-CRM197 conjugate 1.7 with either the adipic acid or squarate linker, 
elicited a PS-specific IgG response after a booster injection, whereas the octasaccharide 
mimic 1.9 gave very low responses or even remained non-immunogenic. Hence, the 
OS-CRM197 conjugate prepared from the single repeating unit of SPn14 can be 
considered as a potential vaccine candidate. 
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Figure 1.5 SPn14 conjugates  
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1.2 Strategies for Oligosaccharide Synthesis 
 
Complex carbohydrates are involved in many biological phenomena and their 
involvement in life-threatening processes, in particular, has associated this class of 
natural compounds with a tremendous diagnostic and therapeutic potential. Many 
synthetic laboratories have focused their research efforts towards carbohydrates 
associated with diseases that consistently rank among the leading causes of death 
worldwide, i.e. bacterial and viral infections, cancer, etc.1 At the core of this phenomenal 
international effort is the belief that a comprehensive knowledge of the structure, 
conformation, and properties of these carbohydrates would aid to elucidation of the 
mechanisms for the pathogenesis of the disease. Consequently, this could lead to the 
development of effective tools for the prevention, diagnosis, and/or treatment of these 
diseases.   
Over the years, glycoscientists have learned to isolate certain classes of naturally 
occurring carbohydrates. The availability of pure natural isolates, however, remained 
inadequate to address the challenges offered by modern glycosciences. As a result, 
glycoscientists have turned to chemical synthesis as a means to access complex 
carbohydrates. The expectations are that the efficient chemical synthesis should yield 
significant quantities of pure natural analogs and would be the only means to access their 
unnatural mimetics. Pharmaceutical and biotechnology companies have already 
demonstrated an interest in producing complex synthetic oligosaccharides or 
glycoconjugates; however, the examples including heparin and its analogs,2 
oligosaccharide antibiotics,3 carbohydrate-based vaccines,4 and other therapeutic agents1,5 
are scarce. Carbohydrates of even moderate complexity, however, still represent a 
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considerable challenge. As such, the development of efficient methods for the 
expeditious synthesis of complex carbohydrates stands out as an important area of 
research.  
The glycosidic linkage is obtained by means of the glycosylation reaction, arguably the 
most important and challenging reaction in carbohydrate chemistry.6 A typical chemical 
glycosylation is based on the nucleophilic displacement of a leaving group (LG, Scheme 
1.1) on the glycosyl donor with a hydroxyl moiety of the glycosyl acceptor. The 
remaining hydroxyls of both units are temporarily masked with protecting groups (P). 
The achievement of high yields and complete stereocontrol is difficult due to complexity 
of the glycosylation process. The necessity to form either a 1,2-cis or a 1,2-trans-
glycosidic bond with complete stereoselectivity remains the main reason chemical O-
glycosylation remains amongst synthetic challenges.6  
Various factors affect the stereoselectivity of glycosylation amongst which the 
neighboring substituent at C-2 is one of the major players. If the use of a base-labile 
ester-protecting groups is permitted, 1,2-trans glycosides can be prepared with the 
assistance of a neighboring participating group.7 These glycosylations proceed primarily 
via a bicyclic acyloxonium ion intermediate that can only accept the top face nucleophilic 
attack resulting in the stereoselective formation of a 1,2-trans glycoside (Scheme 1.1). In 
case of a non-participating substituent, the flattened oxocarbenium ion is formed as the 
major reaction intermediate. As a result, the nucleophilic attack is nearly equally possible 
from either the top (trans, β- for the D-gluco series) or the bottom face (cis, α-) of the 
ring. Even though the α-product is thermodynamically favored (anomeric effect),8 a 
substantial amount of the kinetic β-linked product is often obtained.  
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Scheme  1.1.  Outline of chemical glycosylation 
Another important factor affecting the outcome of glycosylations is the nature of the 
anomeric leaving group. As a result, a large number of glycosyl donors have been 
developed.9 In addition to traditionally used chlorides or bromides,10 more recent 
glycosyl donors such as Schmidt’s O-trichloroacetimidates,11 Mukaiyama’s fluorides,12,13 
alkyl/aryl thioglycosides pioneered by Ferrier, Nicolaou, and Garegg,14 Fraser-Reid’s O-
pentenyl glycosides,15,16 and Danishefsky’s glycal-epoxide system17 have become 
valuable alternatives.  
Traditional linear approaches for the synthesis of oligosaccharides involve extensive 
protecting group manipulations between each glycosylation step.18 Such additional 
manipulations increase the number of total synthetic steps and decrease the efficiency of 
the oligosaccharide assembly reflected in a dramatic drop in yield. This low accessibility 
of medicinally relevant compounds complicates their investigation, and questions the 
feasibility of their application in multi-kilogram drug/vaccine development. This called 
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for revisiting the existing linear strategy for oligosaccharide synthesis and some 
significant improvements have already emerged. More recent strategies for 
oligosaccharide synthesis are typically based on the selective activation of one leaving 
group over another.18,19 These expeditious approaches significantly shorten 
oligosaccharide assembly by minimizing the need for protecting group manipulations 
between glycosylation steps. Nicolaou’s selective activation,12 Fraser-Reid’s armed-
disarmed approach,20 Danishefsky’s glycal assembly,17 Ogawa’s orthogonal 
technique,21,22 Roy’s23 and Boons’24 active-latent concept are only a few of those that 
could be mentioned.  
These excellent innovations have allowed scientists to synthesize complex 
oligosaccharides and glycoconjugates, which were practically inaccessible for decades. 
Nevertheless, those syntheses were still very far from being simple and it has become 
apparent that only selected sequences can be accessed by these innovative techniques: 
each target still required careful selection of methods, conditions, and strategies. These 
notable gaps stimulated additional scientific efforts that recently resulted in the 
development of a new pool of methods for the stereoselective synthesis of challenging 
glycosidic linkages and strategies for expeditious oligosaccharide synthesis. One-pot 
strategies,25 including programmable strategies developed by Ley’s and Wong’s 
groups,26-29 reactivation-based sequential couplings by Huang’s30-32 and van der Marel’s 
groups,33 Crich’s synthesis of β-mannosides,34 Gin’s dehydrative method,35 Seeberger’s 
polymer-supported automated synthesis,36 Lowary’s work on furanosides,37 Gervay’s 
glycosyl iodide approach,38 Hung’s work of one-pot protection of sugars,39 Boons’ 
stereodirected synthesis of α-glycosides,40 and fluorous-tag assisted glycosylations in 
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micro-reactors41 are only few examples of recent significant breakthroughs to mention.  
 
1.2.1 One-pot strategies, an overview 
 
Conceptually, one-pot strategies offer the shortest pathway to oligosaccharides, as the 
sequential glycosylation reactions are performed in a single flask (pot) and do not require 
purification of the intermediates. It is very important for a successful one-pot 
glycosylation that there is complete consumption of the intermediate formed and a high 
yield.  In addition, the requirement for very high or preferably complete stereoselectivity 
in every glycosylation step becomes particularly important.  These will ensure that only 
the target oligosaccharide is being produced as the major product, thus providing high 
efficiency of this technique. Although many variations of the one-pot strategy have been 
developed, these protocols are based on five major concepts (Scheme 1.2) or a 
combination thereof:  
(i) Fine-tuning of all reactants or pure one-pot concept 
(ii) Selective activation or leaving group based concept 
(iii) Chemoselective activation or protecting group based concept 
(iv) In-situ pre-activation strategy or leaving/protecting group independent 
concept 


























































































Scheme  1.2  Major concepts for the one-pot oligosaccharide assembly 
Approach A, the first ever discovered and the conceptually pure in its entirety one-pot 
approach is performed with all reaction components present from the very beginning. It 
requires fine tuning of all reaction components, according to which the most reactive 
leaving group reacts with the most reactive hydroxyl. Subsequent reaction takes place 
between the most reactive leaving group and hydroxyl remaining after the first step has 
been completed, etc. The Approach B is based on selective activation of one type of a 
leaving group over another. Since this is a leaving group based concept, one should be 
flexible with the protecting groups, which is an important factor for the stereoselectivity 
control.  
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The Approach C is relying on the chemoselectivity principle, according to which the 
reactivity difference between the glycosyl donor and the glycosyl acceptor is achieved by 
varying the electronic properties of the protecting groups in either or in both of the 
reaction components. Thus, this approach in its conventional mode requires a set of 
building blocks with the same type of a leaving group, the reactivity of which is 
differentiated by the protecting group pattern.  A common feature of the approaches B 
and C is that both are reactivity- based, regardless whether the difference in reactivity is 
achieved by the protecting groups or the leaving group. Being more reactive under certain 
reaction conditions, the glycosyl donor unit is activated over the less reactive glycosyl 
acceptor. Subsequently, the saccharide obtained then serves as a glycosyl donor under 
adjusted (typically more harsh) reaction conditions. For this purpose, a suitable promoter, 
along with the glycosyl acceptor, is added for the next step. 
Differently, the recently established in-situ preactivation strategy (Approach D) is 
independent on the building block reactivity since the leaving group of the glycosyl 
donor is first converted into a highly reactive species (preactivation). After that, the 
acceptor is added to yield a coupling product bearing the identical leaving at the reducing 
end that can be subsequently pre-activated. On one hand, this approach involves a 
number of additional steps as the glycosylation is virtually a two-step reaction, it is 
compensated by offering more flexibility in the context of relative independency on the 
leaving and/or protecting groups.  
As opposed to the previously describes strategies, approach E is exclusively based on the 
reactivity of glycosyl acceptors. The sequential regioselective glycosylations are often 
accomplished due to very different levels of reactivity between the hydroxyls. In this 
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case, the same type of leaving group can be used. Alternatively, reciprocal reactivity may 
take place, according to which certain hydroxyl may prefer certain class of a glycosyl 
donor. Apparently, if a polyol acceptor is employed, this leads to the formation of 
branched oligosaccharides. A variation of this approach is when other, typically less 
reactive hydroxyls are introduced in the glycosyl donor unit. This would result in a 
bidirectional one-pot glycosylations. Additional hydroxyl can be also generated during 
the glycosylation, such as with the use of the epoxide glycosyl donors, or liberated by the 
in situ removal of a certain labile substituent.  A number of approaches involving mixed 
conventions, namely techniques combining two or more concepts, have been also 
developed. 
 
1.2.1.1 Approach A: One-pot glycosylation based on fine tuning of all reaction 
components 
This concept was introduced by Kahne and co-workers and is illustrated herein by a 
representative synthesis of Ciclamycin 0 trisaccharide depicted in Scheme 1.3.42 The 
strategy takes advantage of the difference in reactivities of phenyl sulfoxide donors 1.11 
and 1.12, as well as glycosyl acceptors 1.11 (masked as TMS ether) and 1.10. All three 
building blocks 1.10-1.13 were mixed in one flask, and to ensure the successful execution 
of this two-step coupling, and the reaction mixture was cooled to -78 oC. The activator 
(TfOH) was then added and rapid coupling between 1.10 and 1.11 took place. The less 
reactive glycosyl donor 1.12 then slowly reacted with the TMS-protected hydroxyl of the 
disaccharide intermediate to provide trisaccharide 1.13 in 25% yield.  
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Scheme  1.3  One-pot synthesis of Ciclamycin 0 trisaccharide 1.13 
Bols and co-workers discovered a new phenomenon according to which conformationally 
modified glycosyl donors protected with bulky TBDMS are exceptionally reactive 
(superarmed).43,44 This superarmed concept was ultimately illustrated by performing the 
one-pot coupling with all three reaction components (thioglycosides 1.14-1.17) mixed 
from the very beginning (Scheme 1.4).44  This type of one-pot technique required the 
differentiation between reactivity levels of both glycosyl donors (1.14 and 1.15) and 
glycosyl acceptors (1.15 and 1.16) – all are bearing the same anomeric leaving group 
(thiophenyl). First, reaction between the super-armed glycosyl donor 1.14 and more 
reactive primary (and also more electron rich due to the neighboring benzyl substituents) 
glycosyl acceptor 1.15 took place. The resulting disaccharide derivative then reacted with 
the remaining glycosyl acceptor 1.16. As a result of this one-pot coupling in the presence 
of NIS/TfOH, trisaccharide 1.17 was obtained in 64% yield. 
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2.1 equiv NIS, TfOH
-88 to -50 oC
(64%)
 
Scheme  1.4  Conformationally superarmed glycosyl donors in one-pot 
glycosylations  
A related one-pot synthesis making use of a reciprocal donor-acceptor selectivity was 
reported by Fraser-Reid and co-workers.45 Thus, when a mixture of diol 1.18, n-pentenyl 
donor 1.19 and n-pentenyl orthoester donor 1.20 was treated with NIS/BF3-OEt2, 
trisaccharide 1.21 was obtained (Scheme 1.5). Since no other trisaccharide regioisomer 
was detected, this result clearly indicated a reciprocal choice of donor 1.20 for the 3-OH 
whereas the donor 1.19 preferred the 2-OH. It should be noted that this particular 
synthesis conceptually differs from the acceptor-based techniques classified as Approach 
E. Herein, all reaction components (including the activators) are present from the very 
beginning, whereas in Approach E, the reactants are added upon completion of the 
previous step.      
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Scheme  1.5  One-pot synthesis based on reciprocal donor-acceptor selectivity 
 
1.2.1.2 Approach B: One-pot glycosylation based on selective activation 
The use of selective activation strategy for oligosaccharide sequencing is easy to 
envisage. As illustrated in Scheme 1.6, it requires a set of suitable leaving groups (LGa, 
LGb, LGc) that can be selectively activated in a sequential manner. It also requires 
suitable activator that would activate one leaving group over another: A (selectively 
activates LGa), B (selectively activates LGb), etc.. This general strategy was first 
popularized by Zen,46 Nicolaou,47,48 Lonn,49 Garegg,50 and others51 for stepwise 
synthesis, and a large number of one-pot syntheses have been developed accordingly. 
Some representative examples of these one-pot syntheses are discussed below. 
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R',R", R'" - neighboring protecting groups  
Scheme  1.6  Oligosaccharide assembly based on selective activation 
 
The first one-pot synthesis based on the leaving group based activation concept was 
reported by Takahashi and co-workers.52  The synthesis involved the use of 
trichloroacetimidate donor 1.22, which was selectively activated over the thioglycoside 
1.23 with TMSOTf (Scheme 1.7). The SPh moiety of the formed, but not isolated, 
tetrasaccharide was then activated with NIS and TfOH over the added glycosyl acceptor 
1.24 to provide hexasaccharide 1.25 in 50% yield over two steps. This approach 
incorporates advantages of the convergent block strategy according to which pre-
synthesized oligosaccharide building blocks i.e. 1.22 and 1.24 are converged together 
during the final assembly.  
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Scheme  1.7  Convergent one-pot synthesis by selective activation 
In a similar fashion, a tetrasaccharide glycosyl glycerol which represents the core 
structure of a glycoglycerolipid of M. taiwanesis, based on a three-component one-pot 
strategy was synthesized.53 A trisaccharide intermediate was formed from the glycosyl 
phosphite 1.26, which was selectively activated over selenoglycoside acceptor 1.27 in the 
presence of TMSOTf. Subsequent addition of acceptor 1.28 and NIS allowed to produce 
the tetrasaccharide 1.29 in 46% yield over-all (Scheme 1.8).   
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Scheme  1.8  One-pot synthesis of glycoglycerolipid analog 
Seeberger and co-workers presented an efficient one-pot synthesis of a pentasaccharide 
implicated as a potent antibiotic against H. pylori.54  Accordingly, disaccharide 
trichloroacetimidate 1.30 was activated with TMSOTf to react regioselectively at the C-4 
hydroxyl group of the thioglycoside 1.31 (Scheme 1.9). Addition of the disaccharide 
acceptor 1.32 to the reaction mixture, followed by the addition of NIS/TfOH to promote 
the thioethyl group of the in situ formed trisaccharide completed the sequence. The 
requisite pentasaccharide 1.33 was isolated in 63% yield over-all.  
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Scheme  1.9  One-pot synthesis of a pentasaccharide antibiotic 
A representative example involving three sequential glycosylation steps is shown in 
Scheme 1.10.55 This three step activation was achieved by the stepwise activation of S-
benzoxazolyl (SBox) glycoside donor 1.34 over S-ethyl glycoside acceptor 1.35 by 
addition of AgOTf. Thioethyl moiety of the resulting disaccharide intermediate was then 
activated over the added S-thiazolinyl (STaz) glycoside 1.36 by the addition of NIS and 
catalytic TfOH. Finally, the STaz moiety of the trisaccharide intermediate is reacted with 
freshly added glycosyl acceptor 1.37 in the presence of additional quantity of AgOTf. As 
a result, the linear tetrasaccharide 1.38 was obtained in 73% yield over three steps.  
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Scheme  1.10  One-pot synthesis of tetrasaccharide 1.38 by the three-step 
sequential selective activation.  
 
In principle, conceptually related Ogawa’s orthogonal strategy offers even more flexible 
oligosaccharide sequencing.21  It only requires a set of two orthogonal leaving groups 
(LGa and LGb) and a pair of activators: A (selectively activates LGa over LGb) and B 
(selectively activates LGb over LGa). Unfortunately, this relatively simple concept is still 
limited to only few examples,21,56 and to the best of our knowledge, only one one-pot 
synthesis involved the features of the orthogonal concept (discussed below in subsection 
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1.2.1.3 Approach C.  One-pot glycosylation based on chemoselective activation 
One of the most conceptually attractive and practically efficient procedures, Fraser-
Reid’s armed-disarmed approach, is based on the principle of chemoselectivity. Thus, 
chemoselective activation of a benzylated (electronically activated, armed) glycosyl 
donor can be achieved over the acylated (electronically deactivated, disarmed) glycosyl 
acceptor bearing the same type of leaving group (Scheme 1.11).58,59 The availability of a 
suitable mild promoter is essential to effectively differentiate the reactivity levels of the 
armed and disarmed reactants. The obtained disaccharide can then be used for subsequent 
glycosylation directly, but would generally require a more potent promoter (or elevated 
temperature) that can activate the disarmed leaving group. Initially developed for O-
pentenyl glycosides,16,59 this approach works very well with many other classes of 




























Scheme  1.11  Chemoselective armed-disarmed strategy 
A significant progress in the area of chemoselective oligosaccharide synthesis has 
emerged with the development of programmable oligosaccharide strategy that became a 
logical extension of studies pioneered by Fraser-Reid’s, van Boom’s, Ley’s, and Wong’s 
groups. Attempts to classify and even predict the outcome of a glycosylation (or a 
sequence) resulted in the development of approaches to quantify the reactivity of building 
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blocks.26,27,60,61 Amongst these, a database of the relative reactivity values (RRVs) of 
different glycosyl donors has been generated compiled into a predictive computer 
program called Optimer.27 It was noted that the optimal chemoselective couplings 
generally occurred when there was a large difference in the RRVs. For example: thus, 
selective activation of glycosyl donor 1.39 (RRV = 17,000) over glycosyl acceptor 1.40 
(RRV = 28.9) in the presence of NIS/TfOH resulted in the formation of a disaccharide 
derivative.27 The latter was not isolated; instead, glycosyl acceptor 1.41 and additional 
NIS were added to the reaction mixture. As a result of this two-step sequential activation, 
trisaccharide 1.42 was isolated in 58% overall yield. Further exploration of this approach 
by Wong’s group has resulted in a well-rounded and extremely useful technology for 








































Scheme  1.12  Programmable synthesis of a trisaccharide 1.42 
If one would rely exclusively on the disarming effect of the neighboring substituents, 
these chemoselective syntheses would be limited to the synthesis of cis-trans patterned 
trisaccharides only. This stimulated subsequent investigation of the arming/disarming 
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effects, and a number of useful improvements have already emerged. Amongst effects 
investigated,63 torsional deactivation by cyclic substituents was arguably the most 
relevant to the one-pot syntheses. Fraser-Reid60 and Ley64 found that the anomeric 
deactivation can also be achieved by the torsional effect of cyclic acetal/ketal protecting 
groups that impart rigidity into the structure. This rigidity hinders the flattening of the 
ring during the formation of the oxocarbenium ion. This disarming effect was further 
studied by Bols,65 who concluded that there is roughly equal deactivation from both 















































Scheme  1.13 One-pot synthesis of trisaccharide controlled by torsional 
deactivation 
For instance, in application to one-pot synthesis, Ley and co-workers reported the 
synthesis of a trisaccharide unit of a group B streptococci polysaccharide antigen as 
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depicted in Scheme 1.13.66 A cyclohexane-1,2-diketal protected thioglycosyl acceptor 
1.44 with its reactivity tuned down via the torsional effect, this in turn would hinder the 
formation of the flattened  cationic transition state. A similar concept was applied to the 
syntheses of linear and branched oligosaccharides by utilizing mixed one-pot conventions 








































NIS/ AgOTf   Et2O
(84%)
NIS/ AgOTf   CH2Cl2
 
Scheme  1.14  One-pot synthesis of trisaccharide 1.50 employing solvent 
effects 
The reactivity difference between similarly protected sugars of different series has to be 
also taken into consideration. In the following example from Oscarson’s group, this 
difference in reactivity along with an interesting solvent effect allowed an efficient one-
pot oligosaccharide synthesis.69  As shown in Scheme 1.14, the first activation could take 
place in Et2O allowing for relatively low glycosylation rate due to limited solubility of 
NIS/ AgOTf in diethyl ether. This required the application of the highly reactive 
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rhamnosyl donor 1.47, which was successfully activated over “armed” benzylated 
acceptor 1.48. Subsequently, the second step is accomplished in CH2Cl2/Et2O allowing 
for much higher glycosylation rate. As a result, trisaccharide 1.50 was synthesized in 
84% yield.  In accordance with the Optimer database, the reactivity ratio between per-

























































Scheme  1.15  Synthesis of tetrasaccharide 1.55 via programmable three step 
synthesis  
A number of three-step sequential one-pot activations using this concept has also been 
reported. For example, sequential activation of building blocks 1.51, 1.52 and 1.53 was 
anticipated based on their relative reactivity, 17000, 162.8, and 13.1, respectively 
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(Scheme 1.15).27 Indeed, glycosyl donor 1.51 was activated over glycosyl acceptor 1.52 
in the presence of NIS and TfOH. The resulting disaccharide intermediate was then 
reacted with the added glycosyl acceptor 1.53 and additional NIS. The trisaccharide 
intermediate was then glycosidated with added acceptor 1.54 to provide the target 
tetrasaccharide 1.55 in 39% yield over-all.  
Another three-step activation sequence utilizes the activator system (BSP/ Tf2O) to carry 
out the one-pot sequential synthesis of α-Gal pentasaccharide derivative 1.60 as depicted 
in Scheme 1.16.70  The synthesis was carried out from the readily available building 



































































Scheme  1.16  Four component one-pot sequential synthesis of α-Gal 
pentasaccharide 
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1.2.1.4 Approach D: One-pot glycosylation based on in-situ preactivation 
 
This strategy integrates the advantages of both the chemoselective and the selective 
activation strategy, but it does not require reactivity tuning of the building blocks. Two-
step activations have been known for long time. In accordance with this concept, both 
glycosyl donor and glycosyl acceptor initially bear the same type of a leaving group 
(LGa). In order to couple these two reactants, the LGa of the potential glycosyl donor unit 
is first converted into a LGb, which is then selectively activated over the LGa of the 
glycosyl acceptor in the presence of a selective activator (Activator B, Scheme 1.17). 
This two-step activation sequence can be reiterated: for this purpose the leaving group 
LGa of the obtained disaccharide is converted into LGb. This will allow the coupling with 





























Scheme  1.17  Two-step activation (or pre-activation) concept. 
This two-step activation concept was discovered by Zen for S-ethyl (LGa) and bromo 
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(LGb) moieties.46 Further expansion to S-phenyl (LGa) and fluoro (LGb) moieties by 
Nicolaou,47,71 gave rise to the development of many useful approached to stereoselective 
glycosylation and expeditious oligosaccharide synthesis. Amongst the most versatile 
procedures is one-pot synthesis based on pre-activation of p-tolyl thioglycoside donor, 
followed by sequential addition of glycosyl acceptor.31   
 
For example, glycosyl donor 1.61 was cooled to –60 oC and the promoter system 
consisting of AgOTf and p-toluenesulfenyl chloride was added (Scheme 1.18).  After 5 
min, glycosyl acceptor 1.62 was added and the reaction mixture was warmed to rt for 15 
min to generate a disaccharide intermediate. The mixture was then again cooled to –60 oC 
and another portion of the promoter was added. After 5 min, glycosyl acceptor 1.63 was 
added and the reaction mixture was warmed to rt. Upon the formation of the trisaccharide 
intermediate, the preactivation/glycosylation sequence was repeated once again with the 
glycosyl acceptor 1.64 to produce the tetrasaccharide 1.65 in 55% over-all yield in only 2 
h.   
 
Another useful utilization of the preactivation concept is the synthesis of the tumor 
associated carbohydrate antigen Globo H hexasaccharide.32  As illustrated in Scheme 
1.19, preactivation of the fucosyl donor 1.66 at -78 oC with p-TolSCl/AgOTf was 
followed by the addition of the first acceptor 1.67 along with a sterically hindered base 
2,4,6-tri-(t-butyl)-pyrimidine (TTBP). The temperature was then raised to -20 oC to 
obtain the trisaccharide intermediate. At this stage, the reaction mixture was cooled to -78 
oC followed by the sequential addition of AgOTf, p-TolSCl, galactose acceptor 1.68, 
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TTBP and then warming up the reaction to -20 oC. After complete disappearance of the 
acceptor 1.68, the temperature was lowered to -78 oC and the sequence was reiterated for 
glycosylation of lactoside 1.69. The resulting Globo H hexasaccharide 1.70 was thus 















































-60 oC -> rt
-60 oC -> rt
















Scheme  1.18  One-pot synthesis via in-situ preactivation 
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1.2.1.5 Approach E: One-pot glycosylation based on bidirectional concept 
 
Many common chemical reactions allow for the differentiation between various hydroxyl 
groups, and glycosylation is no exception. Most commonly, the reactivity differences 
between primary / secondary or equatorial / axial alcohols have been explored. The 
outline of this approach that is amongst the most common techniques to obtain branched 



















Scheme  1.20  Reactivity-based regioselective glycosylation of polyols 
 
For example, as depicted in Scheme 1.21, mannose acceptor diol 1.72 was first 
regioselectively glycosidated at the primary position with n-pentenyl orthoester 1.71 
using NIS/Yb(OTf)3 promoter system. Upon completion of this step, thioglycoside donor 
1.73 was added and the remaining secondary hydroxyl was glycosylated to yield the 
branched trisaccharide 1.74 in 62% overall yield.72 
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Scheme  1.21  Regioselective one-pot glycosylation of glycosyl acceptor 1.74 
In a similar fashion, the one-pot synthesis of trisaccharide 1.77 incorporating the 
intramolecular glycosylation has been accomplished. As shown in Scheme 1.22, the 
intramolecular glycosylation of the tethered glycosyl donor / acceptor cluster 1.75 
occurred regioselectively at the 6-OH. Subsequently, glycosyl donor 1.76 was added to 
affect the coupling on the 3-OH yielding the branched trimannoside derivative 1.77 73 
In a series of publications, Boons developed a bidirectional strategy for oligosaccharide 
synthesis.74 According to this approach, the key building block bears both a leaving 
group and a deactivated (or temporarily masked) hydroxyl moiety. It can first act as a 
glycosyl donor with a reactive glycosyl acceptor. Next, the same unit acts as the glycosyl 
acceptor that is glycosylated directly at the deactivated hydroxyl. Alternatively, an easily 
removable protecting group can be used as the temporary masking functionality that is 
removed prior to the next glycosylation step. 
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Scheme  1.22  One-pot synthesis of trimannoside 1.77. 
 
A very effective application of the bidirectional concept to one-pot synthesis emerged 
with the application of 1,2-anhydro derivatives as glycosyl donors. Apparently, upon 
glycosidation, such epoxide donor liberates 2-OH group, which offers a useful target for 
the direct subsequent glycosylations.75 As shown in Scheme 1.23, epoxide 1.78 and 
glucosamine 1.79 were first reacted in the presence of ZnCl2. This coupling led to the 
formation of a disaccharide containing free hydroxyl group at C-2’. Subsequently, 
thiofucoside 1.80 and promoter NIS/ TfOH were added to yield the trisaccharide 1.81 in 
46% overall yield.  
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Scheme  1.23  Bidirectional one-pot synthesis of trisaccharide 1.81 
A related approach that makes use of p-methoxybenzyl ether (PMB) as an in-situ 
removable protecting group was developed.76 It was observed that although PMB ether is 
stable toward typical electrophilic conditions for thioglycoside activation (NIS/TfOH), it 
can be readily cleaved with 0.2 eq. TfOH. This made possible to perform two sequential 
glycosylations with the intermediate deprotection, all in one-pot. When the first coupling 
reaction between building blocks 1.82 and 1.83 was complete, the PMB ether was 
cleaved by simply elevating the temperature to 0 oC and adding 0.2 eq. of TfOH to 
expose a hydroxyl group for the next glycosylation (Scheme 1.24). The glycosyl donor 
1.84 was then added to the reaction mixture at -45 oC to carry out the second 
glycosylation to affect the formation of globotetraose (Gb4) tetrasaccharide 1.85 in a very 
high overall yield (76%). A similar approach involving reductive opening of benzylidene 
acetals between glycosylation steps was recently reported.77 
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Scheme  1.24  One-pot synthesis of the Gb4 tetrasaccharide 1.85 
 
1.2.2 Miscellaneous one-pot syntheses or approaches based on the mixed 
conventions. 
 
The approaches included in this subsection cannot be classified unambiguously by the 
five concepts A-E discussed above. Somewhat uniquely, these syntheses combine two or 
more different concepts: for example the first example depicted in Scheme 1.25 
incorporates both selective and chemoselective activations, Approaches B and C, 
respectively. The second example (Scheme 1.26) combines features of Approaches B, C, 
and E; in addition, it makes use of the orthogonal strategy that is not yet routinely 
applicable.  
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Ley’s group reported the synthesis of a GPI anchor involving building blocks with well 
defined levels of reactivity (Scheme 1.25).68 Thus, armed and disarmed glycosyl fluorides 
(1.86, 1.87), armed and disarmed selenoglycosides (1.88, 1.89) and torsionally disarmed 
thioglycoside 1.90, which were all sequentially activated to provide the target linear 
pentamannoside 1.91 in 8% overall yield in four steps. 
 
Six-step one-pot glycosylation of heptasaccharide 1.99 was performed by Takahashi and 
coworkers using a manual synthesizer (Quest 210).57 As depicted in Scheme 1.26, this 
one-pot synthesis required the sequential addition of seven reaction components 1.92-
1.98 using four different leaving groups. Sequential activations employed herein 
included: activation of glycosyl bromide 1.92 (activated with AgOTf over S-ethyl 
acceptor), ethyl thioglycosides 1.93 and 1.94 (with MeOTf over fluoride acceptor 1.95), 
tetrasaccharide fluoride (with HfCp2Cl2/ AgOTf over S-phenyl acceptor 1.96) and phenyl 
thioglycosides 1.97 and hexasaccharide (with DMTST in the armed-disarmed fashion). 
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Scheme  1.25  Five-step one-pot synthesis of a GPI anchor pentasaccharide 
1.91 
 
1.2.3 Conclusions and outlook  
 
The invention of new methods and strategies for stereoselective glycoside synthesis and 
convergent oligosaccharide assembly has been critical for the area of glycosciences. At 
the heart of this chapter is the discussion of the strategies for expeditious one-pot 
oligosaccharide synthesis. Recent developments in this area have been categorized, 
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described, and supplemented with the relevant examples. The one-pot approach is 
arguably the simplest concept for oligosaccharide synthesis that, however, is still 
hindered by a number of factors that are also of the primary importance for conventional 
one-step glycosylations. Yield, stereoselectivity, regioselectivity, and conversion rate 
become increasingly important, and if not controlled would lead to complex inseparable 
mixtures of oligomeric isomers.  
 
At this stage, no particular concept for one-pot synthesis has a definite advantage over 
other concepts. Arguably, all concepts have certain limitations, however 3 and even 4-
step syntheses are becoming routinely accessible regardless of the strategy chosen. In one 
intends to obtain larger saccharides, this can be achieved by incorporating the convergent 
strategy, according to which oligosaccharides building blocks are pre-synthesized and 
then coupled in the one-pot fashion. An alternative approach is to make a combined use 
of various conventions that, if cleverly designed, could lead to longer sequences. In the 
last section of this chapter, two examples of such syntheses are described. Although these 
5 and 6-step one-pot syntheses still remain of modest efficiency, the yields achieved were 
8 and 24%, respectively, these innovative approaches clearly outline the direction, in 
which the one-pot synthetic strategies will be developing. It is possible that well-
established one-pot synthesis can be automated, which may simplify large scale 
production of therapeutic agents. 
 
As new developments in the glycosylation reaction emerge, it is expected that these basic 
studies will help to improve the efficiency of the one-pot strategies as well. The use of 
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Scheme  1.26  Six-step one-pot synthesis of a branched heptasaccharide 1.99 
yields in glycosylations. The use of stable building blocks would help to minimize side 
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reactions, leading to unwanted mono- and oligomeric side products. Since in some cases 
complex mixtures are generated, future progress in the detection and separation 
techniques is also expected to have a deep impact on the efficacy of the one-pot 
strategies. Indeed, if more advanced separation techniques were available, this would 
allow to fish out the target oligosaccharide even from the complex multi-component 
mixtures.     
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Despite significant progress in the area of synthetic carbohydrate chemistry, the necessity 
to form a glycosidic bond with complete stereoselectivity remains to be the main reason 
chemical O-glycosylation is still ranked amongst the most challenging problems of 
modern synthetic chemistry. The development of new glycosylation techniques persists 
to be of paramount importance for the rapidly developing area of glycosciences. Factors 
affecting the stereoselectivity of glycosylation include temperature, pressure, structure, 
conformation, solvent, promoter, steric hindrance, or leaving group.1 While some of these 
factors influence the stereoselectivity dramatically, the leaving group is undoubtedly one 
of the major players in this respect. As a result, a number of glycosyl donors have been 
developed,2,3 including glycosyl halides,4,5 trichloroacetimidates,6 and alkyl/aryl 
thioglycosides,7,8. Although these glycosyl donors are most commonly used, all of them 
still have significant drawbacks. For example, thioglycosides are inert under other 
glycosyl donor activation conditions, and therefore can fit into various orthogonal and 
(chemo)selective strategies for complex oligosaccharide assembly.9,10 Unfortunately, 
only modest stereoselectivity is typically achieved with these stable compounds.1 
Conversely, being rather unstable glycosyl donors, trichloroacetimidates or halides 
(especially iodides)11,12 often demonstrate complete stereoselectively in glycosylations.1 
Unfortunately, these compounds are not sufficiently stable to be used in block 
oligosaccharide synthesis via expeditious pathways.9,10 
Previous work in our laboratory on the development of glycosylation methods has 
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resulted in the discovery of novel glycosyl donors with a generic thioimidoyl leaving 
group (SCR1=NR2, 2.1, Figure 2.1). It has been reported that S-benzoxazolyl (2.2, 
SBox)13,14 and, especially, S-thiazolinyl (2.3, STaz)15 moieties are sufficiently stable to 
be used at the anomeric center; also, they can be mildly activated for glycosylation under 




























SBox glycosides STaz glycosides
 
Figure 2.1 Glycosyl thioimidates (SCR1=NR2)  
 
The SBox and STaz glycosyl donors have several useful features. First, these compounds 
can be efficiently synthesized from inexpensive odorless aglycones.14,15 While this is a 
convenient feature for laboratory preparation, it becomes increasingly important for 
industrial applications. Second, glycosidation of 2.2 and 2.3 allowed very high 
stereoselectivity and excellent yields (often over 90%) of glycosidations.14,15 Third, high 
stability of the SBox and STaz glycosides toward major protecting group manipulations 
and other glycosyl donor activation conditions makes it possible to use these moieties as 
a temporary protection of the anomeric center.15,22 Lastly, it has been demonstrated that 
glycosyl thioimidates not only easily fit into existing glycosylation strategies for complex 
oligosaccharide synthesis, but also permit conceptually new strategies, such as temporary 
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deactivation approach.23  
The high stability of both the Staz and SBox glycosides was somewhat unexpected, 
particularly in the context of previous reports. Thus, a fairly low stability was reported for 
a number of other glycosyl thioimidates: benzothiazolyl,16 pyridin-2-yl,17-19 pyrimidin-2-
yl,17,20 imidazolin-2-yl,17 and 1’-phenyl-1H-tetrazolyl.21 The purpose of the work 
described in this chapter is to clarify this disagreement.  
 
2.2 Results and discussion 
 
2.2.1 Synthesis of the thioimidate derivatives 
 
We were interested in expanding our previous studies to a range of five and six-
membered heterocyclic moieties, structurally related to, SBox and STaz glycosides. For 
this purpose we obtained novel per-acylated S-oxazolinyl (2.4), S-oxazinyl (2.5), S-
benzothiazolyl (2.6), S-thiazinyl (2.7) derivatives. It should be noted that per-benzylated 








































Figure 2.2 Novel glycosyl donors with a thioimidoyl leaving group 
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2.2.2 Synthesis of aglycones.  
 
A general procedure to introduce the anomeric moiety (aglycone) involved the use of 
anomeric acetates or bromides as suitable starting compounds for these syntheses. 
Aglycones 2.8-2.11 for the synthesis of 2.2, 2.6, 2.3, and 2.4, respectively, are readily 
available from commercial sources, while tetrahydro-1,3-oxazine-2-thione (2.12)19 and 
tetrahydro-1,3-thiazine-2-thione (2.13)20 needed to be synthesized according to literature 
published procedures. For this purpose, a common precursor 3-aminopropanol was used 
as a staring material. The synthesis of 2.12 was achieved by the reaction of 3-
aminopropanol with CS2 in the presence of triethylamine in methanol at 0 oC followed by 
the treatment with 30 % H2O2.19 Compound 2.13 was obtained by refluxing a mixture of 
3-aminopropanol and CS2 in 1M aqueous KOH.20 The derivatives 2.12 and 2.13 were 

























2.11 2.12 2.13  
Figure 2.3 Aglycones used for the synthesis of glycosyl thioimidates 
 
2.2.3 Synthesis of glycosyl thioimidates 
 
Having acquired the aglycone derivatives suitable for introduction at the anomeric center, 
we turned our attention to the synthesis of acylated glycosyl thioimidates. These 
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syntheses were accomplished by slightly modified experimental procedures in 
comparison to those previously developed for the synthesis of SBox and STaz 
glycosides.8-10 Thus, per-acetylated thioimidoyl derivatives 2.4-2.7 (Figure 2.2) were 
obtained from glucose pentaacetate 2.14 in the presence of TMSOTf at room 
temperature; in this context, SBox and STaz glycosides 2.2 & 2.3 were obtained in the 
presence of BF3-Et2O at low temperature (0oC). The synthesis of acetylated thioimidates 
was also accomplished from acetobromoglucose 2.1521 by the reaction of the potassium 
salt of  2.10-2.13 in acetone or MeCN at room temperature. Similarly, 
benzobromoglucose 2.1621 was employed in the syntheses of per-benzoylated 
thioimidates. It should be noted that while the sodium salt was previously found to be 
advantageous in the synthesis of STaz glycosides 2.3,10 herein improved results were 
obtained with the use of potassium salts. The synthesis of benzoylated thioimidates were 
accomplished in the presence of 18-crown-6. The use of the crown ether was not only 
found to be essential for the efficient conversion but also very influential for the synthesis 
of the desired S-linked derivatives, as opposed to their N-linked counterparts. 
 
While the results obtained for the synthesis of structurally similar benzoxazolyl (2.2) and 
benzothiazolyl (2.6) derivatives were very comparable (entries 1-3 vs 4-6, Table 2.1), 
other pairs of the structurally related derivatives provided very different results. Overall, 
the introduction of the heterocyclic moieties containing endocyclic sulfur atom at the 
anomeric center was significantly more simple and high yielding than that of their 
oxygen-containing counterparts. Thus, the syntheses of thiazolinyl 2.3a and thiazinyl 
2.7a from pentaacetate 2.14 were achieved in high yields of 91% and 84 % (entries 10 
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and 16), respectively, whereas the syntheses of oxazolinyl 2.4a and oxazinyl 2.5a under 
similar reaction conditions failed (entries 4 and 13). Along with these observations, 
notably higher yields were obtained in the syntheses of sulfur-containing heterocyclic 




























XS2.14 2.15 2.16 2.17a: R=Ac
2.17b: R=Bz     2.18a-d 
(Figure 2.4)
 
Figure 2.4 Precursors for the synthesis of glycosyl thioimidates 
 
Table 2.1.  Synthesis of Glycosyl Thioimidates 2.2-2.7. 
# SM Aglycone Conditions Product Yield Side products 
1 2.14 2.8 BF3-Et2O, CH2Cl2, 0 
oC rt 
2.2a 79 %  
2 2.15 2.8 K2CO3, acetone, 50 oC 2.2a 96 %  
3 2.16 2.8, K salt 18-c-6, acetone, rt 2.2b 99 %  
4 2.14 2.9 TMSOTf, CH2Cl2, rt 2.6a 85 %  
5 2.15 2.9, K salt acetone, rt 2.6a 99 %  
6 2.16 2.9, K salt 18-c-6, acetone, rt 2.6b 88 %  
7 2.14 2.10 TMSOTf, CH2Cl2, rt 2.4a 0 % 2.18a (80%) 
8 2.15 2.10, K salt MeCN, rt 2.4a 34 % 2.17 (36%), 
2.18a (24%) 
9 2.16 2.10, K salt 18-c-6, MeCN, rt 2.4b 23 % 2.17 (49%) 
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10 2.14 2.11 BF3-Et2O, CH2Cl2, 0 
oC rt 
2.3a 91 %  
11 2.15 2.11, Na salt MeCN, rt 2.3a 53 % 2.17 (13%), 
18b (11%) 
12 2.16 2.11, Na salt 15-c-5, MeCN, rt 2.3b 50 % 2.17 (41%) 
13 2.14 2.12 TMSOTf, CH2Cl2, rt 2.5a 0 % Complex 
mixture 
14 2.15 2.12, K salt MeCN, rt 2.5a 0 % 2.17 (58%), 
18c (27%) 
15 2.16 2.12, K salt 18-c-6, MeCN, rt 2.5b 12 % 2.17 (70%) 
16 2.14 2.13 TMSOTf, CH2Cl2, rt 2.7a 84 %  
17 2.15 2.13, K salt MeCN, rt 2.7a 22 % 2.17 (54%), 
18d (18%) 
18 2.16 2.13, K salt 18-c-6, MeCN, rt 2.7b 18 % 2.17 (55%) 
19 2.7a - 1. MeONa,  
2. BzCl/pyridine 
2.7b 72 %  
SM – starting material 
Thus, for the synthesis of the sulfur-containing five-membered heterocyclic anomeric 
moieties: 2.3a and 2.3b was obtained in 53% and 50 % yield, respectively (entries 11 and 
12), whereas the syntheses of structurally similar oxygen-containing 2.4a and 2.4b was 
achieved in only 34% and 23 %, respectively. Similar correlation, but lower yields were 
obtained in the syntheses of the six-membered heterocyclic leaving groups (2.5 and 2.7, 
entries 13-19).  
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2.18a 2.18b 2.18c 2.18d  
Figure 2.5 Per-acetylated N-linked derivatives 
 
Although the reaction conditions reported here are optimized in order to favor the 
glycosylation at the softer sulfur atom (S-glycosylation), some of these coupling reactions 
were significantly compromised by competitive side processes. Among those, β-
elimination resulting in the formation of a 1,2-dehydro (glycal) derivative 2.17 and/or N-
glycosylation resulting in the formation of a corresponding N-linked derivative (2.18a-d) 
were found to be the most common (Scheme 2.1, Table 2.1). On a number of occassions, 
glycal 2.17 was obtained as a major product in the syntheses of 2.4a, 2.4b, 2.5a, 2.5b, 
2.7a and 2.7b with the isolated yields ranging from 36 % (entry 8) to 70 % (entry 15). 
Although the corresponding per-acetylated N-linked derivatives (2.18a-d, see Figure 2.4) 
were only obtained in the attempted synthesis of 2.4a from 2.14 (entry 7) as a major 




















Scheme  2.1 Plausible mechanistic pathway for thioimidate activation 
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2.2.4 Glycosidation studies 
 
Glycosidation of perbenzoylated thioimidates 2.4b, 2.6b, and 2.7b were studied under 
essentially the same reaction conditions as those investigated for the glycosidations of 
SBox (2.2b) and STaz (2.3b) glycosides.8-10 Although these novel derivatives appear to 
be somewhat less efficient glycosyl donors than either 2.2b or 2.3b, these results are in 
line with many other glycosylation methods.2 Thus, while typical yields for the synthesis 
of 2.2022 in glycosylations of 2.1923 with 2.2a and 2.3a were in the range of 94-97% 
(Table 2.2, entries 1-4), the yields achieved with either 2.4b, 2.6b, or 2.7b were 
considerably lower (51-81 %, entries 5-10). The use of per-acetylated glycosyl donors 
was found to be impractical due to a competing process of the 2-O-acetyl moiety 
migration from a glycosyl donor to the 6-OH of the glycosyl acceptor 2.19.24  
 
































Entry Donor Promoter Time Yield Ref 
1 2.2b AgOTf 5 min 94 % 9 
2 2.2b MeOTf 1 h 95 % 9 
3 2.3b AgOTf 16 h 97 % 10 
4 2.3b MeOTf 2 h 97 % 10 
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5 2.4b AgOTf 5 min 60 %  
6 2.4b MeOTf 3.5 h 81 %  
7 2.6b AgOTf 16 h 79 %  
8 2.6b MeOTf 2 h 67 %  
9 2.7b AgOTf 30 min 65 %  
10 2.7b MeOTf 16 h 51 %  
 
2.2.5 Hydrolytic Stability 
 
Per-acetylated derivatives 2.2a, 2.3a, 2.4a, 2.6a, and 2.7a were studied under acid 
hydrolysis conditions (synthesis of 2.21, Figure 2.6). Reaction conditions selected for this 
purpose were essentially the same as those previously reported for the hydrolysis of S-
ethyl or S-phenyl glycosides (2.2225 or 2.2326, respectively, Figure 2.5). The first 
procedure involved hydrolysis in the presence of NIS (2 equiv) and TfOH (0.1-0.2 equiv) 
in wet CH2Cl2.27 Under these reaction conditions 2.2a, 2.22, and 2.23 were rapidly 
converted into the hemiacetal 2.21;28 these reactions required 15, 2, and 20 min, 
respectively, whereas the hydrolysis of 2.3a, 2.4a, 2.6a, and 2.7a was significantly slower 



















2.21 2.22 2.23  
Figure 2.6 Hydrolysis product (2.21) and thioglycosides (2.22, 2.23) 
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The second procedure involved hydrolysis in the presence of N-bromosuccinimide (2 
equiv) in aqueous acetone.29  Under these reaction conditions 2.22 was hydrolyzed in 5 
min, 2.3a, 2.7a, and 2.23 were hydrolyzed in 3-5 h, while 2.2a and 2.6a were 
significantly more resistant: their hydrolysis was sluggish and the reaction was not 
completed even in 48 h. These observations clearly illustrate that S-ethyl or S-phenyl 
glycosides are significantly more susceptible for acid hydrolysis under the investigated 
reaction conditions than their thioimidoyl counterparts. This advantageous feature of 






We investigated a number of novel thioimidoyl glycosides, which can be obtained from 
anomeric acetates and halides. When glycosidation of somewhat more basic endocyclic 
oxygen containing heterocyclic aglycones was performed, the isolated yields were 
compromised due to the competing side processes, namely β-elimination and N-
glycosylation. The glycosyl donor properties of these derivatives were studied in 
comparison to other glycosyl donors of this class, SBox and STaz glycosides. Hydrolytic 
stability studies have clearly demonstrated that many glycosyl thioimidates are more 
stable compounds overall than their S-ethyl and S-phenyl counterparts under acidic or 
electrophilic conditions. 
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Column chromatography was performed on silica gel 60 (EM Science, 70-230 mesh), 
reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). The compounds 
were detected by examination under UV light and by charring with 10% sulfuric acid in 
methanol or KMnO4 solution in EtOH. Solvents were removed under reduced pressure at 
<40 oC. CH2Cl2, (ClCH2)2, and MeCN were distilled from CaH2 directly prior to 
application. MeOH was dried by refluxing with magnesium methoxide, distilled and 
stored under argon. Pyridine was dried by refluxing with CaH2 and then distilled and 
stored over molecular sieves (3Å). Anhydrous DMF (EM Science) and ether was used as 
is. AgOTf (Acros) was co-evaporated with toluene (3 x 10 mL) and dried in vacuo for 2-
3 h directly prior to application. Molecular sieves (3Å or 4 Å), used for reactions, were 
crushed and activated in vacuo at 390 °C during 8 h in the first instance and then for 2-3 
h at 390 °C directly prior to application. Optical rotations were measured at Jasco P-1020 
polarimeter. UV-VIS spectra were recorded at HP 8452A Diode Array 
Spectrophotometer. Unless noted otherwise, 1H-n.m.r. spectra were recorded in CDCl3 at 
300 MHz (Bruker Avance), 13C-NMR spectra and two-dimensional experiments were 
recorded in CDCl3 at 75 MHz (Bruker Avance) or at 125 MHz (Bruker ARX-500).  
HRMS determinations were made with the use of JEOL MStation (JMS-700) Mass 
Spectrometer. 
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2.4.2 Preparation of thioimidates 2.4-2.7 
 
2.4.2.1 Method A   
 
General procedure for the synthesis of 2.4a, 2.5a, 2.6a, and 2.7a.: A mixture of 1,2,3,4,6-
penta-O-acetyl-β-D-glucopyranose (2.14, 0.128 mmol), a thiol (2.9, 2.10, or 2.13, 0.192 
mmol) and activated molecular sieves 3 Å (100 mg) in dry CH2Cl2 (1.0 mL) was stirred 
under an atmosphere of argon for 30 min at rt. TMSOTf (0.192 mmol) was then added 
dropwise and the reaction mixture was kept for 45min at rt. After that, additional amounts 
of thiol (0.192 mmol) and TMSOTf (0.192 mmol) were added and the reaction mixture 
was kept for 1 h at reflux (45 oC). Upon completion, the mixture was diluted with 
CH2Cl2, the solid was filtered off and the residue was washed with CH2Cl2. The 
combined filtrate (30 mL) was washed with aq. NaOH (2 x 15mL) and water (3 x 10 
mL), the organic layer was separated, dried and concentrated in vacuo. The residue was 
purified by crystallization from CH2Cl2/ether/hexane or by column chromatography on 
silica gel (ethyl acetate/toluene elution) to afford the corresponding thioimidate. 
2.4.2.2 Method B 
 
General procedure for the synthesis of 2.4a, 2.5a, 2.6a, and 2.7a. : KOH (4.2 mmol) was 
added to a solution of 2.9, 2.10, or 2.13 (4.2 mmol) in a distilled acetone. The reaction 
mixture was refluxed at 60 oC for 3 h, then concentrated in vacuo and dried to afford the 
corresponding potassium salts as white solids, which were sufficiently pure to be used in 
subsequent applications. The resulting potassium salt (4.2 mmol) was added to a stirred 
solution of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (2.15, 3.0 mmol) in dry 
Scope of Novel Glycosyl Thioimidates 
Archana R. Parameswar Page 83 of 208 7/21/2008  
acetone or MeCN (20 mL). The reaction mixture was stirred under argon for 1 h at rt. 
Upon completion, the mixture was diluted with toluene (20 mL) and washed with water 
(10 mL), 1% aq. NaOH (10 mL) and water (3 x 10 mL), the organic phase was separated, 
dried, and concentrated in vacuo. The residue was purified by silica gel column 
chromatography (ethyl acetate/hexane elution) to afford the corresponding thioimidate. 
 
4,5-Dihydrooxazol-2-yl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside (2.4a) was 
obtained as white crystals from 2.15 (Method B) in 34 % yield. Analytical data for 2.4a: 
Rf = 0.44 (acetone/ toluene, 2/3, v/v); m.p. +126-129
 oC ( recrystallised from 
CH2Cl2/ether/hexane); [α]D
24 -3.0o (c = 0.3, CHCl3); UV: λmax = 272 nm; 1H-n.m.r.: δ, 
5.37 (d, 1H, J1,2 = 10.4 Hz, H-1), 5.24 (dd, 1H, J3,4 = 9.2 Hz, H-3), 5.15 (dd, 1H, J2,3 = 9.2 
Hz, H-2), 5.15 (dd, 1H, J4,5 = 9.9 Hz, H-4), 4.40 (m, 2H, CH2O), 4.29 (dd, 1H, J5,6a = 4.6 
Hz, J6a,6b = 12.5 Hz, H-6a), 4.15 (dd, 1H, J5,6b = 2.2 Hz, H-6b), 3.92 (dd, 2H, CH2N), 3.85 
(m, 1H, H-5), 2.08, 2.06, 2.05, 2.03 (4s, 12H, 4 x COCH3) ppm; 13C-n.m.r.: δ, 171.0, 
170.4, 169.7 (x 2), 163.0, 83.6, 76.8, 74.2, 74.4, 70.1, 68.2, 62.1, 55.1, 21.1 (x 2), 21.0, 
20.9 ppm; HR-FAB MS [M+Na]+ calcd for C17H23NNaO10S 456.0940, found 456.0947.  
 
2,3,4,6-Tetra-O-acetyl-1-N-(4,5-dihydro-2-thione-oxazol-3-yl)-β-D-
glucopyranosylamine (2.18a) was isolated as the sole product in the attempt of the 
synthesis of  2.4a from 2.14 (80 %, Method A) and as a side product in the synthesis of 
2.4a from 2.15 (24%, Method B). Analytical data for 2.18a: Rf = 0.41 (ethyl acetate/ 
hexane, 1/1, v/v); [α]D
26 +26.8o (c = 1.13, CHCl3); UV: λmax = 300 nm; 1H-n.m.r.: δ, 5.82 
(d, 1H, J1,2 = 9.4 Hz, H-1), 5.43 (dd, 1H, J3,4 = 9.4 Hz, H-3), 5.08 (dd, 1H, J4,5 = 9.4 Hz, 
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H-4), 5.07 (dd, 1H, J2,3 = 9.5 Hz, H-2), 4.44-4.62 (m, 2H, CH2O), 4.28 (dd, 1H, J5,6a = 4.9 
Hz, J6a,6b = 12.5 Hz, H-6a), 4.11 (dd, 1H, J5,6b = 1.8 Hz, H-6b), 3.77-3.99 (m, 3H, H-5, 
CH2N), 2.03, 2.05, 2.06, 2.09 (4s, 12H, 4 x COCH3) ppm; 13C-n.m.r.: δ, 189.4, 170.7, 




(2.5a) could not be obtained by either Method A or B.  
 
2,3,4,6-Tetra-O-acetyl-1-N-(5,6-dihydro-4H-2-thione-1,3-oxazin-3-yl)-β-D-
glucopyranosylamine (2.18c) was isolated as a colorless film in the attempt of the 
synthesis of 2.5a from 2.15 (27 %, Method B). Analytical data for 2.18c: Rf = 0.50 
(acetone/ toluene, 1/3, v/v); [α]D
26 +25.7o (c = 1.25, CHCl3); UV: λmax = 300 nm; 1H-
n.m.r.: δ, 6.77 (d, 1H, J1,2 = 9.4 Hz, H-1), 5.43 (dd, 1H, J3,4 = 9.6 Hz, H-3), 5.14 (dd, 1H, 
J2,3 = 9.5 Hz, H-2), 5.05 (dd, 1H, J4,5 = 9.6 Hz, H-4), 4.20-4.37 (m, 3H, H-6a, CH2O), 
4.12 (dd, 1H, J5,6b = 1.9 Hz, J6a,6b = 12.5 Hz, H-6b), 3.89-3.94 (m, 1H, H-5), 3.51 (dd, 2H, 
CH2N), 2.13-2.16 (m, 2H, CCH2C), 2.02, 2.05, 2.07, 2.09 (4s, 12H, 4 x COCH3) ppm; 
13C-n.m.r.: δ, 188.5, 170.7, 170.6, 169.9, 169.8, 87.3, 74.5, 72.9, 68.4, 68.2, 68.1, 61.9, 
40.4, 21.1, 20.9 (x 2), 20.7 (x 2) ppm; HR-FAB MS [M+Na]+ calcd for C18H25NNaO10S 
470.1097, found 470.1090. 
 
Benzothiazol-2-yl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside (2.6a) was 
obtained as white crystals from 2.14 (Method A) or 2.15 (Method B) in 85 or 99 % yield, 
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respectively. Analytical data for 2.6a: Rf = 0.38 (ethyl acetate – toluene, 3/7, v/v) ; m.p. 
+121-124 oC (CH2Cl2/ ether/ hexane); [α]D
25 +34.7o (c = 1.04, CHCl3); UV: λmax = 276 
nm; 1H-n.m.r.: δ, 7.40-8.00 (m, 4H, aromatic), 5.59 (d, 1H, J1,2 = 10.2 Hz, H-1), 5.33 (dd, 
1H, J3,4 = 9.2 Hz, H-3), 5.25 (dd, 1H, J2,3 = 9.2 Hz, H-2), 5.19 (dd, 1H, J4,5 = 10.0 Hz, H-
4), 4.32 (dd, 1H, J5,6a = 4.9 Hz, J6a,6b = 12.5 Hz, H-6a), 4.19 (dd, 1H, J5,6b = 1.9 Hz, H-6b), 
3.94 (m, 1H, H-5), 2.05, 2.05, 2.05, 2.03 (4s, 12H, 4 x COCH3) ppm; 13C-n.m.r.: δ, 170.9, 
170.4, 169.7, 162.2, 153.1, 136.2, 126.7 (x 2), 125.4, 122.7 (x 2), 121.4 (x 2), 84.4, 74.1, 
70.1, 68.5, 62.2, 21.0, 20.9 (x 2) ppm; HR-FAB MS [M+Na]+ calcd for C21H23NNaO9S2 
520.0712, found 520.0717.  
 
5,6-Dihydro-4H-1,3-thiazin-2-yl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside 
(2.7a) was prepared as white crystals from 2.14 (Method A) or 2.15 (Method B) in 84 or 
22 % yield, respectively. Analytical data for 2.7a: Rf = 0.53 (ethyl acetate -toluene, 3/7, 
v/v) ; m.p. +102-104 oC (CH2Cl2/ ether/ hexane); [α]D
24 +9.2o (c = 1.03, CHCl3); UV: λmax 
= 274 nm; 1H-n.m.r.: δ, 5.55 (d, 1H, J1,2 = 10.5 Hz, H-1), 5.27 (dd, 1H, J3,4 = 9.2 Hz, H-
3), 5.08-5.15 (m, 2H, J2,3 = 9.2 Hz, H-2, 4), 4.27 (dd, 1H, J5,6a = 4.3 Hz, J6a,6b = 12.4 Hz, 
H-6a), 4.13 (dd, 1H, J5,6b = 2.2 Hz, H-6b), 3.74-3.84 (m, 3H, H-5, CH2N), 3.08 (m, 2H, 
CH2S), 2.08, 2.05, 2.02, 2.02 (4s, 12H, 4 x COCH3) 1.95 (m, 2H, CCH2C), ppm; 13C-
n.m.r.: δ, 171.0, 170.4, 169.7 (x 2), 152.5, 81.0, 74.5, 69.4, 68.5, 62.2, 48.9, 30.0, 28.1, 
20.8, 20.8, 20.7 (x 2), 20.4 ppm; HR-FAB MS[M+Na]+ calcd for C18H25NNaO9S2 
486.0868, found 486.0876.   
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2,3,4,6-Tetra-O-acetyl-1-N-(5,6-dihydro-4H-2-thione-1,3-thiazin-3-yl)-β-D-
glucopyranosylamine (2.18d) was isolated as a side product in the synthesis of 2.7a 
from 2.15 (18 %, Method B). Analytical data for 2.18d: Rf = 0.42 (ethyl acetate/ hexane, 
1/1, v/v); [α]D
26 +40.6o (c = 1.02, CHCl3); UV: λmax = 296 nm; 1H-n.m.r.: δ, 7.08 (d, 1H, 
J1,2 = 9.3 Hz, H-1), 5.41 (dd, 1H, J3,4 = 9.5 Hz, H-3), 5.16 (dd, 1H, J2,3 = 9.4 Hz, H-2), 
5.10 (dd, 1H, H-4), 4.26 (dd, 1H, J5,6a = 4.9 Hz,  J6a,6b = 12.5 Hz, H-6a), 4.13 (dd, 1H, J5,6b 
= 2.1 Hz , H- 6b), 3.87-3.92 (m, 1H, H-5), 3.41-3.66 (m, 2H, CH2N), 2.92 (dd, 2H, 
CH2S), 2.16 - 2.25 (m, 2H, CCH2C), 2.01, 2.04, 2.05, 2.08 (4s, 12H, 4 x COCH3) ppm; 
13C-n.m.r.: δ, 197.0, 170.7, 170.4, 169.8, 169.8, 87.7, 74.5, 72.9, 68.7, 68.3, 61.9, 44.2, 
31.8, 22.7, 20.9, 20.8, 20.7 (x 2) ppm. 
2.4.2.3 General procedure for the synthesis of 2.4b, 2.5b, 2.6b, and 2.7b:   
 
KOH (4.2 mmol) was added to a solution of 2.9, 2.10, 2.12, or 2.13 (4.2 mmol) in a 
distilled acetone. The reaction mixture was refluxed at 60 oC for 3 h, then concentrated in 
vacuo and dried to afford the corresponding potassium salts as white solids, which were 
sufficiently pure to be used in subsequent applications. A potassium salt (4.2 mmol) and 
18-crown-6 (0.42 mmol) were added to a stirred solution of 2,3,4,6-tetra-O-benzoyl-α-D-
glucopyranosyl bromide (2.16, 3.0 mmol) in dry acetone or MeCN (20 mL). The reaction 
mixture was stirred under argon for 1 h at rt. Upon completion, the mixture was diluted 
with toluene (20 mL) and washed with water (10 mL), 1% aq. NaOH (10 mL) and water 
(3 x 10 mL), the organic phase was separated, dried, and concentrated in vacuo. The 
residue was purified by silica gel column chromatography (ethyl acetate/toluene elution) 
to afford the corresponding thioimidate. 
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4,5-Dihydrooxazol-2-yl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside (2.4b) 
was obtained as white crystals in 23 % yield. Analytical data for 2.4b: Rf = 0.41 (acetone-
toluene, 1/4, v/v); m.p. +82-84 oC (CH2Cl2/ ether/ hexane); [α]D
24 +48.1o (c = 1.0, CHCl3); 
UV: λmax = 274 nm; 1H-n.m.r.: δ, 7.20-8.00 (m, 20H, aromatic), 5.93 (dd, 1H, J3,4 = 9.2 
Hz, H-3), 5.56-5.69 (m, 3H, H-1, 3, 4), 4.56 (dd, 1H, J5,6a = 2.8 Hz, J6a,6b = 12.3 Hz, H-
6a), 4.43 (dd, 1H, J5,6b = 5.2 Hz, H-6b), 4.13-4.28 (m, 3H, H-5, CH2O), 3.74 (m, 2H, 
CH2N) ppm; 13C-n.m.r.: δ, 166.0, 165.6, 165.3, 165.0, 162.5, 133.4, 133.2, 133.0, 129.9 
(x 2), 129.7 (x 4), 129.6 (x 3), 128.9, 128.6 (x 2), 128.3 (x 2), 128.3 (x 2), 128.2, 128.1 (x 
2), 125.2, 85.5, 73.9, 70.2, 69.3, 69.2, 62.9, 54.5, 29.6, 21.4 ppm; HR-FAB MS [M+Na]+ 
calcd for C37H31NNaO10S 704.1566, found 704.1573.  
 
5,6-Dihydro-4H-1,3-oxazin-2-yl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside 
(2.5b) was obtained as a colorless film in 12 % yield. Analytical data for 2.5b: Rf = 0.40 
(acetone-toluene, 1/9, v/v); [α]D
25 +25.1o (c = 0.25, CHCl3); UV: λmax = 274 nm; 1H-
n.m.r.: δ, 7.10-8.00 (m, 20H, aromatic), 5.90 (dd, 1H, J2,3 = 8.7 Hz, H-2), 5.55-5.64 (m, 
3H, H-1, 3, 4), 4.54 (dd, 1H, J5,6a = 2.9 Hz, J6a,6b = 12.2 Hz, H-6a), 4.40 (dd, 1H, J5,6b = 
5.3 Hz, H-6b), 4.04-4.21 (m, 3H, H-5, CH2O), 3.33 (m, 2H, CH2N), 1.76 (m, 2H, 
CCH2C) ppm; 13C-n.m.r.: δ, 166.3, 165.9, 165.4, 165.3, 133.7, 133.5, 133.3, 130.2, 130.0 
(x 2), 130.5 (x 4), 130.0 (x 3), 129.6, 129.4 (x 2), 129.0 (x 2), 128.9 (x 2), 128.7, 128.6, 
128.6 (x 2), 128.5, 87.7, 83.8, 75.0, 70.4 (x 2), 69.9, 63.2, 54.8, 29.9 ppm; HR-FAB MS 
[M+Na]+ calcd for C37H31NNaO10S 704.1566, found 704.1573. 
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Benzothiazol-2-yl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside (2.6b) was 
obtained as cream crystals in 88 % yield. Analytical data for 2.6b: Rf = 0.49 (ethyl 
acetate-hexanes, 2/3, v/v); m.p. +212-214 oC (CH2Cl2/ ether/ hexane); [α]D
25 +58.6o (c = 
1.03, CH2Cl2); UV: λmax = 276 nm; 1H-n.m.r.: δ, 7.20-8.10 (m, 24H, aromatic), 6.08 (dd, 
1H, J3,4 = 9.4 Hz, H-3), 5.95 (d, 1H, J1,2 = 10.2 Hz, H-1), 5.71-5.79 (m, 2H, J2,3 = 9.4 Hz, 
H-2, 4), 4.71 (dd, 1H, J5,6a = 2.1 Hz, J6a,6b = 11.8 Hz, H-6a), 4.42-4.55 (m, 2H, H-5, 6b) 
ppm; 13C-n.m.r.: δ, 166.4, 166.1, 165.6, 165.6, 62.5, 153.0, 134.0, 133.9 (x 2), 133.7 (x 
2), 133.4 (x 2), 130.3 (x 2), 130.3 (x 2), 130.1 (x 2), 130.0, 129.4(x 2), 129.0 (x 2), 128.9 
(x 3), 128.8 (x 2), 128.7 (x 2), 128.6, 126.6, 125.2, 122.6, 121.3, 84.6, 74.3, 70.8, 69.7, 
63.6 ppm; HR-FAB MS [M+Na]+ calcd for C41H31NNaO9S2 768.1338, found 768.1323. 
 
5,6-Dihydro-4H-1,3-thiazin-2-yl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside 
(2.7b) was prepared from 2.16 in 18 % yield. Alternatively it was prepared from 2.7a as 
follows: 0.1 N solution of NaOMe in MeOH was added dropwise until pH 9 to the 
solution of 2.7a (0.4 g, 0.863 mmol) in MeOH (20 mL). The reaction mixture was kept 
for 3 h at rt and then neutralized (pH 7) by the addition of Dowex (H+). The resin was 
filtered off, washed with MeOH (5 x 5 mL and the combined filtrate (35 mL) was 
concentrated in vacuo and dried. The stirring solution of the residual white solid (0.27g, 
0.914 mmol) in pyridine (16 mL) was cooled to 0 oC and benzoyl chloride (1.05 mL, 
9.146 mmol) was added dropwise. The temperature was allowed to gradually increase 
and the reaction mixture was left stirring for 16 h at rt. Upon completion, the reaction was 
quenched by slow dropwise addition of MeOH (5 mL), concentrated in vacuo and then 
coevaporated with toluene (3 x 10 mL). The residue was then diluted with CH2Cl2 (35 
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mL), washed with water (20 mL), the combined filtrate was then washed with NaHCO3 
(20 mL), water (20 mL), 1N aqueous HCl (20 mL), and water (3 x 20 mL), the organic 
layer was separated, dried and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate/toluene gradient elution) followed by 
crystallization from CH2Cl2/ ether/ hexane to afford 2.7b as cream crystals in 72 % yield. 
Analytical data for 2.7b: Rf = 0.49 (acetone-toluene, 1/9, v/v); m.p. +93-95 oC (CH2Cl2/ 
ether/ hexane); [α]D
25 +78.6o (c = 1.03, CHCl3); UV: λmax = 276 nm; 1H-n.m.r.: δ, 7.10-
8.00 (m, 20H, aromatic), 5.93 (dd, 1H, J3,4 = 9.4 Hz, H-3), 5.85 (d, 1H, J1,2 = 10.4 Hz, H-
1), 5.53-5.65 (m, 2H, J2,3 = 9.4 Hz, H-2, 4), 4.56 (dd, 1H, J5,6a = 4.6 Hz, J6a,6b = 12.2 Hz, 
H-6a), 4.41 (dd, 1H, J5,6b = 5.6 Hz, H-6b), 4.20 (m, 1H, H-5) ppm; 13C-n.m.r.: δ, 166.5, 
166.1, 165.6, 152.8, 134.0, 133.9, 133.8, 133.6, 130.6 (x 2), 130.8 (x 3), 130.4 (x 3), 
130.3 (x 2), 129.6, 129.4, 129.0 (x 2), 128.9 (x 3), 128.7 (x 4), 81.2, 76.8, 74.7, 70.3, 
69.9, 63.6, 48.9, 28.0, 20.6 ppm; HR-FAB MS [M+Na]+ calcd for C38H33NNaO9S2 
734.1494, found 734.1481.  
 
2.4.3 Synthesis of the disaccharide 2.20 
 
2.4.3.1 General AgOTf-promoted glycosylation procedure.  
 
A mixture a glycosyl donor (0.11 mmol), 2.19 (0.10 mmol), and freshly activated 
molecular sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under an atmosphere of 
argon for 1.5 h. Freshly conditioned AgOTf (0.22 mmol) was added and the reaction 
mixture was stirred for 5 min - 16 h (see Table 2) at rt, then diluted with CH2Cl2, the 
solid was filtered-off and the residue was washed with CH2Cl2. The combined filtrate (30 
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mL) was washed with 20% aq. NaHCO3 (15 mL) and water (3 x 10 mL), the organic 
phase was separated, dried and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate-hexane gradient elution) to afford 
2.20, analytical data for which were essentially the same as those previously reported.22 
2.4.3.2 General MeOTf-promoted glycosylation procedure.  
 
A mixture the glycosyl donor (0.11 mmol), 2.19 (0.10 mmol), and freshly activated 
molecular sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under an atmosphere of 
argon for 1.5 h. MeOTf (0.22 mmol) was added and the reaction mixture was stirred for 1 
- 16 h (see Table 2) at rt, then diluted with CH2Cl2, the solid was filtered-off and the 
residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% 
aq. NaHCO3 (15 mL) and water (3 x 10 mL), the organic phase was separated, dried with 
MgSO4 and concentrated in vacuo. The residue was purified by column chromatography 
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Involvement of complex glycostructures in a variety of damaging and healing processes 
has already been acknowledged by development of carbohydrate-based vaccines1-3 and 
therapeutics.4,5 Chapter 1, section 1.1, describes introduction to this class of 
Streptococcus pneumoniae (SPn) in detail and its lethal effects 
 
Amongst over ninety elucidated SPn serotypes6 (Chapter 1),  SPn6A and SPn6B are 
equally important causes of bacterial infections.7 In addition, this serogroup has been 
ranked within the top three causes of invasive pneumococcal disease worldwide.8 This 
fact stimulated extensive structural studies leading to establishing the structures of 
capsular polysaccharides of both 6A (3.1) and 6B (3.2), (Figure 3.1).9-11 Serotype-specific 
antibodies are formed in response to vaccination with the pneumococcal polysaccharide 
or saccharide-protein conjugate, so it was believed that due to similarity in the 
carbohydrate core structures of SPn6A and SPn6B, the elicited antibodies would be 
cross-reactive against both types.10, 12-14 As a result, only the hydrolytically more stable 
and, hence, mere easily accessible natural isolate of SPn6B was selected and included in 
all currently licensed multi-component vaccines. A number of linear chemical syntheses 
of SPn6B, their mimetics, and conjugates have also emerged.15-20 
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Figure 3.1 Structures of the repeating unit of SPn6A and 6B 
 
Recent cross-reactivity studies challenged the hypothesis of the cross-reactivity by 
determining that SPn6B-based vaccines produce 6B-specific antibodies that cross-react 
with SPn6A at a much lower rate.7,20-22  In this context, similar observations had also been 
made for the capsular polysaccharides types 19F and 19A.23 Hence, the importance of 
including the SPn6A carbohydrate conjugates in the future generations of multi-serotype 
anti-SPn vaccines has been acknowledged.24 However, the achievement of this is 
challenging for a number of reasons, the most important of which is low hydrolytic 
stability of SPn6A isolates that results in their low availability in sufficiently pure form.25 
A possible solution for this would be the chemical synthesis of the related sugar 
derivatives and their application as oligosaccharide-protein conjugate vaccine 
components. Although natural26 and synthetic saccharides15-17 of the SPn6A series have 
been investigated, no systematic studies have yet emerged. Herein, we discuss the 
application of the new thioimidoyl methodology developed in our laboratory to efficient 
stereoselective synthesis of pseudo di-, tri-, and tetrasaccharides (3.1-3.6, Figures 3.1 and 
3.2) structurally related to SPn6A and 6B.  
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Figure 3.2 Synthetic targets of SPn6A and 6B 
 
 
3.2 Retrosynthetic analysis 
 
SPn6A and SPn6B repeating units consist of structurally similar complex pseudo 
tetrasaccharides 3.1 and 3.2, respectively (Figure 3.1), which in the natural 
polysaccharide are connected via a phosphate (5 2”’) linkage. Both 3.1 and 3.2 bear a 
terminal D-galactosyl residue, which is α-glycosidically linked (1,2-cis) to the C-3 of a 
D-glucose unit; the latter is linked via 1,2-cis-glycosidic bond to the C-3 of L-rhamnose, 
which is connected via a α-glycosidic linkage (1,2-trans) to the C-3 of D-ribitol (SPn6A) 
or C-4 of D-ribitol (SPn6B). Efficient chemical synthesis of the repeating units of 
SPn6A, 6B (3.1 and 3.2, respectively) and structurally related glycoconjugates thereof 
(3.3-3.6, Figure 3.2) will help to quickly obtain substantial quantities of pure samples for 
immunological studies and subsequent fully synthetic vaccine development. 
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From the chemical point of view, a number of synthetic challenges could be anticipated. 
It should be noted that, even nowadays chemical synthesis of complex carbohydrates of 
this caliber, especially those containing “difficult” 1,2-cis glycosidic linkages, is still 
regarded as laborious and inefficient.27 Our goal was to investigate whether the 
application of glycosyl thioimidates, suitable building blocks for 1,2-cis 
glycosylation,28,29 would allow high 1,2-cis stereoselectivity and yields when applied to 
the synthesis of pneumococcal oligosaccharides. Therefore, the use of the anomeric 
thioimidoyl moieties, S-benzoxazolyl (SBox) or S-thiazolinyl (STaz), was projected for 
the introduction of 1,2-cis glycosidic linkages of oligosaccharides 3.1, 3.2, 3.5, and 3.6. A 
non-participating group at C-2, O-benzyl, is required to facilitate the introduction of 1,2-
cis-linked galactose and glucose units. Since the thioimidoyl moiety can be selectively 
activated over conventional thioglycosides,30 S-ethyl moiety was chosen for the 
introduction of the rhamnose unit. 
 
Having analyzed the target oligosaccharide structures and possible challenges associated 
with their synthesis, we narrowed down possible candidates for the key building blocks to 
the following compounds: D-galactose (3.7), D-glucose (3.8a and b), L-rhamnose (3.9-
3.11) and D/L- or D-ribitol (3.12 or 3.13, respectively, Scheme 3.1).31A variety of 
rhamnose derivatives were to be investigated in an attempt to optimize the 
stereoselectivity and yield of rhamnosylation.  
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Scheme  3.1 Retrosynthetic analysis of oligosaccharides of SPn6A and 6B 
 
3.3 Synthesis of building blocks 
 
 
Synthesis of the 3-OH ribitol building block 3.12 was carried out from known precursor 
3.14 as shown in Scheme 3.2.32 Thus, allylation of 3.14 was accomplished in 99% yield 
and the resulting compound 3.15 was subjected to acetal cleavage followed by 
benzylation to afford fully protected intermediate 3.17 in over 90% yield for two steps. 
Deallylation of 3.17 using PdCl2 in MeOH lead to glycosyl acceptor 3.12 in 95% yield. It 
is noteworthy that the synthesis of compound 3.12 has been previously accomplished 
using less expeditious pathway.16 Unfortunately, the direct use of 3-OH ribitol 3.14 as 
glycosyl acceptor was found to be impractical. Partial loss of acetal protecting groups 
occurred during glycosylation and resulted in the formation of an inseparable mixture.  
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3.14: R = H








Scheme  3.2  Synthesis of ribitol acceptors 3.12 and 3.13 
Synthesis of 4-OH ribitol building block 3.13, a component of SPn6B was achieved by 
the reduction of known hemiacetal 3.1833 to obtain 3.1934 in 90% yield (Scheme 3.2). The 
intermediate 3.19 was then regioselectively benzylated under phase transfer conditions to 
afford 4-OH glycosyl acceptor 3.13 as a major regioisomer in 52% yield. Other building 
blocks, D-galactose (3.7),28 D-glucose (3.8a and b),30 and L-rhamnose (3.9-3.11),35-37 
have been obtained as described previously. 
 
3.4 Oligosaccharide synthesis 
 
 
For the synthesis of pseudo disaccharides 3.3 and 3.4, the fully protected rhamnose 
building block 3.9 was used as a glycosyl donor. Coupling of 3.9 with ribitol acceptors 
3.12 and 3.13 in the presence of NIS/ TMSOTf afforded glycosides 3.20 and 3.21 with 
complete α-selectivity in 80% and 85% yield, respectively (Schemes 3.3 and 3.4). 
Complete 1,2-trans stereoselectivity achieved herein is credited to the use of a 
neighboring participating substituent in 3.9. The compounds obtained were then 
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subjected to a two-step sequential deprotection: deacylation (NaOMe in MeOH) and 
hydrogenation using palladium on charcoal to obtain the desired pseudo disaccharides 3.3 




































































Scheme  3.4  Synthesis of Pseudo Disaccharide 3.4 of SPn6B  
For the synthesis of pseudo trisaccharides 3.5, disaccharide intermediate 3.22 was 
obtained in 72% yield. This was achieved by selective activation of the STaz moiety of 
glycosyl donor 3.8a over the S-ethyl moiety of glycosyl acceptor 3.10 in the presence of 
silver(I) triflate (Scheme 3.5). This reaction proceeded with completely 1,2-cis 
stereoselectively as no traces of the 1,2- trans linked diastereomer were detected by 
analyzing the crude reaction mixture. Subsequently, the S-ethyl moiety of 3.22 was 
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activated with NIS and TMSOTf for glycosylation of glycosyl acceptors 3.12 and 3.13. 
As a result, saccharides 3.23 (Scheme 3.5) and 3.24 (Scheme 3.6) were isolated in 71% 
and 76% yield, respectively. These rhamnosylations also proceeded with complete α-
stereoselectivity. The protected pseudo trisaccharides 3.23 and 3.24 were subjected to 
standard deprotection conditions, deacylation followed by hydrogenation, to afford 




































































Scheme  3.5. Synthesis of Pseudo Trisaccharide 3.5 of SPn6A  
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Scheme  3.6  Synthesis of Pseudo Trisaccharide 3.6 of  SPn6B  
Additionally, we aimed for the synthesis of pseudo tetrasaccharides 3.1 and 3.2. For this 
purpose, we first investigated selective activation of the SBox moiety of 3.7 over the 
STaz moiety of glucosyl acceptor 3.8b. Unfortunately, this reaction resulted in the 
formation of an unseparable mixture of anomers (α/β = 7/1). This misfortune stimulated 
us to adopt a new strategy, according to which a glucosyl donor bearing the STaz leaving 
group (3.8a) was first selectively activated over the S-ethyl moiety rhamnose acceptor 
(3.11) in the presence of AgOTf. Although this reaction was performed in 1,2-
dichloroethane, a solvent that does not normally favor α-glycosylation, the disaccharide 
3.25 was obtained as a single α−anomer (1,2-cis) in 81% yield (Scheme 3.7). 
Subsequently, 3’-O-acetyl group in 3.25 was removed under Zemplen conditions and the 
resulting disaccharide acceptor 3.26 was coupled with glycosyl donor 3.7. Selective 
activation of the SBox moiety over the S-ethyl moiety was accomplished in the presence 
Synthesis of the repeating unit of Streptococcus pneumoniae 6A and 6B 
Archana R. Parameswar Page 104 of 208 7/21/2008  
of AgOTf. In this case, trisaccharide 3.27 was obtained with complete α selectivity in 
76% yield. No trace of the β-anomer could be detected by analysis of the crude reaction 
mixture. To complete the assembly, the trisaccharide 3.27 was coupled with ribitol 
acceptors 3.12 and 3.13 in the presence of NIS and TMSOTf (Schemes 3.7 and 3.8). As a 
result, pseudo tetrasaccharide derivatives 3.28 and 3.29 were obtained in 70% and 80% 
yield, respectively. Finally, the deprotection of 3.28 and 3.29 was carried out using 
conventional deacylation-hydrogenation sequence to afford pseudo tetrasaccharides 3.1 



























3.25: R = Ac
3.26: R = H









































































Scheme  3.7  Synthesis of Pseudo Tetrasaccharide 3.1 of SPn6A  
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3.5 Conclusions  
 
An efficient convergent approach to the synthesis of pneumococcal oligosaccharides of 
SPn6A and 6B for model immunological studies was developed. Rapid oligosaccharide 
assembly was accomplished by selective activation of the STaz and SBox leaving group 
of glycosyl donors over the S-ethyl anomeric moiety of glycosyl acceptors. Application 
of the STaz and SBox methodology has also allowed completely stereoselective 
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3.6 Experimental part 
 
3.6.1 General   
 
Refer to Chapter 2 (Page 81) 
3-O-Allyl-1,2:4,5-di-O-isopropylidene-D/L-ribitol (3.15). Allyl bromide (0.75 mL, 
8.62 mmol) was added to a stirring solution of 1,2:4,5-di-O-isopropylidene-D/L-ribitol 
(3.14, 1.0 g, 4.3 mmol) in dry DMF (10 mL) at 0 oC. Sodium hydride (60% suspension in 
mineral oil, 12.9 mmol) was added slowly until evolution of hydrogen gas has seized. 
The reaction mixture was stirred for 20 min at rt until complete disappearance of starting 
material as indicated by TLC. The reaction mixture was poured in crushed ice (~100 
mL), stirred for 15 min and extracted with ethyl acetate/ ether (1/1, v/v, 3 x 100 mL). The 
combined organic phase was dried over anhydrous MgSO4 and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate-hexane 
gradient elution) to afford compound 3.15 as a syrup (1.16 g, 99% yield). Analytical data: 
Rf = 0.50 (ethyl acetate - hexanes, 1/5, v/v); [α]D26 -0.7o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 
1.27, 1.35 (2s, 12H, 4 x CH3), 3.57 (dd, 1H, J3,4 = 4.8 Hz, H-3), 3.59-3.99 (m, 4H, H-1, 
5), 4.01-4.05 (m, 2H, H-2, 4), 4.17 (m, 2H, OCH2), 5.06-5.21 (m, 2H, CH2=), 5.80-5.91 
(m, 1H, =CH-) ppm; 13C-n.m.r.: δ, 25.7 (x 2), 25.8 (x 2), 66.2 (x 2), 74.2, 76.6 (x 2), 78.8, 
110.0 (x 2), 117.3, 135.3 ppm, HR-EI MS [M-CH3]+ calcd for C13H21O5 257.1384, found 
257.1389. 
 
3-O-Allyl–D/L-ribitol (3.16).  To a stirred solution of 3.15 (1.16 g, 4.6 mmol) in CH2Cl2 
(10 mL) 90% aq. trifluoroacetic acid (1 mL) was added dropwise and the reaction was 
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kept for 30 min at rt until complete disappearance of the starting material (monitored by 
TLC). The reaction mixture was neutralized with triethylamine (~ 1 mL) and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(methanol-dichloromethane gradient elution) to afford compound 3.16 as a syrup (0.81 g, 
98% yield). Analytical data: Rf = 0.46 (methanol - dichloromethane, 1/5, v/v); [α]D28 -
1.5o (c = 1.0, methanol); 1H-n.m.r. (CD3OD): δ, 3.47 (dd, 1H, J2,3 = 5.7 Hz, H-3), 3.57-
3.63 (m, 2H, H-5), 3.70-3.75 (m, 2H, H-1), 3.79-3.84 (m, 2H, H-2, 4), 4.13-4.16 (m, 2H, 
OCH2), 5.09-5.27 (m, 2H, CH2=), 5.84-5.98 (m, 1H, =CH-) ppm; 13C-n.m.r. (CD3OD): δ, 
65.1 (x 2), 72.6 (x 2), 73.9, 82.1, 117.9, 136.7 ppm; HR-FAB MS [M+Na]+ calcd for 
C8H16O5Na 215.0895, found 215.0895. 
 
3-O-Allyl-1,2,4,5-tetra-O-benzyl-D/L-ribitol (3.17).  Benzyl bromide (2.5 mL, 21.1 
mmol) was added to a stirring solution of 3.16 (0.81g, 4.21 mmol) in dry DMF (15 mL) 
at 0 oC. Sodium hydride (60% suspension in mineral oil, 1.26 g, 31.6 mmol) was added 
slowly until evolution of hydrogen gas has seized. The reaction mixture was stirred for 30 
min at rt until complete disappearance of starting material as indicated by TLC. The 
reaction mixture was poured in crushed ice (~50 mL), stirred for 15 min, extracted with 
ethyl acetate/ether (1/1, v/v, 3 x 80 mL). The combined organic extract was dried over 
anhydrous MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate-hexane gradient elution) to afford compound 
3.17 as a syrup (2.27 g, 98% yield). Analytical data for 3.17 was essentially the same as 
reported previously.16  
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1,2,4,5-Tetra-O-benzyl-D/L-ribitol (3.12).  To a stirring solution of 3.17 (1.5 g, 2.7 
mmol) in MeOH (15 mL), PdCl2 (0.6 g) was added and the reaction was stirred at rt for 
12 h. The solid was then filtered off through celite, washed with methanol (3 x 10 mL) 
and concentrated in vacuo. The residue was purified by column chromatography on silica 
gel (ethyl acetate-hexane gradient elution) to afford compound 3.12 as a syrup (1.29 g, 
93% yield). Analytical data Rf = 0.42 (ethyl acetate - hexanes, 3/7, v/v);  [α]D23 +4.3o (c = 
1.0, CHCl3); 1H-n.m.r.: δ, 3.54-3.60 (m, 2H, H-2,4), 3.63-3.68 (m, 4H, H-1, 5), 3.98 (dd, 
1H, J3,4 = 10.9 Hz, H-3), 4.38-4.62 (m, 8H, 4 x CH2Ph), 7.16-7.25 (m, 20H, aromatic) 
ppm; 13C-n.m.r. δ, 70.7 (x 2), 72.1, 72.5 (x 2), 73.9 (x 2), 78.6 (x 2), 128.1 (x 3), 128.1 (x 
3), 128.2 (x 4), 128.4 (x 4), 128.8 (x 4), 128.9 (x 4), 136.6, 138.9 ppm; HR-FAB MS 
[M+H]+ calcd for C33H37O5 513.2641, found 513.2642. It should be noted that partial 
analytical data for 3.12 was reported previously.16  
 
2,3,5-Tri-O-benzyl-D-ribitol (3.19).  To a stirring suspension of NaBH4 (350 mg, 9.2 
mmol) in absolute ethanol (17 mL) at 0 oC, was added a solution of 2,3,5-tri-O-benzyl-D-
ribose (3.18, 2.28 g, 5.4 mmol) in absolute ethanol (19 mL) and the reaction was stirred 
for 15 min at rt. Upon completion, 96% aq. acetic acid was added until pH 5 (~ 1.0 mL). 
The resulting mixture was diluted with DCM (100 mL), washed with 1M HCl (30 mL), 
and water (2 x 30 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate-hexane gradient elution) to afford compound 3.19 as a syrup (2.07 g, 90% 
yield). Analytical data: Rf = 0.53 (ethyl acetate - hexanes, 2/3, v/v); [α]D22 +19.9o (c = 
1.0, CHCl3); 1H-n.m.r.: δ, 3.55-3.58 (m, 2H, H-5), 3.69-3.76 (m, 2H, H-2, 3), 3.78-3.82 
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(m, 2H, H-1), 3.92-4.02 (m, 1H, H-4), 4.38-4.71 (m, 6H, 3 x CH2Ph), 7.13-7.21 (m, 15H, 
aromatic) ppm; 13C-n.m.r.: δ, 61.6, 71.2, 71.6, 72.6, 74.0, 74.6, 79.9, 80.0, 128.4 (x 3), 
128.5 (x 2), 128.6 (x 2), 128.7 (x 2), 129.0 (x 2), 129.1 (x 4), 138.5, 138.6 (x 2) ppm; 
HR-FAB MS [M+H]+ calcd for C26H31O5 423.2172, found 423.2176. It should be noted 
that the synthesis and partial analytical data of compound 3.19 was previously 
described.34,38 
 
1,2,3,5-Tetra-O-benzyl-D-ribitol (3.13).  To a solution of compound 3.19 (724 mg, 1.71 
mmol) in CH2Cl2 (15 mL), BnBr (0.3mL, 1.22 mmol) was added followed by Bu4NBr 
(110 mg, 0.34 mmol) and 5% aq. NaOH (4.5 mL). The reaction mixture was stirred for 
16 h under reflux (50 oC), then cooled to rt, diluted with CH2Cl2 (50 mL), and washed 
with saturated aq. NaHCO3 (15 mL) and water (3 x 15 mL). The organic phase was 
separated, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexanes gradient elution) to afford 
3.13 as white crystals (458 mg, 52% yield). Also the regioisomer (2,3,4,5-tetra-O-benzyl-
D-ribitol) was isolated in 32% yield. Analytical data for 3.13: Rf = 0.46 (ethyl acetate - 
toluene, 3/7, v/v); [α]D22 +18.1o (c = 1.0, CHCl3); m.p. 40 ºC; 1H-n.m.r.: δ, 3.59-3.61 (m, 
2H, H-5), 3.68-3.73 (m, 1H, H-3), 3.76-3.84 (m, 2H, H-1), 3.92-3.96 (m, 1H, H-2), 3.98-
4.04 (m, 1H, H-4), 4.50-4.75 (m, 8H, 4 x CH2Ph), 7.18-7.33 (m, 20H, aromatic) ppm; 
13C-n.m.r.: δ, 70.3, 71.6, 71.8, 73.1, 74.0 (x 2), 74.3. 79.5, 79.7, 128.1, 128.2 (x 2), 128.3 
(x 3), 128.4 (x 2), 128.5 (x 2), 128.6 (x 2), 128.9 (x 4), 129.0 (x 4), 138.7, 138.8, 138.9, 
139.0 ppm; HR-FAB MS [M+H]+ calcd for C33H37O5 513.2641, found 513.2642. 
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3.6.2 Preparation of disaccharides and oligosaccharides. 
 
Method A.  AgOTf-Promoted activation of the STaz and SBox glycosyl donors.  A mixture 
the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (3Å, 200 mg) in ClCH2CH2Cl (2 mL) was stirred under argon for 1.5 h. 
Freshly conditioned AgOTf (0.22 mmol) was added and the reaction mixture was stirred 
for 15 min at rt, then diluted with CH2Cl2, the solid was filtered-off and the residue was 
washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. NaHCO3 
(15 mL) and water (3 x 10 mL), the organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane gradient elution) or Sephadex LH-20 (methanol – 
dichloromethane, 1/1, v/v elution) to afford a di- or a trisaccharide derivative. 
 
Method B.  NIS/TMSOTf-promoted activation of S-ethyl glycosyl donors.  A mixture the 
glycosyl donor (0.13 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (4Å, 200 mg) in ClCH2CH2Cl (2 mL) was stirred under argon for 1 h. 
NIS (0.25 mmol) and TMSOTf (0.025 mmol) was added at 0 oC and the reaction mixture 
was stirred for 10 min. Upon completion, the solid was filtered-off and the residue was 
washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. Na2S2O3 
(15 mL) and water (3 x 10 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane gradient elution) or Sephadex LH-20 (methanol – 
dichloromethane, 1/1, v/v elution) to afford a di- or an oligosaccharide derivative. 
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3-O-(2,3,4-Tri-O-benzoyl-α-L-rhamnopyranosyl)-1,2,4,5-tetra-O-benzyl-D/L-ribitol 
(3.20).  This compound was obtained by Method B from ethyl 2,3,4-tri-O-benzoyl-1-thio-
L-rhamnopyranoside 3.9 and 3.12 in 80% yield. Analytical data for 3.20: Rf = 0.49 (ethyl 
acetate – hexanes, 3/7, v/v); [α]D22 +56.3o (c =1, CHCl3); 1H-n.m.r.: δ, 1.14 (d, 3H, H-6’), 
3.70-3.77 (m, 2H, H-1), 3.79-3.82 (m, 2H, H-5), 3.89-3.91 (m, 1H, H-2), 3.99-4.01 (m, 
1H, H-4), 4.31-4.34 (m, 2H, H-3, 5’), 4.45-4.75 (m, 8H, 4 x CH2Ph), 5.30 (s, 1H, H-1’), 
5.54-5.67 (m, 2H, H-2’, 4’), 5.73-5.87 (m, 1H, H-3’), 7.21-8.09 (m, 35H, aromatic) ppm;  
13C-n.m.r.: δ, 17.9, 67.9, 69.2, 70.3 (x 2), 71.5, 72.4, 72.7 (x 3), 73.9 (x 3), 78.5, 98.4, 
28.1 (x 3), 128.2 (x 2), 128.4 (x 2), 128.5 (x 6), 128.9 (x 6), 129.0 (x 3), 129.1 (x 2), 
129.2 (x 2), 130.1 (x 3) , 130.4 (x 4), 130.6 (x 2), 133.9 (x 3), 139.9 (x 4), 166.1, 166.2, 
166.4 ppm; HR-FAB MS [M+Na]+ calcd for C60H58O12Na 993.3826, found 993.3840. 
 
4-O-(2,3,4-Tri-O-benzoyl-α-L-rhamnnopyranosyl)-1,2,3,5-tetra-O-benzyl-D-ribitol 
(3.21).  This compound was obtained by Method B from 3.9 and 3.13 in 85% yield. 
Analytical data for 3.21: Rf = 0.51 (ethyl acetate – hexanes, 3/7, v/v); [α]D22  +39.6o (c = 
1, CHCl3); 1H-n.m.r.: δ, 1.15 (d, 3H, H-6’), 3.71-3.90 (m, 6H, H-1, 2, 3, 5), 4.26-4.36 (m, 
1H, H-5’), 4.42-4.81 (m, 9H, H-4, 4 x CH2Ph), 5.48 (s, 1H, H-1’), 5.64 (dd, 1H, J2’,3’ = 
9.9 Hz, H-3’), 5.78-5.87 (m, 2H, H-2’, 4’), 7.19-8.12 (m, 35H, aromatic) ppm; 13C-n.m.r.: 
δ, 18.0, 67.7, 70.6, 70.7, 71.4, 71.6, 72.5, 73.3, 73.9 (x 2), 76.4, 78.7, 79.5, 97.4, 128.1 (x 
2), 128.2 (x 2), 128.3 (x 3), 128.4 (x 3), 128.5 (x 3), 128.6 (x 3), 128.7 (x 2), 128.9 (x 6), 
129.1 (x 2), 129.9 (x 2), 130.0, 130.2 (x 4), 130.5 (x 2), 133.6, 133.8, 133.9, 138.7 (x 2), 
138.9 (x 2), 165.8, 165.9, 166.3 ppm; HR-FAB MS [M+Na]+ calcd for C60H58O12Na 
993.3826, found 993.3840. 
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O-(α-L-Rhamnopyranosyl)-(1→3)-D/L-ribitol (3.3). To a solution of 3.20 (100 mg, 
0.103 mmol) in dry methanol (1.0 mL) was added 1M NaOMe till pH = 10 (~0.1 mL). 
The reaction mixture was stirred for 15 h at rt, then neutralized with Dowex (H+), filtered, 
and concentrated in vacuo. The crude residue was dissolved in ethylacetate / ethanol (1/1, 
v/v, 2.0 mL) and 10% Pd/C (20 mg) was added. The reaction mixture was stirred under 
an atmosphere of H2 for 15 h. The catalyst was then filtered off, washed with methanol 
and the filtrate was concentrated under reduced pressure. The residue was purified by 
column chromatography on Sephadex G-15 (water elution) to afford compound 3.3 as a 
syrup (26.8 mg, 87% yield). Analytical data: Rf = 0.52 (methanol – dichloromethane, 1/1, 
v/v); [α]D26 -45.4o (c = 0.8, H2O);  1H-n.m.r. (D2O).: δ, 1.20 (d, 3H, H-6’), 3.37 (dd, 1H, 
J3’,4’ = 9.7 Hz, H-4’), 3.52-3.58 (m, 2H, H-1b, 5b), 3.66-3.74 (m, 5H, H-1a, 5a, 3, 3’, 5’), 
3.82-3.88 (m, 2H, H-2, 4), 3.90 (dd, 1H, J2’,3’ = 1.7 Hz, H-2’), 4.88 (d, 1H, J1’,2’ = 1.7 Hz, 
H-1’) ppm; 13C-n.m.r. (D2O).: δ, 16.9 (C-6’), 62.7 (C-1), 63.0 (C-5), 69.7 (C-5’), 70.5 (C-
3’), 70.7 (C-2’), 71.1 (C-4), 72.0 (C-2), 72.2 (C-4’), 80.2 (C-3), 100.9 (C-1’) ppm; HR-
FAB MS [M+Na]+ calcd for C11H22O9Na 321.1161, found 321.1171. 
 
O-(α-L-Rhamnopyranosyl)-(1→4)-D-ribitol (3.4).  Compound 3.4 was obtained from 
3.21 in 90% yield as described for the synthesis of compound 3.3. Analytical data: Rf = 
0.43 (methanol – dichloromethane, 1/1, v/v); [α]D25 -34.3o (c =1, H2O);  1H-n.m.r. (D2O).: 
δ, 1.23 (d, 3H, H-6’), 3.51 (dd, 1H, J3’,4’ = 9.6 Hz, H-4’), 3.69 (dd, 1H, J1a,1b = 4.9 Hz, H-
1b), 3.77-3.86 (m, 4H, H-2, 3, 3’, 5’), 3.90 (dd, 1H, H-1a), 3.93 (d, 1H, J5a,5b = 3.1 Hz, H-
5b), 3.95-3.99 (m, 2H H-4, 5a), 4.07 (dd, 1H, J2’,3’ = 1.7 Hz, H-2’), 5.07 (d, 1H,  J1’,2’ = 
1.5 Hz, H-1’) ppm; 13C-n.m.r. (D2O).: δ, 16.9 (C-6’), 59.7 (C-5), 62.9 (C-1), 69.5 (C-2), 
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70.6 (C-3’), 70.7 (C-2’), 71.9 (C-3), 72.3 (C-4’, 5’), 78.9 (C-4), 100.5 (C-1’) ppm; HR-
FAB MS [M+Na]+ calcd for C11H22O9Na 321.1161, found 321.1171. 
 
Ethyl O-(3-O-acetyl-2-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-(1→3)-2,4-
di-O-benzoyl-1-thio-α-L-rhamnopyranoside (3.22).  The title compound was obtained 
by Method A from 2-thiazolinyl 3-O-acetyl-2-O-benzyl-4,6-O-benzylidene-1-thio-β-D-
glucopyranoside (3.8a) and ethyl 2,4-di-O-benzoyl-1-thio-α-L-rhamnopyranoside (3.10) 
in 72% yield. Analytical data: Rf = 0.48 (ethyl acetate – hexanes, 3/7, v/v); [α]D22  +81.9o 
(c = 1, CHCl3); m.p. 74-76 ºC; 1H-n.m.r.: δ, 1.28 (t, 3H, CH2CH3), 1.32 (d, 3H, H-6), 
1.78 (s, 3H, COCH3), 2.59-2.72 (m, 2H, CH2CH3), 3.24 (dd, 1H, J4’,5’ = 9.6 Hz, H-4’), 
3.28-3.37 (m, 2H, H-2’, 6b’), 3.65 (dd, 1H, J4’,5’ = 4.8 Hz, H-5’), 3.84 (dd, 1H, J5’,6a’ = 4.8 
Hz, H-6’), 4.22-4.37 (m, 4H, H-3, 5, CH2Ph), 4.93 (d, 1H, J1’,2’= 3.6 Hz, H-1’), 5.15-5.19 
(m, 2H, H-3’, CHPh), 5.43 (d, 1H, J1,2 = 1.4 Hz, H-1), 5.52-5.60 (m, 2H, H-2, 4), 7.00-
8.05 (m, 20H, aromatic) ppm; 13C-n.m.r.: δ, 14.7, 15.6, 18.2, 21.4, 26.4, 30.3, 63.5, 68.1, 
69.1, 70.9, 71.6, 73.0, 73.4, 73.9, 79.8, 82.9, 96.1, 101.7, 126.8 (x 2), 128.2, 128.3 (x 2), 
128.4 (x 2), 128.8 (x 2), 129.3 (x 4), 130.0 (x 2), 130.3 (x 2), 133.7, 133.9, 137.7, 138.3, 
130.6 (x 2), 166.1, 166.9, 169.8, ppm; HR-FAB MS [M+H]+ calcd for C44H47O12S 




The title compound was obtained by Method B from 3.22 and 3.12 in 71% yield. 
Analytical data: Rf = 0.33 (ethyl acetate – hexanes, 3/7, v/v); [α]D22  +48.7o (c =1, 
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CHCl3); 1H-n.m.r.: δ, 1.15 (d, 3H, H-6’), 1.88 (s, 3H, COCH3), 3.32 (dd, 1H, J1a,1b= 9.6 
Hz, H-1a), 3.39-3.45 (m, 2H, H-2’, 5a), 3.68-3.79 (m, 4H, H-1b, 2, 4, 5b), 3.85-3.90 (m, 
2H, H-3’, H-4’), 3.96-4.02 (m, 1H, H-3), 4.20-4.34 (m, 4H, H-5’, 5’’, 6a’’, 6b’’), 4.46-
4.68 (m, 8H, 4 x CH2Ph), 5.05 (d, 1H, J1’,2’= 3.5 Hz, H-1’), 5.17-5.26 (m, 3H, H-1’’, 3’’, 
CHPh), 5.55-5.58 (m, 2H, H-2’’, 4’’), 7.00-8.07 (m, 40H, aromatic) ppm;  13C-n.m.r.: δ, 
18.3, 21.5, 63.4, 68.1, 69.2, 69.5, 69.6, 70.8, 71.0, 72.7, 72.8 (x 2), 72.9, 73.1, 73.8, 73.9, 
77.3, 77.7, 78.2, 78.6, 79.9, 95.6, 98.4, 101.8, 127.0, 128.1, 128.2 (x 4), 128.3 (x 3), 
128.5 (x 5), 128.8 (x 3), 128.9 (x 4), 129.0 (x 6), 129.1 (x 3), 129.4, 130.2 (x 2), 130.4 (x 
2), 130.7 (x 2), 133.7, 133.9, 166.2, 166.9, 169.8 ppm; HR-FAB MS [M+Na]+ calcd for 
C75H76O17Na 1271.4981, found 1271.4978. 
 
O-(3-O-Acetyl-2-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-(1→3)-O-(2,4-di-
O-benzoyl-α-L-rhamnnopyranosyl)-(1→4)-1,2,3,5-tetra-O-benzyl-D-ribitol (3.24).  
The title compound was obtained by Method B from 3.22 and 3.13 in 76% yield. 
Analytical data: Rf = 0.41 (ethyl acetate – hexanes, 3/7, v/v); [α]D22  +45.7o (c = 1, 
CHCl3); 1H-n.m.r.: δ, 1.07 (d, 3H, H-6’), 1.72 (s, 3H, COCH3), 3.20 (dd, 1H, J3’’,4’’ = 9.6 
Hz, H-4’’), 3.26-3.34 (m, 2H, H-3, 2’’), 3.55-3.67 (m, 4H, H-5, 5’’, 6b’’), 3.70-3.79 (m, 
4H, H-1, 2, 6a’’), 4.12-4.17 (m, 1H, H-5’), 4.25-4.29 (m, 1H, H-4), 4.30-4.36 (m, 1H, 
J1’,2’ = 1.3 Hz, H-1’), 5.47 (dd, 1H, J3’,4’ = 10.9 Hz, H-4’), 5.62 (d, 1H, J2’,3’ = 2.3 Hz, H-
2’) 6.80-8.02 (m, 40H, aromatic) ppm;  13C-n.m.r.: δ, 18.4, 21.5, 63.3, 68.1, 69.2, 70.7 (x 
2), 70.9, 72.2, 72.6, 73.1, 73.3, 74.0, 74.1 (x 2), 74.2, 76.4, 77.2, 79.1, 79.7, 79.9, 94.9, 
97.4, 101.7, 126.9 (x 3), 128.1, 128.2 (x 2), 128.3 (x 5), 128.4 (x 3), 128.5 (x 2), 128.6 (x 
4), 128.8 (x 2), 129.0 (x 8), 129.1 (x 2), 129.3, 130.1, 130.2, 130.3 (x 2), 130.7 (x 2), 
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133.7, 133.9, 137.7, 138.4, 138.8 (x 2), 139.0 (x 3), 166.3, 166.8, 169.8 ppm;  HR-FAB 
MS [M+Na]+ calcd for C75H76O17Na 1271.4981, found 1271.4978. 
 
O-(α-D-Glucopyranosyl)-(1→3)-O-(α-L-rhamnopyranosyl)-(1→3)-D/L-ribitol (3.5).  
The title compound was obtained from 3.23 in 80% yield as described for the synthesis of 
compound 3.3. Analytical data: Rf = 0.52 (methanol – dichloromethane- water, 9/9/2, 
v/v); [α]D26  +37.1o (c = 0.7, H2O); 1H-n.m.r. (D2O).: δ, 1.36 (d, 3H, H-6’), 3.53 (dd, 1H, 
J4’’,5’’ = 9.2 Hz, H-4’’), 3.60-3.65 (m, 2H, H-4’, 2’’), 3.68-3.74 (m, 2H, H-1b, 5b), 3.82-
3.93 (m, 8H, H-1a, 3, 5a, 3’, 5’, 3’’, 6a’’, 6b’’), 3.98-4.05 (m, 3H, H-2, 4, 5’’), 4.25 (dd, 
1H, J2’,3’ = 2.7 Hz, H-2’), 5.07 (d, 1H, J1’,2’ = 1.8 Hz, H-1’), 5.15 (d, 1H, J1’’,2’’ = 3.8 Hz, 
H-1’’) ppm; 13C-n.m.r. (D2O): δ, 17.0 (C-6’), 60.6 (C-5’), 62.7 (C-1), 63.0 (C-5), 67.4 
(C-2’), 69.7 (C-4’’), 69.8 (C-6’’), 70.5 (C-4’), 71.1 (C-2’’), 71.8 (C-5’’), 72.1 (C-2, 4), 
73.3 (C-3’’), 75.8 (C-3’), 80.2 (C-3), 95.9 (C-1’’), 100.5 (C-1’) ppm; HR-FAB MS 
[M+Na]+ calcd for C17H32O14Na 483.1690, found 483.1684. 
 
O-(α-D-Glucopyranosyl)-(1→3)-O-(α-L-rhamnopyranosyl)-(1→4)-D-ribitol (3.6).  
The title compound was obtained from 3.24 in 88% yield as described for the synthesis of 
compound 3.3. Analytical data: Rf = 0.55 (methanol – dichloromethane- water, 9/9/2, 
v/v); [α]D25  +13.2o (c = 1.0, H2O);  1H-n.m.r. (D2O).: δ, 1.35 (d, 3H, H-6’), 3.51 (dd, 1H, 
J4’’,5’’ = 9.5 Hz, H-4’’), 3.60-3.64 (m, 2H, H-4, 2’’), 3.68 (dd, 1H, J1a,1b = 6.7 Hz, H-1b), 
3.78-3.94 (m, 9H, H-1a, 2, 3, 5b, 3’, 5’, 3’’, 6a’’, 6b’’), 3.96-4.05 (m, 3H, H-4, 5a, 5’’), 
4.28 (dd, 1H, J2’,3’ = 2.4 Hz, H-2’), 5.12 (d, 1H, J1’,2’ = 1.6 Hz, H-1’), 5.14 (d, 1H, J1’’,2’’ = 
3.8 Hz, H-1’’) ppm;  13C-n.m.r. (D2O).: δ, 17.1 (C-6’), 59.8 (C-5), 60.6 (C-6’), 62.9 (C-
Synthesis of the repeating unit of Streptococcus pneumoniae 6A and 6B 
Archana R. Parameswar Page 116 of 208 7/21/2008  
1), 67.4 (C-2’), 69.7 (C-3’’, 5’), 70.6 (C-4’’), 71.8 (C-2’’), 71.9 (C-4’), 72.0 (C-3), 72.3 
(C-5’’), 73.3 (C-2), 75.9 (C-3’), 79.0 (C-4), 95.9 (C-1’’), 100.2 (C-1’) ppm; HR-FAB MS 
[M+Na]+ calcd for C17H32O14Na 483.1690, found 483.1684. 
 
Ethyl O-(3-O-acetyl-2-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-(1→3)-2,4-
di-O-benzyl-1-thio-α-L-rhamnopyranoside (3.25). The title compound was obtained 
by Method A from 3.8a and ethyl 2,4-di-O-benzyl-1-thio-α-L-rhamnopyranoside (3.11) 
in 80% yield. Analytical data for 3.25 were essentially the same as reported previously.30 
 
Ethyl O-(2-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-(1→3)-2,4-di-O-
benzyl-1-thio-α-L-rhamnopyranoside (3.26).  A solution of NaOMe in MeOH (1.0 M, 
0.2 mL, 1.0 mmol) was added to a stirred suspension of 3.25 (160 mg, 0.35 mmol) in 
methanol (2.0 mL) and the reaction mixture was stirred for 15 h at rt. The reaction was 
then neutralized with Dowex (H+), filtered, and concentrated in vacuo to yield crude 3.26 
as a white foam 99%. Analytical data: Rf = 0.38 (ethyl acetate - hexanes, 3/7, v/v); [α]D27 
7.5o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 1.20 (t, 3H, CH2CH3), 1.29 (d, 3H, H-6), 2.54 (q, 2H, 
CH2CH3), 3.44-3.52 (m, 2H, H-2’, 5’), 3.62-3.70 (m, 3H, H-3, 4’, 6a’), 3.98-4.05 (m, 4H, 
H-2, 4, 5, 6b’), 4.06-4.21 (m, 2H, H-3’, OH), 4.55-4.96 (m, 6H, 3 x CH2Ph), 5.12 (d, 1H, 
J1’,2’ = 3.5 Hz, H-1’), 5.26 (d, 1H, J1,2 =  1.8 Hz, H-1), 5.47 (s, 1H, CHPh), 7.20-7.37 (m, 
20H, aromatic) ppm;  13C-n.m.r.: δ, 15.2, 18.0, 25.6, 30.0, 62.9, 68.8, 69.1, 70.8, 72.7, 
73.0, 79.3, 80.4, 81.6, 82.0, 95.2, 102.2, 126.7 (x 2), 127.9 (x 2), 128.0 (x 2), 128.2, 128.3 
(x 2), 128.4 (x 4), 128.5 (x 2), 128.6 (x 2), 128.7 (x 2), 129.3, 137.4, 137.9, 138.2, 138.3 
ppm; HR-FAB MS [M+Na]+ calcd for C42H48O9SNa 751.2917, found 751.2929. 
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Ethyl O-(2-O-benzyl-3,4,6-tri-O-acetyl-α-D-galactopyranosyl)-(1→3)-O-(2-O-
benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-(1→3)-2,4-di-O-benzyl-1-thio-α-L-
rhamnopyranoside (3.27).  The title compound was obtained by Method A from 
benzoxazolyl 3,4,6-tri-O-acetyl-2-O-benzyl-1-thio-β-D-galactopyranoside 3.7 and 3.26 in 
76% yield.  Analytical data: Rf = 0.49 (ethyl acetate - hexanes, 3/7, v/v); [α]D26 +48.8o (c 
= 1.0, CHCl3); 1H-n.m.r.: δ, 1.25 (t, 3H, CH2CH3), 1.32 (d, 3H, H-6), 1.84, 1.97, 2.00 (3s, 
9H, 3 x COCH3), 2.56-2.66 (q, 2H, CH2CH3), 3.55 (dd, 1H, J5’’,6a’’ = 6.3 Hz, J6a’’,6b’’ = 
11.1 Hz, H-6b’’), 3.63-3.74 (m, 5H, H-2, 4, 2’, 4’, 2’’), 3.76-3.87 (m, 1H, H-6a’’), 4.04-
4.10 (m, 4H, H-3, 5, 5’, 6b’), 4.18 (dd, 1H, J5’,6a’= 5.4 Hz, J6a’,6b’ = 10.3 Hz, H-6a’), 4.25 
(d, 1H, CH2Ph), 4.39 (dd, 1H, J3’,4’ = 9.4 Hz, H-3’), 4.47-4.52 (m, 2H, H-5’’, ½ CH2Ph), 
4.61-4.74 (m, 4H, 2 x CH2Ph), 4.96 (d, 1H, ½ CH2Ph), 5.21 (d, 1H, J4’’,5’’ = 2.3 Hz, H-
4’’), 5.25 (d, 1H, J1’,2’ = 3.4 Hz, H-1’), 5.30-5.38 (m, 3H, H-1, 3’’, CHPh), 5.57 (d, 1H, 
J1’’,2’’ = 3.6 Hz, H-1’’), 6.95-7.43 (m, 25H, aromatic) ppm;  13C-n.m.r.: δ, 15.3, 18.2, 20.8, 
20.9 (x 2), 21.0 (x 2), 25.7, 31.2, 61.7, 62.7, 66.2 (x 2), 68.8 (x 2), 69.2, 71.2, 72.5 (x 2), 
72.9 (x 2), 75.7, 75.9, 80.3, 81.6, 82.9, 94.2, 96.6, 102.3, 126.7 (x 2), 126.8 (x 3), 127.3, 
127.7 (x 3), 127.9, 128.0 (x 4), 128.3 (x 3), 128.7 (x 5), 128.8 (x 3), 129.5, 137.4, 137.8, 
138.0, 138.2, 170.2, 170.3, 170.6, ppm;  HR-FAB MS [M+H]+ calcd for C61H70O17SNa 




rhamnnopyranosyl)-(1→3)-1,2,4,5-tetra-O-benzyl-D/L-ribitol (3.28) The title 
compound was obtained by Method B from 3.12 and 3.27 in 70% yield. Analytical data: 
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Rf = 0.47 (ethyl acetate - hexanes, 2/3, v/v); [α]D25 +55.4o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 
1.27 (d, 3H, H-6’), 1.82, 1.96, 1.98 (3s, 3H, 3 x COCH3), 3.52-3.57 (m, 2H, H-4’, 5b), 
3.60-3.65 (m, 5H, H-1a, 4, 4’’,6a’’, 6a’’’), 3.69-3.76 (m, 6H, H-2, 2’, 2’’’, 4’’’, 6b’’, 
6b’’’), 3.79-3.86 (m, 3H, H-5a, 3’, 5’), 3.95 (dd, 1H, H-2’’), 3.99 (m, 1H, H-5’’), 4.05-
4.13 (m, 4H, H-1b, 3, 3’’, 5’’’), 4.26 (d, 1H, ½ CH2Ph), 4.32-4.68 (m, 14H, 7 x CH2Ph), 
4.99 (d, 1H, ½ CH2Ph), 5.16 (d, 1H, J1’’’,2’’’ = 2.1 Hz, H-1’’’), 5.18 (d, 1H, J1’’,2’’ = 3.4 Hz, 
H-1’’), 5.33 (dd, 1H, J3’’’,4’’’ = 3.3 Hz, H-3’’’), 5.38 (s, 1H, CHPh), 5.56 (d, 1H, J1’,2’ = 3.4 
Hz, H-1’), 6.95-7.40 (m, 45H, aromatic) ppm;  13C-n.m.r.: δ, 18.5, 20.9, 21.2 (x 2), 30.1, 
62.0, 62.6, 66.4, 69.1, 69.3 (x 2), 70.3, 70.5, 71.3, 72.6, 72.8, 73.0 (x 2), 73.1 (x 2), 73.7, 
73.8, 74.6, 76.0, 78.3 (x 3), 78.9, 79.9, 83.2, 93.1, 96.7, 98.8, 102.5, 126.9 (x 2), 127.5 (x 
2), 127.8 (x 2), 127.9 (x 6), 128.0 (x 2), 128.1 (x 2), 128.3 (x 2), 128.4 (x 2), 128.5 (x 3), 
128.6 (x 2), 128.7 (x 5), 128.7 (x 3), 128.8 (x 2), 128.9 (x 2), 129.7, 137.6 (x 2), 138.2 (x 
2), 138.4 (x 2), 138.5 (x 2), 138.6 (x 2), 138.7 (x 2), 138.8 (x 2), 138.9 (x 2), 170.3, 





rhamnnopyranosyl)-(1→4)-1,2,3,5-tetra-O-benzyl-D-ribitol (3.29).  The title 
compound was obtained by Method B from 3.13 and 3.27 in 76% yield. Analytical data: 
Rf = 0.49 (ethyl acetate - hexanes, 3/7, v/v); [α]D27 +54.9o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 
1.25 (d, 3H, H-6’), 1.84, 1.97, 1.99 (3s, 3H, 3 x COCH3), 3.55-3.60 (m, 2H, H-5), 3.63-
3.77 (m, 10H, H-1, 2, 3, 2’, 4’, 2’’’, 4’’’, 6a’’, 6b’’’), 3.79-3.90 (m, 4H, H-4, 3’, 5’, 6b’’), 
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3.96-3.99 (m, 2H, H-2’’, 5’’), 4.08-4.11 (m, 1H, H-3’’), 4.20 (dd, 1H, J5’’’,6a’’’ =  2.7 Hz, 
J6a’’’,6b’’’ =  9.2 Hz, H-6a’’’), 4.23 (dd, 2H, CH2Ph), 4.29-4.32 (m, 1H, H-5’’’), 4.38-4.70 
(m, 12H, 6 x CH2Ph), 5.08 (dd, 2H, CH2Ph), 5.26 (d, 1H, J1’’’,2’’’ = 3.5 Hz, H-1’’’), 5.31 
(d, 1H, J1’’,2’’ = 3.4 Hz, H-1’’), 5.33  (s, 2H, H-3’’’, CHPh), 5.56 (d, 1H, J1’,2’ = 3.5 Hz, H-
1’), 7.14-7.43 (m, 45H, aromatic) ppm;  13C-n.m.r.: δ, 14.6, 18.6 (x 2), 21.1 (x 2), 21.3 (x 
3), 23.2, 30.2 (x 2), 32.4, 62.2, 62.6, 66.6, 69.2, 69.5, 70.4, 71.4, 72.6, 72.8, 72.9, 73.2, 
73.8, 73.9, 74.2, 74.9, 76.1, 78.8, 79.8, 83.3, 96.8, 97.4, 102.5, 127.1 (x 2), 127.6 (x 3), 
127.9 (x 4), 128.0, 128.1 (x 2), 128.2 (x 2), 128.3 (x 3), 128.4 (x 2), 128.5, 128.6 (x 2), 
128.7 (x 3), 128.77 (x 2), 128.80 (x 6), 128.83 (x 3), 128.9 (x 2), 129.0 (x 2), 129.1 (x 2), 
129.7, 137.7, 138.3, 138.6 (x 3), 138.7, 138.8, 138.9, 142.4, 142.7, 142.9, 170.4, 170.6, 




rhamnopyranosyl)-(1→3)-D/L-ribitol (3.1).  The title compound was obtained from 
3.28 in 75% yield as described for the synthesis of compound 3.3. Analytical data: Rf = 
0.33 (methanol – dichloromethane- water, 9/9/2, v/v); [α]D26  +78.2o (c = 0.8, H2O); 1H-
n.m.r. (D2O): δ, 1.25 (d, 3H, H-6’), 3.53 (dd, 1H, J4’,5’ = 9.7 Hz, H-4’), 3.58-3.65 (m, 4H, 
H-2’’, 4’’, 5a, 6a’’), 3.70 (dd, 2H, J6a’’’,6b’’’ = 11.2 Hz, H-6a’’’, 6b’’’), 3.72-3.82 (m, 8H, 
H-1a, 1b, 2, 3, 5b, 3’, 5’, 2’’’), 3.84-3.90 (m, 3H, H-4, 3’’, 3’’’), 3.92-3.96 (m, 3H, H-
4’’’, 5’’, 6b’’), 4.15 (dd, 1H, J2’,3’ = 2.3 Hz, H-2’), 4.19 (dd, 1H, J4’’’, 5’’’ = 6.3 Hz, H-5’’’), 
4.97 (d, 1H, J1’,2’ = 1.7 Hz, H-1’), 5.05 (d, 1H, J1’’,2’’ = 6.0 Hz, H-1’’), 5.33 (d, 1H, J1’’’,2’’’  
= 3.9 Hz, H-1’’’) ppm; 13C-n.m.r. (D2O).: δ, 16.9, 60.3, 61.1, 62.5, 62.9, 67.1, 68.8, 69.3, 
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69.6, 69.7, 70.0, 70.3, 70.4, 70.9, 71.0, 71.7, 71.9, 75.5, 79.8, 80.1, 95.6, 99.5, 100.3 
ppm; HR-FAB MS [M+Na]+ calcd for C23H42O19Na 645.2218, found 645.2210. 
 
O-(α-D-Galactopyranosyl)-(1→3)-O-(α-D-glucopyranosyl)-(1→3)-O-(α-L-
rhamnopyranosyl)-(1→4)-D-ribitol (3.2).  The title compound was obtained from 3.29 
in 78% yield as described for the synthesis of compound 3.3. Selected analytical data: Rf 
= 0.33 (methanol – dichloromethane- water, 9/9/2, v/v); [α]D27  +70.7o (c = 1.0, H2O);  
1H-n.m.r. (D2O).: δ, 1.26 (d, 3H, H-6’), 3.53 (dd, 1H, J4’,5’ = 9.7 Hz, H-4’), 3.58-3.64 (m, 
4H, H-1b, 5b, 2’’, 6a’’), 3.66-3.75 (m, 8H, H-1a, 2, 5’, 4’’, 6b’’, 2’’’, 6a’’’, 6b’’’ ), 3.78-
3.81 (m, 2H, H-3, 3’’’), 3.83-3.89 (m, 4H, H-4, 5a, 3’, 3’’), 3.94-3.96 (m, 2H, H-2’, 5’’’), 
5.02 (broad s, 1H, H-1’), 5.06 (d, 1H, J1’’, 2’’ = 3.7 Hz, H-1’’), 5.34 (d, 1H, J1’’’, 2’’’ = 3.8 
Hz, H-1’’’) ppm;  13C-n.m.r. data for 2 was essentially the same as reported previously;39  
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Streptococcus pneumoniae (SPn) have become one of the most frequent causes of 
invasive bacterial infections, particularly in patients with weakened or immature immune 
system.1 The study of the pneumococcal disease over the last 120 years has led to 
important scientific and clinical insights.2 It was also established that serogroup 6 has 
been consistently ranked second-third most frequent cause of invasive pneumococcal 
disease worldwide.3,4 This fact stimulated extensive structural5-7 and synthetic studies8-13 
of SPn6 oligosaccharides and derivatives thereof. Type 6 pneumococci are a frequent 
cause of pneumococcal disease in infants together with 14, 19F and 23F which are the so- 
called pediatric types.14,15 
 
For the most part, relatively small oligosaccharide fragments are poorly immunogenic. 
Hence, many synthetic targets get equipped with a spacer moiety, suitable for conjugation 
to the carrier protein. These conjugates were proven to significantly increase the 
immunoresponse and are immunogenic even in infants who are at greatest risk to 
infection.16-18(see Chapter 1.1). In continuation to the study aimed towards stereoselective 
synthesis of pneumococcal oligosaccharides,19 this chapter is dealing with the synthesis 
of spacer-containing pseudo tetrasaccharides (4.1 and 4.2) and derivatives thereof (4.3-
4.6) structurally related to the repeating units of SPn6 (Figure 4.1).  The spacer moiety 
will be essential for conjugation with a carrier protein and for subsequent immunological 
studies.  
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4.6: C-E  
Figure 4.1 Spacer containing analogs of SPn6A & 6B 
 
4.2 Results and discussion  
 
Efficient chemical synthesis of the spacer-containing oligosaccharides of SPn6 and 
derivatives thereof will help to quickly obtain substantial quantities of pure samples for 
conjugation and immunological studies. In chapter 3, we have already shown that the 
pseudo di-, tri- and tetrasaccharides of SPn6 series could be synthesized via selective 
activation strategy in overall excellent yields and complete stereoselectivity.19 This 
chapter describes the synthesis of spacer containing oligosaccharides (4.1-4.6), using a 
similar strategy. Nevertheless, some adjustments had been made. Recall that the synthesis 
of pseudo-tetrasaccharides 3.1 and 3.2 the assembly of ABCD tetrasaccharide was 
performed in (B+C)+A+D fashion (see Chapter 3). Herein the synthesis of spacer 
containing derivatives 4.1 and 4.2 was carried out in: A+B+(C+D) fashion. This strategic 
Synthesis of spacer containing analogs of SPn6A & 6B 
Archana R. Parameswar Page 127 of 208 7/21/2008  
adjustment required further optimization of the anomeric selectivity, and for this purpose 
two types of galactose building block have been investigated (4.7a and b, Scheme 4.1). 
Our expectation was that anisoyl group at C-4 of the galactose building block (4.7) would 
be particularly beneficial for galactosylation.20 The D-gluco and L-rhamno units will be 
introduced by using simple building blocks 4.8-4.10, whereas the synthesis of the spacer 
containing ribitol units 4.9 and 4.10 would require particular attention (Scheme 4.1).  
 
The synthesis of the SBox galactose building block (4.7) was carried out from the known 
precursor ethyl 4-O-anisoyl-2,3,6-tri-O-benzyl-1-thio-β-D-galactopyranoside (4.7)20 via 
conventional protocol involving a bromination – thioglycosylation sequence.21 2-Benzyl-
triacetate SBox galactoside 3.7 provided excellent results for the synthesis of spacerless 
oligosaccharides (see Chapter 3) and was also generated for comparison studies.21 Known 
derivatives 3.9-3.10 were projected for the introduction of units B and C and their 





































4.7: R1= Bn, R2= An
 
Scheme  4.1  Retrosynthetic analysis of spacer containing oligosaccharides of SPn6 
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Synthesis of the 3-OH ribitol building block 4.9 was carried out from known precursor 
4.119 as shown in Scheme 4.2. First, diol 4.11 was subjected to alkylation via 
dibutylstannylidene assistance that ensured excellent regioselective protection of the 
primary hydroxyl. The resulting compound 4.12, obtained in 62% yield, was then 
subjected to benzylation to afford 4.13, and the latter was deallylated using PdCl2 in 
MeOH to afford compound 4.14 in 60% yield. The bromide 4.14 was then converted to 
the corresponding azide derivative via conventional nucleophilic displacement to allow 
the requisite glycosyl acceptor 4.9 in 89% yield. For the synthesis of 4-OH ribitol 
building block 4.10, the previously synthesized precursor 3.1919 was alkylated and 
converted to azido derivative using similar reaction conditions as described for the 
synthesis of acceptor 4.9 (Scheme 4.2). 
 
Having obtained the key monosaccharide building blocks, we turned our attention to the 
oligosaccharide assembly. For the synthesis of pseudo-disaccharides 4.5 and 4.6, per-
benzoylated rhamnose building block 3.9 was used as a glycosyl donor. Coupling of 3.9 
with ribitol acceptors 4.9 and 4.10 in the presence of NIS/ TfOH afforded glycosides 4.16 
and 4.17 with complete α-selectivity in 75% and 87% yield, respectively (Schemes 4.3 
and 4.4). The compounds obtained were then subjected to a two-step sequential 
deprotection: deacylation (NaOMe in MeOH) and hydrogenation using palladium on 
charcoal in 5% HCl in EtOH to obtain pseudo disaccharides 4.5 and 4.6 in 85% and 90%, 
respectively.  
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Scheme  4.3. Synthesis of spacer containing Pseudo Disaccharide 4.5 of SPn6A 
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2. H2, Pd/C, EtOH



























Scheme  4.4. Synthesis of spacer containing Pseudo Disaccharide 4.6 of SPn6B 
For the synthesis of pseudo trisaccharides 4.3 and 4.4, the S-ethyl anomeric moiety of 
disaccharide 3.22, obtained from 3.8a and 3.10 as described previously,19 was activated 
with NIS/TfOH for glycosylation of glycosyl acceptors 4.9 and 4.10. As a result, 
saccharides 4.18 and 4.19 were isolated in 80% and 78% yield, respectively. These 
rhamnosylations also proceeded with complete α-stereoselectivity. The protected pseudo-
trisaccharides 4.18 and 4.19 were then subjected to the standard deprotection sequence, 
as described above for the synthesis of 4.5 and 4.6, to afford compounds 4.3 and 4.4 in 
88% and 78% yield, respectively (Schemes 4.5 and 4.6).  
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Scheme  4.6. Synthesis of spacer containing Pseudo Trisaccharide 4.4 of SPn6B 
 
Finally, we were aiming for the synthesis of pseudo-tetrasaccharides 4.1 and 4.2. For this 
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purpose, galactose derivative 3.7 was used as a glycosyl donor in a coupling with 4.8. 
Unfortunately, this coupling resulted in a very poor stereoselectivity (α/β = 3/1). This 
was a rather unexpected result considering the success of our previous galactosylation 
using the A+BC strategy19 (Chapter 3). To improve this, we investigated galactose donor 
4.7, containing anisoyl group at the C-4 position, a known concept to improve the 
outcome of α-galactosylations20. The SBox leaving group of 4.7 was then selectively 
activated over the SEt moiety of glucosyl acceptor 4.8. This reaction was carried out in 
diethyl ether/dichloroethane (5/1, v/v) mixture of solvents to further enhance the 
stereoselectivity. This fine-tuning of reaction conditions using a combination of 
previously elaborated methodologies allowed us to obtain the disaccharide 4.20 in 
excellent 99% yield and very good stereoselectivity. (α/β=14/1, Scheme 4.7).  
 
For the synthesis of the disaccharide acceptor 4.21, rhamnose building block 3.10 was 
glycosidated with ribitol acceptor 4.9 to afford the requisite disaccharide 4.21 in 65% 
yield. To complete the assembly, the disaccharide donor 4.20 was coupled with the 
disaccharide acceptor 4.21 in the presence of NIS and catalytic TfOH. As a result, pseudo 
tetrasaccharide derivative 4.22 was obtained in 66% yield. Finally, the deprotection of 
4.22 was carried out using conventional deacylation-hydrogenation sequence to afford 
pseudo tetrasaccharide 4.1 in 70%.  
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Scheme  4.7. Synthesis of spacer containing Pseudo Tetrasaccharide 4.1 of SPn6A  
 
For the synthesis of pseudo tetrasaccharide 4.2, corresponding to the carbohydrate part of 
the repeating unit of SPn6B, disaccharide acceptor 4.23 was obtained from building 
blocks 3.10 and 4.10 in 78% yield. Glycosylation of 4.23 with the disaccharide donor 
4.20 led to the fully protected pseudo-tetrasaccharide 4.24 in 70% yield with complete α-
stereoselectivity. The conventional deprotection of 4.24 afforded the target compound 4.2 
in 76% yield (Scheme 4.8).  
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Scheme  4.8. Synthesis of spacer containing Pseudo Tetrasaccharide 4.2 of SPn6B  
 
4.3 Conclusion  
 
In conclusion, we have developed an efficient convergent strategy for the synthesis of a 
range of spacer-containing pneumococcal oligosaccharides of serogroup 6.  The pseudo-
tetrasaccharide assembly was carried out with excellent stereoselectivity. This convergent 
assembly was carried out in lesser number of steps as compared to the synthesis of 
spacerless tetrasaccharide (Chapter 3). Further studies related to the synthesis of other 
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spacer-containing oligosaccharides and their conjugation to the carrier protein and 
subsequent immunological studies will be discussed in the subsequent chapters.  
4.4 Experimental part 
 
4.4.1 General 
Refer to Chapter 2 (p.81) 
Benzoxazolyl 4-O-anisoyl-2,3,6-tri-O-benzyl-1-thio-β-D-galactopyranoside (4.7). The 
solution of ethyl 4-O-anisoyl-2,3,6-tri-O-benzyl-1-thio-β-D-glucopyranoside20 (3.98 g, 
6.34 mmol) and activated molecular sieves (3 Å, 3.17 g) in CH2Cl2 (95 mL) was stirred 
under argon for 1 h. Freshly prepared solution of Br2 in CH2Cl2 (60 mL, 1/165, v/v) was 
then added and the reaction mixture was kept for 5 min at rt. After that, the solid was 
filtered-off and the filtrate was concentrated in vacuo at rt. Crude residue was then treated 
with KSBox (7.6 mmol) and 18-crown-6 (0.76 mmol) in dry acetone (12 mL) under 
argon for 16 h at rt. Upon completion, the mixture was diluted with dichloromethane, the 
solid was filtered-off and the residue was washed with dichloromethane. The combined 
filtrate (200 mL) was washed with 1% aq. NaOH (50 mL) and water (3 x 50 mL).The 
organic layer was separated, dried with MgSO4, and concentrated in vacuo. The residue 
was purified by silica gel column chromatography (ethyl acetate-toluene gradient elution) 
to afford 4.7 as a syrup (2.2 g, 50 %). Analytical data for 4.7: Rf = 0.46 (ethyl acetate - 
hexanes, 3/7, v/v); [α]D29 +10.8o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 3.40-3.53 (m, 2H, H-6a, 
6b), 3.69 (s, 3H, -OCH3), 3.74 (dd, 1H, J2,3 = 2.8 Hz, H-3), 3.89-3.97 (m, 2H, H-2, 5), 
4.18-4.82 (m, 6H, 4 x CH2Ph), 5.36 (dd, 1H, J3,4 = 2.3 Hz, H-4), 6.76-7.98 (m, 25H, 
aromatic) ppm; 13C-n.m.r.: δ, 56.2, 67.5, 68.6, 72.4, 74.3, 76.4, 81.9, 85.7, 110.7, 114.4, 
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119.7, 122.7, 124.9, 125.1, 128.3, 128.4, 128.5 (x 2), 128.8 (x 4), 128.9, 129.1, 132.7, 
138.1, 138.2, 138.3, 142.4, 161.9, 164.2, 165.9 ppm; HR-FAB MS [M+H]+ calcd for 
C42H40NO8 S 718.2475, found 718.2452. 
 
3-O-Allyl-2,5-di-O-benzyl-1-O-(4-bromobutyl)-D-ribitol (4.12).  To a solution of 3-O-
allyl-2,5-di-O-benzyl-D-ribitol 4.119 (871 mg, 2.34 mmol) in benzene (18 mL), freshly 
activated molecular sieves (4Å, 4 g) was added and the mixture was stirred under argon 
for 1 h. Bu2SnO (786 mg, 3.2 mmol) and Bu4NBr (784 mg, 2.4 mmol) were then added 
followed by the addition of 1,4-dibromobutane (1.3 mL, 14.0 mmol). The reaction 
mixture was refluxed for 20 h under argon, then cooled to rt. Molecular sieves were 
filtered off through a pad of celite, rinsed with toluene (2 x 5 mL), and the combined 
filtrate was then concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexanes gradient elution) to afford 4.12 as a 
colorless liquid (730 mg, 62% yield). Analytical data for 4.12: Rf = 0.50 (ethyl acetate - 
hexanes, 2/3, v/v); [α]D28 +70.1o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 1.63-1.68 (m, 2H, 
CH2sp), 1.84-1.89 (m, 2H, CH2sp), 2.81 (d, 1H, -OH), 3.33-3.43 (m, 4H, 2 x CH2sp), 
3.54-3.63 (m, 3H, H-3,5), 3.64-3.68 (m, 2H, H-1), 3.77-3.79 (m, 1H, H-2), 3.87-3.91 (m, 
1H, H-2), 3.87-3.91 (m, 1H, H-4), 4.00-4.11 (m, 2H, OCH2), 4.44-4.66 (m, 4H, 2 x 
CH2Ph), 5.08-5.18 (m, 2H, CH2=), 5.72-5.87 (m, 1H, =CH-), 7.24-7.28 (m, 10H, 
aromatic) ppm; 13C-n.m.r.: δ, 28.8, 30.2, 34.3, 70.8, 70.9, 71.4, 71.8, 73.0, 73.3, 73.9, 
79.3, 79.6, 117.4, 128.1, 128.2, 128.3 (x 2), 128.4 (x 2), 128.9 (x 2), 129.0 (x 2), 135.5, 
138.6, 138.9 ppm; HR-FAB MS [M+Na]+ calcd for  C26H35BrO5 Na 529.1566, found 
529.1542. 
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3-O-Allyl-2,4,5-tri-O-benzyl-1-O-(4-bromobutyl)-D-ribitol (4.13).  Benzyl bromide 
(0.3 mL, 2.1 mmol) was added to a stirring solution of 4.12 (0.73 g, 1.44 mmol) in dry 
DMF (10 mL) at 0 oC. Sodium hydride (60% suspension in mineral oil, 0.12 g, 2.8 mmol) 
was added slowly until evolution of hydrogen gas has seized. The reaction mixture was 
stirred for 5 h at rt until complete disappearance of the starting material, as indicated by 
TLC. The reaction mixture was poured in crushed ice (~50 mL), stirred for 15 min, 
extracted with ethyl acetate/ether (1/1, v/v, 3 x 30 mL). The combined organic extract 
was dried with anhydrous MgSO4, filtered and concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (ethyl acetate-hexane gradient elution) 
to afford compound 4.13 as a colorless liquid (0.72 g, 84% yield). Analytical data for 
4.13: Rf = 0.57 (ethyl acetate - hexanes, 2/3, v/v); [α]D28 -2.2o (c = 1.0, CHCl3); 1H-
n.m.r.: δ, 1.87-2.00 (m, 2H, CH2sp), 2.13-2.27 (m, 2H, CH2sp), 3.64-3.68 (m, 4H, 2 x 
CH2sp), 3.85-4.10 (m, 7H, H-1, 2, 3, 4, 5), 4.38-3.41 (m, 2H, OCH2), 4.75-5.00 (m, 6H, 3 
x CH2Ph), 5.36-5.50 (m, 2H, CH2=), 6.08-6.13 (m, 1H, =CH-), 7.54-7.65 (m, 15H, 
aromatic) ppm; 13C-n.m.r.: δ, 26.6, 28.5, 29.9, 70.3, 70.5, 70.9, 72.3, 72.5, 72.9, 73.5, 
78.6, 78.7, 116.5, 127.6, 127.7, 127.8 (x 2), 127.9 (x 4), 128.4 (x 4), 128.5 (x 2), 128.6, 
135.2, 135.4, 138.4, 138.6, 138.8 ppm; HR-FAB MS [M+H]+ calcd for  C33H42BrO5 
597.2216, found 597.2198. 
 
2,4,5-Tri-O-benzyl-1-O-(4-bromobutyl)-D-ribitol (4.14).  To a stirring solution of 4.13 
(0.7 g, 1.2 mmol) in MeOH (7 mL), PdCl2 (0.25 g) was added and the reaction was 
stirred at rt for 3 h. The solid was then filtered off through a pad of celite, rinsed with 
ethyl acetate (3 x 10 mL) and the combined filtrate was concentrated in vacuo. The 
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residue was purified by column chromatography on silica gel (ethyl acetate-hexane 
gradient elution) to afford compound 4.14 as a yellow syrup (0.42 g, 60% yield). 
Analytical data for 4.14: Rf = 0.45 (ethyl acetate - hexanes, 3/7, v/v); [α]D25 -3.8o (c = 
1.0, CHCl3); 1H-n.m.r.: δ, 1.69-1.76 (m, 2H, CH2sp), 1.80-1.98 (m, 2H, CH2sp), 2.97 (d, 
1H, -OH), 3.40-3.47 (m, 4H, 2 x CH2sp), 3.53-3.63 (m, 3H, H-4, 5), 3.68-3.80 (m, 3H, H-
1,2), 4.03-4.06 (m, 1H, H-3), 4.49-4.75 (m, 6H, 3 x CH2Ph), 7.26-7.33 (m, 15H, 
aromatic) ppm; 13C-n.m.r.: δ, 27.2, 28.4, 29.6, 33.9, 70.4, 70.7, 70.9, 71.2 (x 2), 71.8, 
72.2 (x 3), 73.7 (x 2), 77.6, 78.1, 127.8, 127.9 (x 2), 128.1 (x 2), 128.5 (x 4), 128.6 (x 2), 
138.3, 138.6 ppm; HR-FAB MS [M+H]+ calcd for C30H38BrO5 559.1887, found 
559.1885. 
 
1-O-(4-Azidobutyl)-2,4,5-tri-O-benzyl-D-ribitol (4.9). Sodium azide (86 mg, 1.75 
mmol) was added to a stirring solution of 4.14 (0.42 g, 0.75 mmol) in dry DMF (6 mL). 
The reaction was heated at 60 oC for 5 h, then poured in crushed ice (~30 mL), stirred for 
15 min, and extracted with ethyl acetate (3 x 20 mL). The combined organic extract was 
dried with anhydrous MgSO4 and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate-hexane gradient elution) to afford 
compound 4.9 as a colorless syrup (0.35 g, 89% yield). Analytical data for 4.9:  Rf = 0.48 
(ethyl acetate - hexanes, 2/3, v/v); [α]D29 -4.8o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 1.56 (bs, 
4H, 2 x CH2sp), 2.95 (bs, 1H, -OH), 3.17-3.24 (m, 2H, CH2sp), 3.33-3.35 (m, 2H, 
CH2sp), 3.52-3.60 (m, 2H, H-2, 4), 3.62-3.73 (m, 4H, H-1, 5), 3.95 (bs, 1H, H-3), 4.40-
4.67 (m, 6H, 3 x CH2Ph), 7.15-7.25 (m, 15H, aromatic) ppm; 13C-n.m.r.: δ, 25.8, 26.9, 
51.3, 70.6, 71.3, 71.4, 72.1, 72.4, 73.9, 78.3, 78.4, 127.6 (x 2), 127.7, 127.8 (x 2), 127.9 
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(x 4), 128.3 (x 5), 128.4 (x 4), 138.2, 138.5  ppm; HR-FAB MS [M+H]+ calcd for 
C30H38N3O5 520.2811, found 520.2827. 
 
2,3,5-Tri-O-benzyl-1-O-(4-bromobutyl)-D-ribitol (4.15).  The title compound was 
obtained from 3.1919 as described for the synthesis of compound 4.12 in 60% yield. 
Analytical data for 4.15: : Rf = 0.56 (ethyl acetate - hexanes, 2/3, v/v); [α]D29 +16.3o (c = 
1.0, CHCl3); 1H-n.m.r.: δ, 1.60-1.65 (m, 2H, CH2sp), 1.81-1.88 (m, 2H, CH2sp), 2.77 (bs, 
1H, -OH), 3.30-3.39 (m, 4H, 2 x CH2sp), 3.53-3.61 (m, 3H, H-3, 5), 3.66-3.71 (m, 2H, H-
1), 3.84-3.96 (m, 1H, H-2), 4.10-4.12 (m, 1H, H-4), 4.42-4.63 (m, 6H, 3 x CH2Ph), 7.21-
7.29 (m, 15H, aromatic) ppm; 13C-n.m.r.: δ, 28.4, 29.8, 33.9, 70.4, 70.6, 71.0, 71.3, 72.6, 
73.5  (x 2), 73.8, 79.0, 79.3, 127.7, 127.8 (x 2), 127.9 (x 2), 128.0, 128.2 (x 2), 128.5 (x 
4), 128.6, 138.1, 138.5, 138.6 ppm; HR-FAB MS [M+H]+ calcd for C30H38BrO5 
559.1887, found 559.1885 
 
1-O-(4-Azidobutyl)-2,3,5-tri-O-benzyl-D-ribitol (4.10).  The title compound was 
obtained from 4.15 as described for the preparation of compound 4.9 in 80% yield. 
Analytical data for 4.10: Rf = 0.40 (ethyl acetate - hexanes, 3/7, v/v); [α]D29 +29.0o (c = 
1.0, CHCl3); 1H-n.m.r.: δ, 1.61 (bs, 4H, 2 x CH2sp), 2.83 (d, 1H, -OH), 3.19-3.23 (m, 2H, 
CH2sp), 3.38-3.40 (m, 2H, CH2sp), 3.54-3.58 (m, 3H, H-3, 5), 3.66-3.72 (m, 2H, H-1), 
3.82-3.87 (m, 1H, H-2), 3.93 (bs, 1H, H-4), 4.42-4.69 (m, 6H, 3 x CH2Ph), 7.18-7.29 (m, 
15H, aromatic) ppm; 13C-n.m.r.: δ, 25.9, 27.0, 51.4, 70.4, 70.9, 71.0, 71.3, 72.6, 73.5, 
73.9, 79.0, 79.3, 127.7, 127.8 (x 2), 127.9 (x 4), 128.0 (x 2), 128.1 (x 2), 128.5 (x 4), 
128.6 (x 2), 138.2, 138.6  ppm; HR-FAB MS [M+H]+ calcd for C30H38N3O5 520.2811, 
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found 520.2827. 
4.4.2 Preparation of pseudo-oligosaccharides 
 
Method A.  AgOTf-Promoted activation of the SBox glycosyl donors.  A mixture of the 
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (3Å, 200 mg) in ClCH2CH2Cl (2 mL) was stirred under argon for 1.5 h. 
Freshly conditioned AgOTf (0.22 mmol) was added and the reaction mixture was stirred 
for 15 min at rt, then diluted with CH2Cl2, the solid was filtered-off and the residue was 
washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. NaHCO3 
(15 mL) and water (3 x 10 mL), the organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane gradient elution) to afford a pseudo-oligosaccharide derivative. 
 
Method B.  NIS/TfOH-promoted activation of S-ethyl glycosyl donors.  A mixture the 
glycosyl donor (0.13 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (4Å, 200 mg) in ClCH2CH2Cl (2 mL) or ether/ DCE was stirred under 
argon for 1 h. NIS (0.25 mmol) and TfOH (0.025 mmol) were added at -30 oC to 0 oC and 
the reaction mixture was stirred for 10 min. Upon completion, the solid was filtered-off 
and the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed 
with 20% aq. Na2S2O3 (15 mL) and water (3 x 10 mL). The organic phase was separated, 
dried over MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) or Sephadex LH-20 
(methanol – dichloromethane, 1/1, v/v elution) to afford a pseudo-oligosaccharide 
derivative. 
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1-O-(4-Azidobutyl)-3-O-(2,3,4-tri-O-benzoyl-α-L-rhamnopyranosyl)-2,4,5-tri-O-
benzyl-D-ribitol (4.16). The title compound was obtained by Method B from 3.9 and 4.9 
in 75% yield. Analytical data for 4.16: Rf = 0.50 (ethyl acetate – hexanes, 3/7, v/v); [α]D29 
+37.8o (c = 1, CHCl3); 1H-n.m.r.: δ, 1.11 (d, 3H, H-6’), 1.58 (bs, 4H, 2 x CH2sp), 3.18 (s, 
2H, CH2sp), 3.36 (d, 2H CH2sp), 3.66-3.70 (d, 4H, H-1, 5), 3.72-3.75 (m, 1H, H-2), 3.82-
3.86 (m, 1H, H-4), 4.20-4.32  (m, 2H, H-3, 5’), 4.40-4.60 (m, 6H, 3 x CH2Ph), 5.21 (s, 
1H, H-1’), 5.52-5.59 (m, 2H, H-2’, 4’), 5.67 (dd, 1H, J2’,3’ = 3.1 Hz, H-3’), 7.17-8.06 (m, 
30H, aromatic) ppm;  13C-n.m.r.: δ, 18.2, 26.4, 27.5, 51.9, 67.8, 69.0, 70.7, 71.2, 71.3, 
71.5, 72.4, 72.6, 72.7, 73.8, 78.3, 98.3, 128.2 (x 3), 128.4 (x 3), 128.5 (x 6), 128.9 (x 6), 
129.0 (x 3), 129.2 (x 3), 129.6, 129.8, 130.1, 130.3 (x 4) , 130.5 (x 2), 133.7, 133.9, 
134.0, 138.8, 139.0, 166.1, 166.2, 166.4 ppm; HR-FAB MS [M+Na]+ calcd for 
C57H59N3O12Na 1000.3996, found 1000.3963. 
 
1-O-(4-Aminobutyl)-3-O-(α-L-rhamnopyranosyl)-D-ribitol (4.5). To a solution of 
4.16 (60 mg, 0.06 mmol) in dry methanol (1.0 mL) was added 1M NaOMe till pH = 9 
(~0.1 mL). The reaction mixture was stirred for 15 h at rt, then neutralized with Dowex 
(H+), filtered, and concentrated in vacuo. The crude residue was dissolved in a mixture of 
ethanol/HCl (20 mL, 12/0.03, v/v) and 10% Pd/C (130 mg) was added. The reaction 
mixture was stirred under an atmosphere of H2 for 8 h. When TLC showed the formation 
of ninhydrin positive spot on the baseline, the catalyst was filtered off and the filtrate was 
neutralized with Dowex (OH-) resin and concentrated under reduced pressure. The 
residue was co-evaporated with water (2 x 2 mL) and then purified by column 
chromatography on Sephadex G-15 (water elution) to afford compound 4.5 as a syrup (19 
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mg, 85% yield). Analytical data for 4.5: [α]D26 -24.4o (c = 0.5, H2O);  1H-n.m.r. (D2O): δ, 
1.32 (d, 3H, H-6’), 1.72-1.74 (m, 4H, 2 x CH2sp), 2.99-3.02 (m, 2H, CH2sp), 3.51 (dd, 
1H, J3’,4’ = 9.6 Hz, H-4’), 3.62-3.65 (m, 2H, CH2sp), 3.69-3.71 (m, 2H, H-1b, 5b), 3.75-
3.90 (m, 5H, H-1a, 5a, 3, 3’, 5’), 3.99-4.03 (m, 2H, H-2, 4), 4.08-4.10 (m, 1H, H-2’), 4.99 
(d, 1H, J1’,2’ = 1.7 Hz, H-1’) ppm; 13C-n.m.r. (D2O).: δ, 16.9, 24.8, 26.1, 39.8, 62.7, 69.7, 
70.3, 70.5, 70.7, 70.8, 71.1, 71.8, 72.2, 80.4, 100.9 ppm; HR-FAB MS [M+H]+ calcd for 
C15H32O9N 370.2077, found 370.2071. 
 
1-O-(4-Azidobutyl)-4-O-(2,3,4-tri-O-benzoyl-α-L-rhamnopyranosyl)-2,3,5-tri-O-
benzyl-D-ribitol (4.17). The title compound was obtained by Method B from 3.9 and 
4.10 in 87% yield. Analytical data for 4.17: Rf = 0.50 (ethyl acetate – hexanes, 3/7, v/v); 
[α]D25 +61.2o (c = 1, CHCl3); 1H-n.m.r.: δ, 1.07 (d, 3H, H-6’), 1.59 (s, 4H, 2 x CH2sp), 
3.13 (d, 2H, CH2sp), 3.41-3.50 (m, 2H, CH2sp), 3.61-3.67 (m, 3H, H-3, 5), 3.71 (d, 1H, 
H-2), 3.74-3.80 (m, 2H, H-1), 4.18-4.23 (m, 1H, H-5’), 4.28-4.33 (m, 1H, H-4), 4.37-4.70 
(m, 6H, 3 x CH2Ph), 5.36 (dd, 1H, J1’,2’ = 7.4 Hz, H-1’), 5.55 (dd, 1H, J3’,4’ = 9.9 Hz, H-
3’),5.66-5.77 (m, 2H, H-2’, 4’), 7.11-8.02 (m, 30H, aromatic) ppm; 13C-n.m.r.: δ, 18.2, 
26.5, 27.6, 51.9, 67.7, 70.7, 71.3, 71.5, 71.6, 72.5, 73.4, 74.0, 74.1, 76.4, 78.8, 79.6, 97.4, 
128.2, 128.3 (x 2), 128.4 (x 3), 128.5 (x 2), 128.7 (x 2), 128.9 (x 2), 129.0 (x 6), 129.2 (x 
2), 129.9, 130.1, 130.2, 130.3 (x 4), 130.4 (x 2), 130.6 (x 2), 133.7, 133.9, 134.0, 138.7, 
138.8, 139.1, 166.1, 166.2, 166.4 ppm; HR-FAB MS [M+Na]+ calcd for C57H59N3O12Na 
1000.3996, found 1000.3963. 
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1-O-(4-Azidobutyl)-4-O-(α-L-rhamnopyranosyl)-D-ribitol (4.6). The title compound 
was obtained from 4.17 using same reaction conditions as described for the synthesis of 
compound 4.5 in 90% yield. Analytical data for 4.6: [α]D26 -81.5o (c = 1.0, H2O);  1H-
n.m.r. (D2O): δ, 1.34 (d, 3H, H-6’), 1.71-1.82 (m, 4H, 2 x CH2sp), 3.06-3.09 (m, 2H, 
CH2sp),  3.52 (dd, 1H, J3’,4’ = 9.7 Hz, H-4’), 3.60-3.69 (m, 3H, H-1b, CH2sp ), 3.75-3.85 
(m, 4H, H-2, 3, 3’, 5’), 3.89-3.95 (m, 4H, H-1a, 4, 5), 4.07 (dd, 1H, J2’,3’ = 1.7 Hz, H-2’), 
5.06 (dd, 1H,  J1’,2’ = 1.5 Hz, H-1’) ppm; 13C-n.m.r. (D2O): δ, 17.1, 24.1, 26.1, 39.7, 59.6, 
69.6, 70.6, 70.7, 70.9, 71.7, 72.3, 72.4, 78.6, 100.3 ppm; HR-FAB HR-FAB MS [M+H]+ 




ribitol (4.18). The title compound was obtained by Method B from 3.22 and 4.9 in 80% 
yield. Analytical data for 4.18: Rf = 0.38 (ethyl acetate – hexanes, 3/7, v/v); [α]D22  +50.3o 
(c = 0.8, CHCl3); 1H-n.m.r.: δ, 1.07 (d, 3H, H-6’), 1.55 (bs, 4H, 2 x CH2sp), 1.73 (s, 3H, 
COCH3), 3.13-3.19 (m, 2H, CH2sp), 3.22 (dd, 1H, J1a,1b= 9.6 Hz, H-1a), 3.32-3.40 (m, 
3H, H-2’, CH2sp), 3.59-3.73 (m, 5H, H-1b, 2, 4, 5), 3.79-3.83 (m, 3H, H-3, 3’, 4’), 4.14-
4.19 (m, 3H, H-5’, 5’’, 6b’’), 4.24-4.30 (m, 1H, H-6a’’), 4.39-4.69 (m, 8H, 4 x CH2Ph), 
4.99 (dd, 1H, J1’,2’= 3.2 Hz, H-1’), 5.10-5.17 (m, 3H, H-1’’, 3’’, CHPh), 5.45-5.51 (m, 
2H, H-2’’, 4’’), 6.94-7.99 (m, 35H, aromatic) ppm;  13C-n.m.r.: δ, 17.8, 20.9, 25.9, 27.1, 
51.4, 62.9, 67.6, 68.7, 68.9, 69.0, 70.5, 70.6, 70.8, 70.9, 72.1, 72.2, 72.4, 72.6, 73., 79., 
95.1, 97.8, 101.3, 126.5 (x 2), 127.7 (x 4), 127.8 (x 4), 127.9 (x 4), 128.0 (x 6), 128.3 (x 
4), 128.5 (x 6), 128.7 (x 4), 129.6, 129.8, 130.2, 133.3, 133.4, 137.2, 137.9, 138.4, 138.5, 
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138.6, 165.7, 166.4, 169.3 ppm; HR-FAB MS [M+Na]+ calcd for C72H77N3O17Na 
1278.5151, found 1278.5138. 
 
O-(α-D-Glucopyranosyl)-(1→3)-O-(α-L-rhamnnopyranosyl)-(1→3)-1-O-(4-
aminobutyl)-D-ribitol (4.3). The title compound was obtained from 4.18 as described 
for the synthesis of compound 4.5 in 88% yield. Analytical data for 4.3: [α]D25  +33.2o (c 
= 1.0, H2O); 1H-n.m.r. (D2O): δ, 1.35 (d, 3H, H-6’), 1.74-1.79 (m, 4H, 2 x CH2sp), 3.06-
3.08 (m, 2H, CH2sp), 3.51 (dd, 1H, J4’’,5’’ = 9.2 Hz, H-4’’), 3.58-3.65 (m, 4H, H-4’, 
2’’,CH2sp), 3.68-3.72 (m, 2H, H-1b, 5b), 3.77-3.93 (m, 8H, H-1a, 3, 5a, 3’, 5’, 3’’, 6a’’, 
6b’’), 3.99-4.03 (m, 2H, H-2, 4), 4.09-4.11 (m, 1H, H-5’’), 4.23 (dd, 1H, J2’,3’ = 2.6 Hz, 
H-2’), 5.05 (d, 1H, J1’,2’ = 1.7 Hz, H-1’), 5.15 (d, 1H, J1’’,2’’ = 3.5 Hz, H-1’’) ppm; 13C-
n.m.r. (D2O): δ, 17.2, 24.1, 26.1, 39.7, 60.7, 62.7, 62.9, 67.3, 69.7, 69.8 70.5, 70.7, 71.1, 
71.7, 72.0, 72.5, 73.3, 75.7, 80.4, 95.8, 100.5 ppm; HR-FAB MS [M+H]+ calcd for 




ribitol (4.19). The title compound was obtained by Method B from 3.22 and 4.10 in 78% 
yield. Analytical data for 4.19: Rf = 0.41 (ethyl acetate – hexanes, 3/7, v/v); [α]D22  +58.7o 
(c = 1, CHCl3); 1H-n.m.r.: δ, 1.09 (d, 3H, H-6’), 1.59 (bs, 4H, 2 x CH2sp), 1.76 (s, 3H, 
COCH3), 3.15 (bs, 2H, CH2sp), 3.26 (dd, 1H, J3’’,4’’ = 9.3 Hz, H-4’’), 3.38-3.45 (m, 4H, 
H-3, 2’’, CH2sp), 3.60-3.74 (m, 5H, H-2, 5, 5’’, 6b’’), 3.78-3.86 (m, 3H, H-1, 6a’’), 4.12-
4.15 (m, 1H, H-5’), 4.22-4.28 (m, 1H, H-4), 4.33 (s, 1H, H-3’),  4.38-4.70 (m, 8H, 4 x 
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CH2Ph), 5.12-5.18 (m, 3H, H-1’’, 3’’, CHPh), 5.36 (dd, 1H, J1’,2’ = 1.5 Hz, H-1’), 5.54 
(dd, 1H, J3’,4’ = 9.8 Hz, H-4’), 5.66 (d, 1H, J2’,3’ = 2.7 Hz, H-2’), 6.95-8.11 (m, 35H, 
aromatic) ppm;  13C-n.m.r.: δ, 17.9, 20.9, 25.9, 27.1, 51.4, 62.8, 67.6, 68.7, 70.1, 70.4, 
71.0, 71.1, 71.7, 72.1, 72.6, 72.9, 73.5, 75.7, 78.6, 79.2, 79.4, 94.4, 96.8, 101.2, 126.5 (x 
2), 127.6, 127.7 (x 3), 127.8 (x 2),  127.9 (x 3),128.0 (x 6), 128.1 (x 3), 128.3 (x 3), 128.5 
(x 6), 128.6 (x 3), 128.8, 129.6, 129.7, 129.8, 130.2, 133.2, 133.4, 137.2, 137.9, 138.2, 
138.3, 138.5, 165.7, 166.3, 169.3 ppm;  HR-FAB MS [M+Na]+ calcd for C72H77N3O17Na 
1278.5151, found 1278.5138 
 
O-(α-D-Glucopyranosyl)-(1→3)-O-(α-L-rhamnnopyranosyl)-(1→4)-1-O-(4-
aminobutyl)-D-ribitol (4.4). The title compound was obtained from 4.19 as described 
for the synthesis of compound 4.5 in 78% yield. Analytical data for 4.4: [α]D27  +25.4o (c 
= 0.4, H2O);  1H-n.m.r. (D2O).: δ, 1.35 (d, 3H, H-6’), 1.70-1.72 (m, 4H, 2 x CH2sp), 2.82-
2.84 (m, 2H, CH2sp), 3.51 (dd, 1H, J4’’,5’’ = 9.5 Hz, H-4’’), 3.61-3.65 (m, 4H, H-4’, 2’’, 
CH2sp), 3.75-3.87 (m, 7H, H-1, 2, 3, 5’, 3’’, 6a’’), 3.91-3.95 (m, 5H, H-5, 3’, 5’’, 6b’’), 
4.01-4.04 (m, 1H, H-4), 4.27 (dd, 1H, J2’,3’ = 2.5 Hz, H-2’), 5.12 (d, 1H, J1’,2’ = 1.3 Hz, H-
1’), 5.18 (d, 1H, J1’’,2’’ = 3.2 Hz, H-1’’) ppm;  13C-n.m.r. (D2O): δ, 17.1, 24.5, 26.2, 40.0, 
59.6, 60.6, 67.4, 69.7 (x 2), 70.5 (x 2), 71.2, 71.6, 71.7, 72.0, 72.4, 73.2, 75.9, 78.8, 95.9, 
99.9 ppm; HR-FAB MS [M+H]+ calcd for C21H42NO14 532.2605, found 532.2606 
 
Ethyl O-(4-O-anisoyl-2,3,6-tri-O-benzyl-α-D-galactopyranosyl)-(1→3)-2-O-benzyl-
4,6-O-benzylidene-1-thio-β-D-glucopyranoside (4.20). The title compound was 
obtained by Method A from 4.7 and 4.8 in 99% yield. Analytical data for 4.20: Rf = 0.50 
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(ethyl acetate – hexanes, 3/7, v/v); [α]D29 +42.7o (c = 1, CHCl3); 1H-n.m.r.: δ, 1.15 (t, 3H, 
CH3), 2.77- 2.81 (m, 2H, CH2), 3.16 (dd, 1H, J5’,6a’ = 5.2 Hz, J6a’,6b’ = 4.9 Hz, H-6a’), 3.34 
(dd, 1H, J5’,6b’ = 6.9 Hz, H-6b’), 3.46-3.51 (m, 1H, H-4), 3.57 (dd, 1H,  J3,4 = 4.9 Hz, H-
3), 3.81 (dd, 1H, J6a,6b = 10.3 Hz, H-6b), 3.85-3.91 (m, 4H, H-6a, 2’, -OCH3), 4.05 (dd, 
1H, J3’,4’ = 3.2 Hz, J2’,3’ = 6.9 Hz, H-3’), 4.12-4.19 (m, 4H, 2x CH2Ph), 4.33-4.37 (m, 2H, 
H-5, 5’), 4.52 (dd, 1H, J2,3 = 3.2 Hz, H-2), 4.57-4.83 (m, 4H, 2 x CH2Ph), 5.05 (dd, 1H, 
J1,2 = 7.1 Hz, H-1), 5.45 (dd, 1H, J4’,5’ = 2.6 Hz, H-4’), 5.50 (s, 1H, CHPh), 5.71 (dd, 1H, 
J1’,2’ = 3.5 Hz, H-1’), 6.85-7.95 (m, 30H, aromatic) ppm;  13C-n.m.r.: δ, 15.3, 25.3, 53.6, 
67.5, 68.9 (x 2), 70.1, 72.0, 72.3, 72.9, 74.7, 75.4, 75.8, 76.4, 80.3, 82.6, 85.2, 96.8, 
102.1, 113.7 (x 2), 127.4, 127.6 (x 2), 127.7, 127.8 (x 2), 128.1 (x 2), 128.2 (x 5), 128.4 
(x 5), 128.5 (x 3), 128.6 (x 3), 128.7 (x 3), 129.5, 132.1 (x 2), 137.3, 137.7, 138.3, 138.6 
ppm; HR-FAB MS [M+H]+ calcd for C57H61O12S 969.3883, found 969.3884. 
 
1-O-(4-Azidobutyl)-3-O-(2,4-di-O-benzoyl-α-L-rhamnnopyranosyl)-2,4,5-tri-O-
benzyl-D-ribitol (4.21). The title compound was obtained by Method B from 3.10 and 
4.9 in 65% yield. Analytical data for 4.21: Rf = 0.57 (ethyl acetate – hexanes, 2/3, v/v); 
[α]D28 -14.9o (c = 1, CHCl3); 1H-n.m.r.: δ, 1.11 (d, 3H, H-6’), 1.59 (bs, 4H, 2 x CH2sp), 
3.18-3.22 (m, 2H, CH2sp), 3.31-3.35 (m, 2H, CH2sp), 3.62-3.73 (d, 4H, H-1, 5), 3.78-
3.86 (m, 2H, H-2, 4), 4.15-4.24  (m, 3H, H-3, 3’, 5’), 4.42-4.63 (m, 6H, 3 x CH2Ph), 
5.13-5.21 (m, 2H, H-1’, 4’), 5.32-5.34 (m, 1H, H-2’), 7.19-8.11 (m, 25H, aromatic) ppm;  
13C-n.m.r.: δ, 17.7, 25.9, 27.2, 51.5, 67.0, 68.6, 69.3, 70.7, 71.0, 72.1, 72.3, 73.3, 73.5, 
75.8, 77.9, 97.5, 127.7 (x 2), 127.9 (x 3), 128.0 (x 6), 128.4 (x 6), 128.7 (x 4), 129.6, 
129.7, 130.1 (x 4), 133.7 (x 2) , 138.4 (x 2), 138.6, 166.1, 167.4 ppm; HR-FAB MS 
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The title compound was obtained by Method B from 4.20 and 4.21 in 66% yield. 
Analytical data for 4.22: Rf = 0.60 (ethyl acetate - hexanes, 2/3, v/v); [α]D28 +55.6o (c = 
1.0, CHCl3); 1H-n.m.r.: δ, 1.19 (d, 3H, H-6’), 1.60-1.64 (m, 4H, 2 x CH2sp), 3.24 (d, 4H, 
H-6a’’’, 6b’’’, CH2sp), 3.38-3.42 (m, 2H, CH2sp), 3.45-3.53 (m, 2H, H- 4’’,6a’’), 3.59 
(dd, 1H, H-2’’), 3.67-3.70 (m, 5H, H-1, 5, 2’’’), 3.76-3.80 (m, 3H, H-5’’, 6b’’, 3’’’), 3.85 
(s, 3H, -OCH3), 3.88-3.93 (m, 2H, H-2, 4), 3.97-4.05 (m, 1H, H-3), 4.07 (dd, 1H, J3’’, 4’’ = 
4.8 Hz, H-3’’), 4.17-4.28 (m, 4H, H-5’, 5’’’, CH2Ph), 4.36-4.40 (m, 3H, H-3’, CH2Ph), 
4.45-4.77 (m, 10H, 5 x CH2Ph), 5.08 (d, 1H, J1’’,2’’ = 3.5 Hz, H-1’’), 5.28 (s, 1H, H-1’’’), 
5.30 (s, 2H, H-1’, CHPh), 5.52 (dd, 1H, J3’’’,4’’’ = 3.3 Hz, H-4’’’), 5.62-5.66 (m, 2H, H-2’, 
4’), 6.81-8.09  (m, 55H, aromatic) ppm;  13C-n.m.r.: δ, 17.9, 25.9, 27.1, 36.8, 51.4, 55.6, 
62.6, 67.1, 67.8, 68.0, 68.4, 68.8, 68.9, 69.4, 70.8, 70.9, 71.7, 71.9, 72.1, 72.2, 72.3, 72.4, 
72.8, 72.9, 73.2, 73.4, 74.7, 75.9, 77.7, 77.8, 77.9, 82.9, 94.9, 96.8, 97.7, 101.9, 113.6, 
123.1, 126.8 (x 2), 127.3, 127.4, 127.6 (x 2), 127.7 (x 2), 127.9 (x 5), 127.96 (x 3), 128.0 
(x 4), 128.1 (x 6),  128.2 (x 2), 128.3 (x 4), 128.5 (x 6), 128.6 (x 3), 128.7, 128.8, 129.2, 
129.7, 129.8, 129.9, 130.2, 132.0 (x 4), 133.3, 133.5, 137.4, 137.5, 138.4, 138.5 (x 2), 
138.6 (x 2), 138.8, 163.3, 165.6, 165.8, 166.2 ppm; HR-FAB MS [M+Na]+ calcd for 
C105H109N3O23Na 1802.7344, found 1802.7366. 
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O-(α-D-Galactopyranosyl)-(1→3)-O-(α-D-glucopyranosyl)-(1→3)-O-(α-L-
rhamnopyranosyl)-(1→3)-1-O-(4-aminobutyl)-D-ribitol (4.1). The title compound was 
obtained from 4.22 in 70% yield similarly to that described for the synthesis of 
compound 4.5, the only difference being pH=12 to ensure rapid removal of the anisoyl 
moiety. Analytical data for 4.1: [α]D25  +80.8o (c = 1.0, H2O);  1H-n.m.r. (D2O).: δ, 1.21 
(d, 3H, H-6’), 1.71-1.76 (m, 4H, 2 x CH2sp), 3.04-3.07 (m, 2H, CH2sp), 3.55-3.69 (m, 
16H), 3.71-3.88 (m, 14H), 3.92-4.07 (m, 8H), 4.22-4.27 (m, 2H, H-2’, 5’’’), 5.02 (d, 1H, 
J1’,2’ = 1.8 Hz, H-1’), 5.13 (d, 1H, J1’’,2’’ = 6.3 Hz, H-1’’), 5.40 (d, 1H, J1’’’,2’’’  = 3.7 Hz, H-
1’’’) ppm; 13C-n.m.r. (D2O): δ, 17.1, 24.1, 26.1, 39.7, 60.5, 61.2, 62.7 (x 2), 67.1, 68.9, 
69.5, 69.7, 69.8, 70.1, 70.2, 70.4, 70.7, 71.1, 71.8, 72.4 (x 2), 75.5, 79.9, 80.4, 90.0, 95.7, 
99.7, 100.5 ppm; HR-FAB MS [M+H]+ calcd for C27H52NO19 694.3134 found 694.3141. 
 
1-O-(4-Azidobutyl)-4-O-(2,4-di-O-benzoyl-α-L-rhamnnopyranosyl)-2,3,5-tri-O-
benzyl-D-ribitol (4.23). The title compound was obtained by Method B from 3.10 and 
4.10 in 78% yield. Analytical data for 4.23: Rf = 0.49 (ethyl acetate – hexanes, 3/7, v/v); 
[α]D29 +3.2o (c = 0.9, CHCl3); 1H-n.m.r.: δ, 1.07 (d, 3H, H-6’), 1.56 (s, 4H, 2 x CH2sp), 
2.40 (d, 1H, -OH), 3.06-3.09 (m, 2H, CH2sp), 3.38-3.40 (d, 2H, CH2sp), 3.57-3.65 (m, 
3H, H-2, 3, 5), 3.70-3.73 (m, 2H, H-1), 4.00-4.14 (m, 2H, H-3’, 5’), 4.22 (bs, 1H, H-4), 
4.36-4.86 (m, 6H, 3 x CH2Ph), 5.14 (dd, 1H, J1’,2’ = 9.8 Hz, H-1’), 5.31-5.37  (m, 2H, H-
2’, 4’), 7.14-8.05 (m, 25H, aromatic) ppm; 13C-n.m.r.: δ, 18.2, 26.4, 27.6, 51.8, 67.3, 
67.7, 70.9, 71.3, 71.5, 73.1, 74.0, 74.1 (x 2), 76.0, 76.2, 78.5, 79.7, 97.0, 128.2, 128.3 (x 
2), 128.4 (x 3), 128.5 (x 2), 128.6 (x 2), 128.9 (x 6), 129.1 (x 2), 129.2 (x 2), 130.2, 130.5 
(x 2), 130.6 (x 2), 134.1 (x 2), 138.7, 138.9 (x 2), 166.6, 167.8  ppm; HR-FAB MS 
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The title compound was obtained by Method B from 4.20 and 4.23 in 70% yield. 
Analytical data for 29: Rf = 0.56 (ethyl acetate - hexanes, 2/3, v/v); [α]D29 +54.8 o (c = 
1.0, CHCl3); 1H-n.m.r.: δ, 1.15 (d, 3H, H-6’), 1.64 (bs, 4H, 2 x CH2sp), 3.21-3.23 (m, 4H, 
CH2sp, H-6a’’’, 6b’’’), 3.40-3.43 (m, 3H, CH2sp, H-6b’’), 3.44-3.47 (m, 1H, H-6a’’), 
3.49-3.51 (dd, 1H, H-2’’), 3.57-3.61 (m, 2H, H-2’’’, H-4’’), 3.64-3.70 (m, 5H, H-2, 3, 5, 
3’’’), 3.74-3.80 (m, 6H, H-1, 5’’, -OCH3), 3.86-3.90 (m, 1H, H-3), 3.96 (dd, 1H, J3’’,4’’ = 
9.5 Hz, H-3’’), 4.17-4.21 (m, 3H, H-5’, CH2Ph), 4.24-4.26 (m, 1H, H-5’’’), 4.33-4.35 (m, 
1H, H-4), 4.40-4.54 (m, 9H, H-3’, 4 x CH2Ph), 4.59-4.75 (m, 4H, 4 x CH2Ph), 5.16 (d, 
1H, J1’’,2’’ = 3.3 Hz, H-1’’), 5.28 (s, 2H, H-1’’’, CHPh), 5.45 (s, 1H, H-1’), 5.49 (bs, 1H, 
H-4’’’), 5.66 (dd, 1H, J4’, 5’ = 9.8 Hz, H-4’), 5.74 (bs, 1H, H-2’), 6.80-8.09 (m, 55H, 
aromatic) ppm;  13C-n.m.r.: δ, 17.9, 26.0, 27.1, 51.4, 55.6, 62.5, 67.0, 67.7, 68.1, 68.4, 
68.9, 70.2, 71.1, 71.6, 71.7, 71.8, 72.0, 72.7, 72.9, 73.0, 73.2, 73.6, 73.8, 74.7, 75.9, 76.0, 
77.4 (x 3), 78.7, 79.3, 82.8, 94.2, 96.7, 96.8, 101.8, 113.5 (x 2), 123.1, 126.7 (x 2), 127.3 
(x 2), 127.4, 127.6 (x 2), 127.8 (x 2), 127.9 (x 6), 128.0 (x 3), 128.1 (x 3), 128.15 (x 5), 
128.19 (x 3), 128.25 (x 3), 128.3 (x 3), 128.4 (x 2), 128.6 (x 6), 128.7 (x 2), 128.8 (x 2), 
129.2, 129.7, 129.9, 130.2, 131.9, 133.3, 133.5, 137.3, 137.4, 138.3 (x 2), 138.4, 138.5 (x 
2), 138.8, 163.3, 165.6, 165.7, 166.1 ppm; HR-FAB MS [M+Na]+ calcd for 
C105H109N3O23Na 1802.7344, found 1802.7366. 
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O-(α-D-Galactopyranosyl)-(1→3)-O-(α-D-glucopyranosyl)-(1→3)-O-(α-L-
rhamnopyranosyl)-(1→4)-1-O-(4-aminobutyl)-D-ribitol (4.2).  The title compound 
was obtained from 4.24 as described for the synthesis of compound 4.1 in 76% yield. 
Analytical data for 4.2: [α]D25  +73.8o (c = 0.8, H2O);  1H-n.m.r. (D2O).: δ, 1.23 (d, 3H, 
H-6’), 1.72-1.74 (m, 4H, 2 x CH2sp), 2.98-3.01 (m, 2H, CH2sp), 3.57-3.63 (m, 6H), 3.63-
3.70 (m, 7H), 3.71-3.84 (m, 12H), 3.87-3.99 (m, 9H), 4.01-4.05 (m, 2H), 4.28-4.31 (m, 
2H, H-2’, 5’’’), 5.11 (d, 1H, J1’,2’ = 1.8 Hz, H-1’), 5.16 (d, 1H, J1’’,2’’ = 3.3 Hz, H-1’’), 
5.45 (d, 1H, J1’’’,2’’’  = 3.7 Hz, H-1’’’) ppm; 13C-n.m.r. (D2O).: δ, 17.5, 24.4, 26.1, 39.8, 
60.7, 61.4, 62.1, 63.9, 67.0, 68.2, 69.9, 70.4, 70.6 (x 2), 71.1, 71.7, 72.1, 72.8, 72.9, 73.3, 
76.5, 79.8, 81.1, 96.8, 100.6, 101.5 ppm; HR-FAB MS [M+H]+ calcd for C27H52NO19 
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Streptococcus pneumoniae (SPn) is one of the most common gram-postive pathogens and 
causes many life-threatening diseases. These pathogenic pneumococci display one of 
many structurally varied carbohydrate capsules which in turn serves as a cover against 
external influences and renders the bacterium more or less resistant to non-specific host 
defense.1 As mentioned in chapter 3, 90 different pnemococcal types have been identified 
with distinct serological patterns and chemical structures.2 It is also well known that not 
all 90 serotypes are equally pathogenic. For example, serotypes 6A and 6B account for 
4.7% and 7%, respectively, for the number of cases of invasive pneumococcal disease in 
the United States.3 Since they are medically vital, the molecular natures of both SPn6A 
and 6B have been studied widely.  
 
It has been shown that the 6A/ 6B polysaccharides are actually isopolymers containing 
galactose-glucose-rhamnose-ribitol phosphate, with 6B differing only in the rhamnose-
ribitol linkage.4 Very recently, two subtypes in pneumococci were identified by the 
classic quellung reactions.5,6 Chemical studies of these capsular PS (polysaccharide’s) 
showed that the major subtype produces capsular PS galactose-glucose-rhamnose-ribitol 
phosphate which matches the 6A PS, thus the major subtype retained the name as 
serotype 6A.6 In comparision, the repeating unit of the minor subtype was found to be 
glucose-glucose-rhamnose-ribitol phosphate, hence the minor subtype was designated as 
serotype 6C.6 Based on the genetic differences between serotype 6A and 6C,5 it was 
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concluded that 6C should be included as the third member of serogroup 6 in view of its 
serological and structural relation to serotype 6A. Serotype 6C thus represents the 91st 
pneumococcal serotype, with 90 pneumococcal serotypes having previously been 
recognized. Currently available pneumococcal vaccines contain only 6B PS as it is 
presumed to induce cross-protection against 6A. Since there is significant structural 
difference of SPn6C from the currently used serotype SPn6B  (Figure 5.1), the cross- 
protection against 6C may be inadequate, and the currently available pneumococcal 
vaccines may reduce the prevalence of 6A but not 6C.5 This also makes 6C a very 
important and interesting model to study the genetic evolution in bacteria. Hence, it was 
concluded that all pneumococcal isolates should be tested for serotype 6C along with 































































Figure 5.1 Chemical repeat units of serotypes 6A, 6B and 6C 
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5.2 Results and Discussions 
 
As seen from Figure 5.1, the only structural difference between SPn6A and 6C is that the 
galactose unit present at the terminal end of SPn6A is replaced by the glucose unit for 
SPn6C. This chapter will describe the efficient chemical synthesis of both the pseudo-
tetrasaccharide (5.1, Figure 5.2) and the spacer containing pseudo-tetrasaccharide (5.2, 
Figure 5.2) corresponding to the repeating unit of SPn6C by adopting similar techniques 
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  4.9: R=CH2-CH2-CH2-CH2-N3
3.8a: R1=thiazolinyl, R2=Ac
  4.8: R1=Et, R2=H
5.3
 
Scheme  5.1 Retrosynthetic analysis of SPn6C 
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For the synthesis of pseudo-tetrasaccharide 5.1 (Scheme 5.2), two methods were adopted 
for the synthesis. The first method involved the synthesis of the ABCD tetrasaccharide by 
the (B + C) + A + D method as illustrated in Chapter 3. Building blocks of D-glucose 
(3.8a and 4.8), L-rhamnose (3.10 and 3.11) and D- ribitol (3.12 and 4.9) required for the 
synthesis of SPn6C via two different approaches were synthesized as described in 
chapters 3 and 4. D-glucose derivative (5.3) was synthesized using the same method that 
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Scheme  5.2  Synthesis of Pseudo Tetrasaccharide 5.1 by (B + C) + A + D 
method 
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Glycosidation of the SBox glucosyl donor 5.3 with the SEt disaccharide acceptor 3.26 
(see Chapter 3) was carried out to obtain the trisaccharide 5.4 in 60% yield with complete 
α-selectivity. To complete the assembly, the trisaccharide 5.4 was coupled with ribitol 
acceptor 3.12 in the presence of NIS and TMSOTf (Scheme 5.1). The resulting pseudo-
tetrasaccharide derivative of SPn6C 5.5 was obtained in 89% yield with complete 
stereoselectivity. The tetrasaccharide was then subjected to a two-step sequential 
deprotection: deacylation (NaOMe in MeOH) and hydrogenation using palladium on 
charcoal in EtOH to obtain 85% of pseudo tetrasaccharide 5.1. 
 
The second method involved the synthesis of the tetrasaccharide 5.1 (Scheme 5.3) by the 
alternative A + B + (C + D) method in accordance with that developed in Chapter 4. 
Glucosyl donor 5.3 7 bearing the SBox leaving group was selectively activated over the 
SEt moiety of glucosyl acceptor 4.8. This reaction was carried out in dichloromethane 
using AgOTf as promoter and the disaccharide 5.6 was obtained in 75% yield and 
importantly with complete stereoselectivity. For the synthesis of the disaccharide 
acceptor 5.7, rhamnose building block 3.10 was glycosidated with ribitol acceptor 4.11 to 
afford the requisite disaccharide in 65% yield. To complete the assembly, the 
disaccharide donor 5.6 was coupled with the disaccharide acceptor 5.7 in the presence of 
NIS and catalytic TfOH. As a result, pseudo-tetrasaccharide derivative 5.8 was obtained 
in 66% yield. Deprotection of 5.8 was carried out under the same conditions from 5.5 to 
5.1 to obtain the resulting pseudo-tetrasaccharide derivative 5.1 
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Scheme  5.3  Synthesis of Pseudo Tetrasaccharide 5.8 by A + B + (C + D) 
method 
 
The synthesis of the spacer containing pseudo-tetrasaccharide 5.2 (Scheme 5.4) was 
accomplished using the same protocol as described for the synthesis of 5.8. The 
disaccharide donor 5.6 was coupled to the ribitol acceptor 4.21 (refer to Chapter 4) using 
NIS/ TfOH as a promoter to afford the pseudo-tetrasaccharide 5.9 in 74% yield. The 
deprotection of 5.9 was carried out using conventional deacylation-hydrogenation 
sequence to afford the target compound 5.2 in 72%. 
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. 
(i) NaOMe, MeOH
(ii) H2, Pd/ C, 5% HCl-EtOH


































































In conclusion, the first reported chemical synthesis of the newly discovered 
pneumococcal serotype SPn6C (discovered 2007) was accomplished using an efficient 
convergent approach. 
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5.4 Experimental part 
5.4.1 General 
 
Refer to Chapter 2 (p.81) 
5.4.2 Preparation of pseudo-oligosaccharides 
 
Method A.  AgOTf-Promoted activation of the SBox glycosyl donors.  A mixture of the 
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (3Å, 200 mg) in ClCH2CH2Cl or CH2Cl2 (2 mL) was stirred under argon 
for 1.5 h. Freshly conditioned AgOTf (0.22 mmol) was added and the reaction mixture 
was stirred for 15 min at rt, then diluted with CH2Cl2, the solid was filtered-off and the 
residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% 
aq. NaHCO3 (15 mL) and water (3 x 10 mL), the organic phase was separated, dried over 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate - hexane gradient elution) to afford a pseudo-oligosaccharide 
derivative. 
 
Method B.  NIS/TfOH-promoted activation of S-ethyl glycosyl donors.  A mixture the 
glycosyl donor (0.13 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (4Å, 200 mg) in ClCH2CH2Cl (2 mL) or ether/ DCE was stirred for 1 h 
under argon. NIS (0.25 mmol) and TfOH (0.025 mmol) was added at -30oC to 0oC and 
the reaction mixture was stirred for 10 min. Upon completion, the solid was filtered-off 
and the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed 
with 20% aq. Na2S2O3 (15 mL) and water (3 x 10 mL). The organic phase was separated, 
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dried over MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) or Sephadex LH-20 





rhamnopyranoside (5.4) The title compound was obtained by Method A from 
benzoxazolyl 3,4,6-tri-O-acetyl-2-O-benzyl-1-thio-β-D-glucopyranoside 5.3 and 3.26 in 
60% yield.  Analytical data: Rf = 0.55 (ethyl acetate - hexanes, 2/3, v/v); [α]D25 +75.0o (c 
= 1.0, CHCl3); 1H-n.m.r.: δ, 1.19 (t, 3H, CH2CH3), 1.36 (d, 3H, H-6), 1.90, 1.93, 1.99 (3s, 
9H, 3 x COCH3), 2.55-2.69 (q, 2H, CH2CH3), 3.35 (dd, 1H, J2’’,3’’ = 3.6 Hz, H-2’’), 3.57-
3.79 (m, 6H, H-3, 2’, 4’, 6b’, 6a’’’, 6b’’’), 4.07-4.14 (m, 5H, H-2, 5, 5’, 6a’, ½ CH2Ph), 
4.21 (dd, 1H, J4,5= 4.8 Hz, H-4), 4.33-4.39 (m, 2H, H-3’, 5’’), 4.44-4.50 (m, 2H, CH2Ph), 
4.61-4.71 (m, 4H, 2 x CH2Ph), 4.82 (dd, 1H, J4’’,5’’ = 3.8 Hz, H-4’’), 4.99 (d, 1H, ½ 
CH2Ph), 5.27 (d, 1H, J1’,2’ = 3.5 Hz, H-1’), 5.37-5.44 (m, 3H, H-1, 3’’, CHPh), 5.49 (dd, 
1H, J1’’,2’’ = 3.6 Hz, H-1’’), 6.79-7.45 (m, 25H, aromatic) ppm;  13C-n.m.r.: δ, 15.7, 18.5, 
21.3, 21.4, 21.5, 26.1, 30.3, 61.9, 63.2, 67.4, 68.7, 69.2, 69.6, 71.2, 72.1, 72.8, 72.9, 73.9, 
75.7, 75.9, 76.4, 80.6, 81.8, 83.1, 94.5, 96.3, 102.9, 127.2 (x 2), 127.8 (x 2), 128.2, 128.3 
(x 2), 128.4, 128.6, 128.7 (x 2), 128.8 (x 2), 128.9 (x 2), 129.0 (x 2), 129.06 (x 2), 129.08 
(x 3), 129.1 (x 2), 129.3, 130.0, 137.7, 137.8, 137.9, 138.4, 138.7, 170.3, 170.7, 171.3, 
ppm;  HR-FAB MS [M+H]+ calcd for C61H70O17SNa 1129.4231, found 1129.4238. 
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 O-(3,4,6-Tri-O-acetyl-2-O-benzyl-α-D-glucopyranosyl)-(1→3)-O-(2-O-benzyl-4,6-
O-benzylidene-α-D-glucopyranosyl)-(1→3)-O-(2,4-di-O-benzyl-α-L-
rhamnnopyranosyl)-(1→3)-1,2,4,5-tetra-O-benzyl-D-ribitol (5.5) The title compound 
was obtained by Method B from 3.12 and 5.4 in 89% yield. Analytical data: Rf = 0.46 
(ethyl acetate - hexanes, 2/3, v/v); [α]D25 +55.4o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 1.18 (d, 
3H, H-6’), 1.80, 1.84, 1.90 (3s, 3H, 3 x COCH3), 3.27 (dd, J2’’’,3’’’ = 3.6 Hz, H-2’’’), 3.50-
3.70 (m, 10H, H-1, 5, 4’, 2’’, 6a’’, 6b’’, 6a’’’, 6b’’’), 3.75-3.79 (m, 1H, H-5’), 3.85-3.87 
(m, 1H, H-2’), 3.90-3.95 (m, 1H, H-4’’), 4.00-4.06 (m, 5H, H-2, 3’, 3’’, ½ CH2Ph), 4.21-
4.33 (m, 5H, H-3, 4, 5’’’, CH2Ph), 4.35-4.52 (m, 9H, 4.5 x CH2Ph), 4.57-4.61 (m, 3H, 1.5 
x CH2Ph), 4.71 (dd, 1H, J4’’’,5’’’ = 10.2 Hz, H-4’’’), 4.93 (d, 1H, ½ CH2Ph), 5.12-5.14 (m, 
2H, H-1’,1’’), 5.28-5.34 (m, 2H, H-3’’’,CHPh), 5.40 (d, 1H,  J1’’’,2’’’ = 3.5 Hz, H-1’’’), 
6.72-7.34 (m, 45H, aromatic) ppm;  13C-n.m.r.: δ, 18.2, 20.8, 20.9, 21.0, 61.5, 62.5, 66.9, 
68.2, 69.1, 70.1, 70.3, 70.6, 71.7, 71.9, 72.1, 72.4, 72.8, 73.5, 73.6 (x 2), 74.5, 74.6, 75.3, 
75.7, 78.0, 78.5, 78.7, 79.5, 82.7, 92.9, 95.8, 98.5, 102.5, 126.8 (x 2), 127.4 (x 2), 127.5 
(x 3), 127.6 (x 3), 127.7 (x 4), 127.8 (x 2), 127.9 (x 3), 128.0, 128.1 (x 2), 128.2 (x 2), 
128.3 (x 3), 128.4 (x 6), 128.5 (x 6), 128.6 (x 6), 129.6, 137.3, 137.4, 137.5, 138.1, 138.3, 
138.4, 138.5, 138.6, 138.7, 169.9, 170.3, 170.8 ppm; HR-FAB MS [M+Na]+ calcd for 
C92H100O22Na 1579.6604, found 1579.6609. 
 
O-(α-D-Glucopyranosyl)-(1→3)-O-(α-D-glucopyranosyl)-(1→3)-O-(α-L-
rhamnopyranosyl)-(1→3)-D-ribitol (5.1) To a solution of 5.5 (100 mg, 0.103 mmol) in 
dry methanol (1.0 mL) was added 1M NaOMe till pH = 10 (~0.1 mL). The reaction 
mixture was stirred for 15 h at rt, then neutralized with Dowex (H+), filtered, and 
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concentrated in vacuo. The crude residue was dissolved in ethylacetate / ethanol (1/1, v/v, 
2.0 mL) and 10% Pd/C (20 mg) was added. The reaction mixture was stirred under an 
atmosphere of H2 for 15 h. The catalyst was then filtered off, washed with methanol and 
the filtrate was concentrated under reduced pressure. The residue was purified by column 
chromatography on Sephadex G-15 (water elution) to afford compound 5.1 as a film 
(26.8 mg, 85% yield). Analytical data: Rf = 0.35 (methanol – dichloromethane- water, 
9/9/2, v/v); [α]D27  +69.2o (c = 1.0, H2O); 1H-n.m.r. (D2O): δ, 1.35 (d, 3H, H-6’), 3.50 (dd, 
1H, J4’’’,5’’’ = 9.7 Hz, H-4’’’), 3.58-3.62 (m, 3H, H-4’, 5’’, 2’’’), 3.66-3.95 (m, 14H, H-1, 
2, 5, 3’, 5’, 2’’, 5’’, 3’’’, 6a’’, 6b’’, 6a’’’, 6b’’’), 3.97-4.01 (m, 2H, H-4, 4’’), 4.04-4.09 
(m, 3H, H-3, 3’’, 5’’’), 4.25 (dd, 1H, J2’,3’ = 2.4 Hz, H-2’), 5.06 (d, 1H, J1’,2’ = 1.6 Hz, H-
1’), 5.14 (d, 1H, J1’’,2’’ = 3.8 Hz, H-1’’), 5.41 (d, 1H, J1’’’,2’’’  = 3.8 Hz, H-1’’’) ppm; 13C-
n.m.r. (D2O).: δ, 17.0, 60.4, 60.6, 62.7, 62.8, 63.0, 67.3, 69.7, 69.8, 69.9, 70.2, 70.4, 70.5, 
71.1, 71.8, 72.0, 72.1 (x 2), 72.4, 73.3, 75.7, 80.1, 80.3, 95.9, 99.7, 100.5 ppm; HR-FAB 
MS [M+Na]+ calcd for C23H42O19Na 645.2218, found 645.2210. 
  
Ethyl O-(3,4,6-Tri-O-acetyl-2-O-benzyl-α-D-glucopyranosyl)-(1→3)-2-O-benzyl-4,6-
O-benzylidene-1-thio-β-D-glucopyranoside (5.6) The title compound was obtained by 
M ethod A from Benzoxazolyl 3,4,6-tri-O-acetyl-2-O-benzyl-1-thio-β-D-glucopyranoside 
5.3 and ethyl 2-O-benzyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside 4.8 in 72% 
yield. Analytical data: Rf = 0.5 (ethyl acetate – hexanes, 2/3, v/v); [α]D25  +85.9o (c = 1, 
CHCl3); m.p. 74-76 ºC; 1H-n.m.r.: δ, 1.35 (t, 3H, CH2CH3), 1.93, 1.95, 1.99 (3s, 9H, 3 x 
COCH3), 2.71-2.90 (m, 2H, CH2CH3), 3.38 (dd, 1H, J2’,3’ = 3.6 Hz, H-2’), 3.49-3.59 (m, 
2H, H-2, 6a), 3.65 (dd, 2H, J6a’,6b’ = 1.9 Hz, H-6a’, H-6b’), 3.73-3.87 (m, 2H, H-4, 5), 
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4.08-4.19 (m, 3H, H-6b, 5’, ½ CH2Ph), 4.34 (dd, 1H, J3,4 = 4.9 Hz, H-3), 4.54 (d, 1H, ½ 
CH2Ph), 4.65 (d, 1H, J1,2 = 9.47 Hz, H-1), 4.69 (d, 1H, ½ CH2Ph), 4.84 (dd, 1H, J3’,4’= 9.9 
Hz, H-4’), 5.13 (d, 1H, ½ CH2Ph), 5.40-5.46 (m, 2H, H-3’, CHPh), 5.63 (d, 1H, J1’,2’= 3.5 
Hz, H-1’),  6.85-7.43 (m, 15H, aromatic) ppm; 13C-n.m.r.: δ, 15.2, 20.7, 20.8, 21.0, 25.3, 
60.5, 61.2, 67.1, 68.0, 68.9, 70.1, 70.9, 71.5, 75.3, 75.8, 79.5, 82.2, 86.1, 95.8, 102.4, 
126.6 (x 2), 127.4, (x 4), 127.8 (x 3), 128.4, 128.5 (x 3), 128.6 (x 3), 129.7, 137.1, 137.4, 
137.8, 169.7, 170.2, 170.7, ppm; HR-FAB MS [M+Na]+ calcd for C41H48O13SNa 
803.2713, found 803.2722. 
 
3-O-(2,4-di-O-benzoyl-α-L-rhamnnopyranosyl)-1,2,4,5-tetra-O-benzyl-D-ribitol  
(5.7) The title compound was obtained by Method B from 3.10 and 3.12 in 65% yield. 
Analytical data for 4.21: Rf = 0.42 (ethyl acetate – hexanes, 3/7, v/v); [α]D25 -8.3o (c = 1, 
CHCl3); 1H-n.m.r.: δ, 1.04 (d, 3H, H-6’), 3.56-3.70 (d, 4H, H-1, 5), 3.76-3.79 (m, 1H, H-
2), 3.88-3.91 (m, 1H, H-4), 4.08-4.20  (m, 3H, H-3, 3’, 5’), 4.37-4.59 (m, 8H, 4 x 
CH2Ph), 5.05-5.16 (m, 2H, H-1’, 4’), 5.27-5.29 (m, 1H, H-2’), 7.04-8.03 (m, 30H, 
aromatic) ppm;  13C-n.m.r.: δ, 18.1, 67.4, 69.0, 69.5, 70.6, 70.7, 72.5, 72.6, 72.7, 73.7 (x 
2), 73.9, 74.0, 76.1, 78.4, 78.6, 97.8, 128.0 (x 2), 128.1 (x 2), 128.2, 128.3 (x 2), 128.4(x 
4), 128.5 (x 2), 128.8 (x 4), 128.9 (x 3), 129.0 (x 2), 129.1 (x 2), 130.0, 130.1, 130.4 (x 
2), 130.5 (x 2), 138.8 (x 2), 138.9, 139.0, 166.5, 167.7 ppm; HR-FAB MS [M+Na]+ calcd 
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rhamnnopyranosyl)-(1→3)-1,2,4,5-tetra-O-benzyl-D-ribitol (5.8). The title compound 
was obtained by Method B from 5.6 and 5.7 in 66% yield. Analytical data for 5.8: Rf = 
0.41 (ethyl acetate - hexanes, 2/3, v/v); [α]D25 +55.6o (c = 1.0, CHCl3); 1H-n.m.r.: δ, 1.09 
(d, 3H, H-6’), 1.80, 1.94, 1.99 (3s, 3H, 3 x COCH3), 3.24 (dd, J2’’’,3’’’ = 3.5 Hz, H-2’’’), 
3.45-3.59 (m, 4H, H-2, 5, 2’’), 3.67-3.82 (m, 7H, H-1, 5’’, 6a’’, 6b’’, 6a’’’, 6b’’’), 3.87-
3.90 (m, 1H, H-4’’), 3.94-4.00 (m, 3H, H-3, 4, 3’’), 4.11-4.13 (m, 1H, J5’’’, 6a’’’ = 10.4 Hz, 
H-5’’’), 4.24-4.31 (m, 3H, H-5’,CH2Ph), 4.35-4.40 (m, 1H, H-3’), 4.45-4.74 (m, 11H, H-
4’’’, 5 x CH2Ph), 5.13 (d, 1H, J1’’,2’’ = 3.4 Hz, H-1’’), 5.21-5.27 (m, 4H, H-1’, 1’’’, 3’’’,  
CHPh), 5.58-5.64 (m, 2H, H-2’,4’), 6.70-8.12  (m, 45H, aromatic) ppm;  13C-n.m.r.: δ, 
17.8, 20.7, 20.9, 21.0, 29.9, 61.3, 62.6, 66.9, 67.8, 67.9, 68.9, 69.3, 70.3, 70.6, 71.6, 72.3 
(x 2), 72.7, 73.4 (x 2), 75.2, 78.1, 82.5, 94.6, 95.5, 97.8, 102.2, 126.8 (x 3), 127.4 (x 3), 
127.7 (x 8), 127.9 (x 3), 128.0 (x 4), 128.1 (x 8),  128.3 (x 5), 128.5 (x 8), 128.8 (x 3), 
129.5, 129.6, 129.8, 129.9 (x 2), 130.2 (x 2), 133.4, 133.7, 137.2, 137.3, 137.5, 138.5 (x 
2), 138.6, 163.3, 165.7, 166.1, 169.8, 170.2, 170.8 ppm; HR-FAB MS [M+Na]+ calcd for 




rhamnnopyranosyl)-(1→3)-1-O-(4-azidobutyl)-2,4,5-tri-O-benzyl-D-ribitol (5.9). The 
title compound was obtained by Method B from 5.6 and 4.21 in 74% yield. Analytical 
data for 5.9: Rf = 0.41 (ethyl acetate - hexanes, 2/3, v/v); [α]D25 +55.6o (c = 1.0, CHCl3); 
1H-n.m.r.: δ, 1.22 (d, 3H, H-6’), 1.64-1.68 (m, 4H, 2 x CH2sp), 1.82, 1.96, 2.01 (3s, 3H, 3 
x COCH3), 3.24-3.28 (m, 3H, H-2’’’, CH2sp), 3.40-3.45 (m, 2H, CH2sp), 3.48-3.62 (m, 
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4H, H-2, 5, 2’’), 3.70-3.85 (m, 7H, H-1, 5’’, 6a’’, 6b’’, 6a’’’, 6b’’’), 3.91-3.95 (m, 2H, H-
4, 4’’), 3.98-4.03 (m, 2H, H-3, 3’’), 4.11-4.14 (m, 1H, H-5’’’), 4.25-4.33 (m, 2H, H-5’, ½ 
CH2Ph), 4.38-4.43 (m, 2H, H-3’, ½ CH2Ph), 4.50-4.54 (m, 2H, CH2Ph), 4.68-4.78 (m, 
7H, H-4’’’, 3 x CH2Ph), 5.16 (d, 1H, J1’’,2’’ = 3.5 Hz, H-1’’), 5.23-5.30 (m, 4H, H-1’, 1’’’, 
3’’’, CHPh), 5.64-5.68 (m, 2H, H-2’,4’), 6.75-8.16  (m, 45H, aromatic) ppm;  13C-n.m.r.: 
δ, 17.8, 20.7, 20.9, 21.0, 26.0, 27.1, 51.4, 61.2, 62.6, 66.9, 68.8, 68.9, 68.9, 69.1, 70.6, 
70.8, 70.9, 71.6, 72.1, 72.2, 72.4, 72.7, 73.4, 75.2, 77.9, 82.4, 94.5, 95.5, 97.8, 102.2, 
126.8 (x 2), 127.4 (x 3), 127.7 (x 2), 127.8 (x 5), 127.9 (x 3), 128.0 (x 5), 128.1 (x 5),  
128.3 (x 5), 128.5 (x 5), 128.8 (x 3), 129.5, 129.6, 129.7, 129.9 (x 2), 130.2 (x 2), 133.4, 
133.7, 137.1, 137.3, 137.5, 138.4 (x 2), 138.5, 165.7, 166.1, 169.9, 170.2, 170.8 ppm; 
HR-FAB MS [M+Na]+ calcd for C89H97N3O24Na 1614.6360 found 1614.6372. 
 
O-(α-D-Glucopyranosyl)-(1→3)-O-(α-D-glucopyranosyl)-(1→3)-O-(α-L-
rhamnopyranosyl)-(1→3)-1-O-(4-aminobutyl)-D-ribitol  (5.2). To a solution of 5.9 
(60 mg, 0.06 mmol) in dry methanol (1.0 mL) was added 1M NaOMe till pH = 9 (~0.1 
mL). The reaction mixture was stirred for 15 h at rt, then neutralized with Dowex (H+), 
filtered, and concentrated in vacuo. The crude residue was dissolved in a mixture of 
ethanol/HCl (12/0.03, v/v) and 10% Pd/C (70 mg) was added. The reaction mixture was 
stirred under an atmosphere of H2 for 8 h. When TLC showed the formation of ninhydrin 
positive spot on the baseline, the catalyst was filtered off and the filtrate was neutralized 
with Dowex (OH-) resin and concentrated under reduced pressure. The residue was co-
evaporated with water (2 x 2 mL) and then purified by column chromatography on 
Sephadex G-15 (water elution) to afford compound 4.5 as a film (72% yield). Analytical 
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data for 5.2: [α]D27  +69.4o (c = 1.0, H2O);  1H-n.m.r. (D2O).: δ, 1.35 (d, 3H, H-6’), 1.73-
1.83 (m, 4H, 2 x CH2sp), 3.08-3.10 (m, 2H, CH2sp), 3.51 (dd, 1H, J4’’’,5’’’  = 9.9 Hz, H-
4’’’), 3.60-3.68 (m, 5H, H-4’, 5’’, 2’’’, CH2sp), 3.71-3.93 (m, 14H, H-1, 2, 5, 3’, 5’, 2’’, 
5’’, 3’’’, 6a’’, 6b’’, 6a’’’, 6b’’’), 3.95-4.02 (m, 2H, H-4, 4’’), 4.06-4.12 (m, 3H, H-3, 3’’, 
5’’’), 4.24-4.27 (m, 1H, H-2’), 5.05 (d, 1H, J1’,2’ = 1.7 Hz, H-1’), 5.15 (d, 1H, J1’’,2’’ = 3.6 
Hz, H-1’’), 5.41 (d, 1H, J1’’’,2’’’  = 3.7 Hz, H-1’’’) ppm; 13C-n.m.r. (D2O).: δ, 17.1, 24.1, 
26.1, 39.7, 60.5, 60.6, 62.7, 67.2, 69.7 (x 2), 69.8, 70.2 (x 2), 70.4 (x 2), 70.7, 71.1, 71.8, 
72.1 (x 2), 73.2, 75.6, 80.1, 80.4, 95.8, 99.6, 100.5 ppm; HR-FAB MS [M+H]+ calcd for 
C27H52NO19 694.3134 found 694.3141. 
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Early in the last century it was discovered that non-immunogenic, low-molecular weight 
saccharides, known as haptens, which mimic determinants of bacterial polysaccharides, 
can be made immunogenic when linked to protein carriers.1 Since then, this principle has 
been applied multiple times and a large number of neoglycoconjugates have been 
synthesized for use in experimental vaccines.2,3 
 
One of the important characteristics of glycoconjugates is the number of oligosaccharide 
units incorporated in the carrier as a result of conjugation. There are many existing 
methods for conjugation of carbohydrates to proteins.4,5 Chapter 1 (section 1.1) describes 
























Figure 6.1 Glycoconjugation reaction using squarate linker 
The method adopted for the synthesis of neoglycoconjugates of SPn6 oligosaccharides 
was the method originally described by Tietze, which is based on the selective reaction of 
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amines with squaric acid diesters.6 The first ester function of the squaric acid diester 
reacts at neutral pH, to form a monoamide between the ligand and the ester. The second 
ester group can subsequently be coupled to another amino group in basic medium via 
controlled formation of 1,2- bisamide of the squaric acid. This allows for subsequent 
coupling of two different amine components to obtain a distinct conjugate without the 
formation of mixtures (Figure 6.1). 
 
Further, the method is simple, it makes use of relatively inexpensive, commercially 
available reagents, it has gained popularity in synthetic vaccine development because it 
allows preparation of neoglycoconjugates with a wide range of hapten:carrier ratios.7,2,8 
The main advantage of this method is that it does not result in cross linked poorly defined 
lattice type products and that some of the excess hapten used at the onset of the reaction 
can be recovered.  
6.2 Results & Discussion 
 
The spacer containing oligosaccharides (4.1-4.6 and 5.2, Figure 6.2) were synthesized as 
described in Chapters 4 and 5. The free amino group present in the oligosaccharides 4.1-
4.6 and 5.2 was subjected to elongation by the reaction of 3,4-diethoxy-3-cyclobutene-
1,2-dione (squaric acid diethyl ester) in 50 mM potassium phosphate buffer (pH 7).   
When TLC indicated completion of the reaction (12 h), the reaction mixtures were 
purified by reverse phase chromatography to obtain the hapten-squarate adducts (6.1- 
6.7). The identity and purity of these compounds were confirmed by proton NMR and 
HRMS measurements. 
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          50 mM
Potassium phosphate
pH 7.0 buffer
 4.1, 4.2, 4.3, 4.4, 
     4.5, 4.6, 5.2
      (Hapten)
Hapten-Squarate adducts 
     (6.1- 6.7), Figure 6.3  
Scheme  6.1 General protocol for preparation of serotype 6 squarates 
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Figure 6.3 Squarates of SPn6A-6C  
Glycoconjugates of the SPn6 series were prepared using a model carrier, bovine serum 
albumin (BSA, molecular mass 66430 Da).9,10 BSA has 59 lysine residues9,11 each 
bearing a terminal amino group of which only 30-35 have amino groups that are 
accessible for chemical coupling.12 In general, BSA-neoglycoconjugates are ideal for 
inhibition studies or for binding to solid phases (such as agarose, ELISA plates or 
biosensor surfaces) useful for separation or analysis of proteins, bacteria or cells.  
One of the important characteristics of glycoconjugates is the number of hapten units 
incorporated in the carrier protein as a result of conjugation.10 This could in principle be 
determined by matrix-assisted laser desorption/ ionization-time of flight mass 
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spectrometry (MALDI-TOF MS). The quality of the MALDI-TOF spectra depends 
largely on the mode of sample preparation and the nature of the contaminants, hence this 
method is normally applied to characterize the mass of highly purified products. The 
utility of Surface Enhanced Laser Desorption Time of Flight mass spectrometry (SELDI-
TOF) in combination with the protein chip system® was introduced by Kovac’s group to 
monitor the conjugation of synthetic oligosaccharides to protein.10 It combines solid-
phase chromatography with the power of LDI-TOFMS analysis. The technique uses a 
variety of chemically active surfaces capable of retaining proteins or modified 
derivatives, depending upon their intrinsic properties.13   After proteins have bound to the 
surface, contaminants may be washed out and the retained sample can be directly 
analyzed by the detector unit. An important point to note is that, when a conjugation 
reaction is monitored by SELDI-TOFMS, a portion of the reaction mixture can be 
withdrawn, and processed when the desired carbohydrate-protein ratio is reached, the rest 
of the material is allowed to react until the conjugate shows the next desired 
predetermined molecular weight. The obtained squarate adducts (6.1-6.7, Figure 6.3) 
were subjected to a conjugation reaction using BSA in pH 9 borate buffer (Scheme 6.2) 
and the progress of the reaction was monitored by SELDI-TOFMS 
 
pH 9.0
40 mM borate buffer BSA
Hapten-Squarate-BSA conjugates
         (6.8- 6.14), Figure 6.4
Hapten-Squarate adducts (6.1- 6.7)
 
Scheme  6.2  General protocol for preparation of serotype 6 conjugates 
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It is well known that the number of hapten units incorporated into the protein is one of 
the most important factors for inducing antibodies. Since these conjugates were prepared 
with the objective to be tested for immunogenic activity, the ability to prepare these 
neoglycoconjugates with narrow, well-defined hapten-squarate: protein ratios was 
important. For preliminary studies, our target was to obtain the conjugates to have a 
hapten-squarate / BSA ratio between 5 and 10. Hence, the reactions were set up so that at 
the onset of the reaction, the molar 6.1-6.7/ BSA ratio was 6:1 (see Experimental Part- 
Table 6.2).  
From a chemical perspective, it should make no difference whether the conjugation 
involves a larger or smaller linker-equipped carbohydrate. It has been observed that 
squaric acid derivatives made from monosaccharides are generally more reactive than 
those made from larger oligosaccharides.13  In order for a derivatized hapten to react with 
the carrier protein, these larger molecules have to penetrate deeper into the 3-dimensional 
structure of the protein, where the individual ε-amino groups present in the lysine 
residues all are not equally accessible.7  Therefore, with all other reaction parameters 
equal, the reaction time required to achieve a certain loading with mono- or disaccharide 
derivative is generally shorter than the case with tetra- or higher oligosaccharides.13 Also, 
increasing the concentration of the hapten increases the rate and efficiency of 
conjugations by squaric acid chemistry.11 For example, to obtain the tetrasaccharide 
conjugate 6.9, loading of 3 was observed within 7 h of stirring and did not change until 
25 h (see Table 6.2), in which case the excess hapten-squarate (sq) 6.2 had to be added to 
the reaction. Target loading of 5 was then observed after 62 h of adding excess starting 
material. Longer reaction times and lower conjugation efficiency were more prominent in 
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case of the tri- and tetrasaccharide conjugates (see Tables 6.1 and 6.2).   
It is also proved that pH is a very important factor for squaric acid chemistry 
conjugations. pH 9 or slightly more basic  has been generally considered optimal for 
these conjugations.14,15 Hence salts obtained from pH 9 borate buffer was added in cases 
where longer reaction times was observed.  
When the desired loading was achieved (between 4 to 8, see table 6.2), the conjugation 
reactions were terminated by neutralization first and then subjected to ultrafiltration; the 
retained material was lyophilized to obtain the pure hapten-squarate-BSA conjugates 

































































Figure 6.4 Conjugates of SPn6A- 6C  
The final results of the conjugation reactions of SPn6 series with BSA have been 
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summarized in Table 6.1 
 
Table 6.1   Data Sheet of SPn6 Conjugates 
 
 
                  
6.3 Conclusions  
 
In conclusion, a range of glycoconjugates of SPn6 series was obtained. The increasing 
mass of the glycoconjugate formation was monitored by SELDI-TOF mass spectrometry. 
The conjugates are being tested for immunological activity by our collaborator Dr. Moon 
Nahm and his coworkers at UAB (University of Alabama, Birmingham) medical school 
whose laboratory serves as the WHO reference laboratory for pneumococcal serology. 









Mol. Wt.  
 % yield Conjugtn’ 
efficiency 
6.1 / 6.8 8 : 1 4.0 69527.50 55% 50% 
6.2 / 6.9 12 : 1 5.2 70502.19 98% 42% 
6.3 / 6.10 6 : 1 5.0 70344.94 93% 83% 
6.4 / 6.11 6 : 1 5.0 69493.86 98% 83% 
6.5 / 6.12 12 : 1 8.3 71534.90 96% 69% 
6.6 / 6.13 10 : 1 7.3 69713.19 95% 75% 
6.7 / 6.14 12 : 1 5.1 68734.70 84% 42% 
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identify the most active component towards the development of a fully synthetic 
pneumococcal conjugate vaccine. 
6.4 Experimental part 
 
6.4.1 General procedure for preparation of squarate intermediates (6.1-6.7) 
 
Diethyl squarate (0.08 mmol) was added to a solution of the amine spacer containing 
oligosaccharides 4.1-4.6 and 5.2 (0.04 mmol) in a potassium phosphate pH 7.0 buffer (2 
mL). The mixture was stirred overnight (15 h) at rt. When TLC on silica gel (4/3/3/2 
CHCl3/ MeOH/ AcOH/ H2O, v/v/v/v) showed complete conversion to a faster moving 
squarate derivative, the reaction mixture was concentrated. Purification of these 
intermediates was carried out on strata- X reverse phase tubes from Phenomenex (33 µm 
polymeric reverse phase) which were conditioned by washing with MeOH (70 mL), 
followed by water (90 mL). Elution of the product was effected with water (3 x 10 mL), 
followed by stepwise gradient of MeOH in water (5%, 10 mL of eluent in each step). An 
aqueous solution of the pure material, thus obtained from purification, was filtered 
through a Sterile Millipore syringe driven filter unit (0.22 µM) and then lyophilized to 
give the pure white or pale yellow solids that was used for conjugation reactions. 
6.4.2 General procedure for the preparation of neoglycoconjugates (6.8-6.14) 
 
Squaric acid adducts 6.1-6.7, (1.0 mg, 0.0018 mmol) was transferred into the glass 
reaction vessel containing BSA (20 mg, 0.0003 mmol) using pH 9, borate buffer (45 µL, 
40 mmol).   The reaction was gently stirred at rt and the progression of the conjugation 
was periodically monitored by SELDI-TOF MS. When the desired loading was achieved 
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(see Table 6.2), the reaction mixture was neutralized with pH 7 phosphate buffer. The 
resulting mixture was transferred into a centrifugal filter device (Amicon Ultra-15) which 
was subjected to centrifugation at 4000 r.p.m for 12 min. After that, the filter was again 
subjected to centrifugation with washings from aq. 10mM (NH4)2CO3 (7 x 15 mL) to 
remove low molecular mass material. The retained material was then filtered through a 
Sterile Millipore syringe driven filter unit (0.22 µM) and then lyophilized to afford the 
conjugates as white solids in good yields. 
6.4.3 General procedure for SELDI-TOFMS analysis 
  
SELDI-TOF was measured using Bio-Rad Laboratories Inc. Protein Chip data Manager 
Software 3.0.7. The ProteinChip® arrays used were NP-20, Normal Phase protein chip 
aluminium strips that contain 8 active sites having silicon-oxide groups. Conjugation 
reactions were performed as described below:  
6.4.3.1 Blank preparation 
 
1 mg of BSA was diluted with water (6 µL) in a centrifuge tube (stock solution). A 
portion of this stock solution (2 µL) was applied on the Protein Chip®. The chip was air 
dried, washed twice with water (5 µL) with drying in between the washes. Finally 
saturated solution of sinapinic acid (2 µL, prepared by dissolving 15 mg of sinapinic acid 
in 1:1 mixture of acetonitrile and 1% TFA, centrifugating twice at 4000 r.p.m for 3 min) 
was applied and dried. 
6.4.3.2 Sample preparation 
 
A sample of the stirring crude reaction mixture (1 µL) was diluted with water (9 µL) in a 
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centrifuge tube. A portion of this solution (2 µL) was applied on the chip. The chip was 
air dried, washed with water (2 x 5 µL) with drying in between the washes. Finally 
saturated solution of sinapinic acid (2 µL) was applied and dried. 
 
Table 6.2   Monitoring conjugation reactions of SPn6 Conjugates 
Hapten-sq / 
Conjugate 











  6.7 / 6.14 6:1 










6.6 / 6.13 10:1 5 2.5 70056.96 8.0 
6.5 / 6.12 6:1 
 














6.4 / 6.11 6:1 5 19 70436.35 6.5 
6.3 / 6.10  
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(Selected NMR DATA/ SELDI-TOF MS) 
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Figure A-6 13C {1H} NMR spectrum of 1, 2, 4, 5-tetra-O-benzyl D/L- ribitol (3.12) 
 
Appendix 




















Figure A-7 2-D NMR: COSY spectrum of 1, 2, 4, 5-tetra-O-benzyl- D/L- ribitol 
(3.12) 
Appendix 





































































































































Figure A-17 13C {1H} NMR spectrum of O-(α-L-Rhamnopyranosyl)-(1→4)-D-ribitol 
(3.4) 
Appendix 














































































Figure A-21 2-D NMR: COSY spectrum of O-(α-D-Glucopyranosyl)-(1→3)-O-(α-L-
rhamnopyranosyl)-(1→3)-D/L-ribitol (3.5) 
Appendix 


















Figure A-23 13C{1H} NMR spectrum of O-(α-D-Glucopyranosyl)-(1→3)-O-(α-L-
rhamnopyranosyl)-(1→4)-D-ribitol (3.6) 
Appendix 

























Figure A-24 2-D NMR: COSY spectrum of O-(α-D-Glucopyranosyl)-(1→3)-O-(α-L-
rhamnopyranosyl)-(1→4)-D -ribitol (3.6) 
Appendix 






































































































































Figure A-31 13C{1H} NMR spectrum of O-(α-D-Glucopyranosyl)-(1→3)-O-(α-D-
Glucopyranosyl)-(1→3)-O-(α-L-rhamnopyranosyl)-(1→3)-D/L-ribitol (5.1) 
Appendix 
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